Cerebellar protein e3 ubiquitin ligase inhibitor and chimeric compound targeting protein degradation
By designing new CRBN ligands to construct protein degradation targeted chimera (PROTACs), the problem of domain protein degradation regulation in the existing technology is solved, the efficacy and safety of drugs are improved, and new application potential is provided for the pharmaceutical field. .
Patent Information
- Application Number
- PCT/CN2024/095621
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-03
- Filing Date
- 2024-05-27
- Publication Date
- 2024-11-28
AI Technical Summary
Existing CRBN ligands have design challenges in protein degradation targeted chimera (PROTACs), and it is difficult to effectively regulate the degradation of domain proteins, affecting the efficacy and safety of drugs.
Design and synthesize novel CRBN ligands to construct protein degradation targeted chimera (PROTACs) to improve their application potential in medicine through specific chemical structure optimization.
More effective protein degradation regulation is achieved, the efficacy and safety of drugs are improved, and new possibilities are provided for the application of CRBN ligands in PROTACs.
Smart Images

Figure PCTCN2024095621-FTAPPB-I100001 
Figure PCTCN2024095621-FTAPPB-I100002 
Figure PCTCN2024095621-FTAPPB-I100003
Abstract
Description
Cerebellar protein E3 ubiquitin ligase inhibitors and chimeric compounds targeting protein degradation Technical Field
[0001] The present invention relates to cerebellum protein E3 ubiquitin ligase inhibitors and protein degradation targeting chimeras (PROTAC) compounds containing the same, and their use in medicine. Background Art
[0002] Cerebellin (CRBN) is a brain-associated protein with ionolytic protease activity. It interacts with DNA damage binding protein-1 (DDB1), cullin 4 (Cul4A or Cul4B), and regulatory factor cullin 1 (RoC1) to form a functional E3 ubiquitin ligase complex (CRBN-CRL4). Substrate binding leads to proteolysis via the ubiquitin-proteasome pathway. Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide, when bound to CRBN, recruit new substrates to CRBN-CRL4, leading to increased ubiquitination and proteasome-dependent degradation, which is used to treat cancer and other diseases.
[0003] On this basis, CRBN ligands have been widely used in protein degradation, and a series of protein degradation targeting chimeras (PROTACs) based on CRBN ligands have been developed. Due to the effect of CRBN ligands on the target, they may also degrade domain proteins. Therefore, the design and synthesis of new CRBN ligands are of great significance for the further development of PROTACs molecules.
[0004] The present invention will disclose a series of novel CRBN ligands and further synthesize corresponding PROTACs molecules.
[0005] Summary of the Invention
[0006] The first aspect of the present invention provides a compound as shown in Formula I or its isomers, isotopic derivatives, polymorphs, prodrugs, or pharmaceutically acceptable salts or solvates:
[0007] Among them, G a and G b are independently selected from O, S, and Se; in one embodiment, G a and G b Each independently is O;
[0008] R 31 , and R 32 Each time it appears, it is independently CRa R b ;
[0009] R 33 、R 34 、R a , and R b Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of said alkyl groups, heteroalkyl groups, an alkenyl group, an alkynyl group, an alkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, 33 、R 34 、R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, hydroxyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, and a C3-C6 heterocyclyl containing 1, 2, 3, or 4 heteroatoms independently selected from N, O, P, and S, wherein said alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyl, and heterocyclyl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cycloalkyl, and heterocyclyl; in one embodiment, R 33 、R 34 、R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, hydroxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and C1-C6 alkoxy, wherein said alkyl, haloalkyl, hydroxyalkyl and alkoxy are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl and hydroxy; in one embodiment, R 33 、R 34 、R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and C1-C3 alkoxy;
[0010] n is 0, 1, 2, or 3;
[0011] When R 35 and R 36 The carbon atom to which it is attached, and R 41 Together they form a ring, and when d1 is 1:
[0012] R 35 and R 36 Each independently selected from CR a R b 、C(=S)、C(=O)、NR a or SO2, and R 35 and R 36 At least one of them is C(=O);
[0013] R 41 is N;
[0014] R 37 and R 38 The carbon atom connected to it forms And R 39 and R 40 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 39 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, and a hydroxyl group;
[0015] or R 38 and R 39 The carbon atom connected to it forms And R 37 and R 40each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of the alkyl groups, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group;
[0016] or R 39 and R 40 The carbon atom connected to it forms And R 37 and R 38 each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of the alkyl groups, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group;
[0017] R d 、R e 、R f 、R g 、R D 、R E 、R F 、R J 、R K 、R L 、R Q 、R W 、R M , and R G Each occurrence is independently C(R m )2、NR m , C(=O), O or S; in one embodiment, R d and R e Each occurrence has at least one O and R D and RE At least one of each occurrence is O; in one embodiment, R d and R e Each time it appears, there is at least one O, and R D and R E Each occurrence has one and at least one value of O; in one embodiment, R d and R e Each time it appears, there is one and only one O, and R D and R E Each time it appears, there is one and one is O;
[0018] W 3 、W 4 、W 5 and W 6 Each time it appears, it is independently CR m or N, in one embodiment, W 3 、W 4 、W 5 and W 6 Each occurrence is independently CH or N; and
[0019] R h and R H Each time it appears, it is NR independently. 1h 、C(=O), SO2 or CR 2h R 3h In one embodiment, R h and R H Each occurrence is independently NH, C(=O), C(Cl)H or C(OH)H; in one embodiment, R h and R H Each occurrence is independently NH;
[0020] When d1 is 0, R 35 and R 41 When forming a ring with the carbon atom to which it is attached:
[0021] R 35 -N(R a )-W 11 -, W 11 Selected from CR a R b 、C(=O)、C(=S)、NR a and SO2, in one embodiment W 11 is C(=O); in one embodiment, R 35 is -N(CH3)-C(=O)-;
[0022] R 41 is N;
[0023] R 37 and R 38 The carbon atom connected to it forms And R 39 and R 40 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 39 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group;
[0024] or R 38 and R 39 The carbon atom connected to it forms And R 37 and R 40 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 37 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group;
[0025] or R 39 and R 40 The carbon atom connected to it forms And R 37 and R 38each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of the alkyl groups, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group;
[0026] R d1 、R e1 、R f1 、R g1 、R D1 、R E1 、R F1 , and R G1 Each occurrence is independently C(R m )2、NR m , C(=O), O or S; in one embodiment, R d1 , and R e1 Each occurrence has at least one O and R D1 , and R E1 Each time it appears, there is at least one occurrence and at least one of them is O;
[0027] W 31 and W 41 Each time it appears, it is independently CR m or N, in one embodiment CH or N; and
[0028] R h1 and R H1 Each time it appears, it is NR independently. 1h 、C(=O), SO2 or CR 2h R 3h In one embodiment, R h1 and R H1 Each occurrence is independently NH, C=O, CHCl or CHOH;
[0029] When R 36 and R 41 There is no chemical bond between 35 and R 36 The carbon atom to which it is attached, and R 41 No ring is formed and d1 is 1:
[0030] R 35 is a single bond;
[0031] R 41 Selected from-NR a -、-NR a CO-, C1-C6 alkylene, C1-C6 haloalkylene; in one embodiment, R 41 Selected from -NH-CO-, -NH- and -N(CH3)-;
[0032] R 37 and R 38 The carbon atom connected to it forms And R 39 、R 40 and R 36 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 39 、R 40 and R 36 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; in one embodiment, R 39 、R 40 and R 36 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group;
[0033] or R 38 and R 39 The carbon atom connected to it forms And R 37 、R 40 and R 36Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 37 、R 40 and R 36 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; in one embodiment, R 37 、R 40 and R 36 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group;
[0034] or R 39 and R 40 The carbon atom connected to it forms And R 36 、 R 37 and R 38 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 36 、R 37 and R 38 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; and in one embodiment, R 36 、R37 and R 38 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group;
[0035] or R 40 and R 36 The carbon atom connected to it forms And R 37 、R 38 and R 39 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 37 、R 38 and R 39 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; and in one embodiment, R 37 、R 38 and R 39 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group;
[0036] R 3a 、R 3b 、R 4a 、R 4b 、R 3A 、R 3B 、R 4A , and R 4B Each occurrence is independently selected from C(R a )2、NR a , C(O), O and S, and R 3A or R 4A Each occurrence has at least one O and R 3a or R 4aAt least one of each occurrence is O or N(CH3); in one embodiment, R 3A or R 4A Each occurrence has at least one O and R 3a or R 4a Each time it appears, there is at least one occurrence and at least one of them is O;
[0037] W 3a and W 4a Each time it appears, it is independently CR a or N, and W 3a and W 4a At least one of them is a N atom;
[0038] R a and R A Each time it appears, it is NR independently. 4h 、C(=O), SO2 or CR 2h R 3h In one embodiment, R a and R A Each time it appears, it is NR independently. 4h , SO2 or CR 2h R 3h In one embodiment, R A or R a is -NH or -NC(O)CH3; and
[0039] R 4h selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein said alkyl group, heteroalkyl group, alkoxy group, cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkylamino group, an alkylacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group; and
[0040] When R 41 Selected from-NR a CO-, and R 38 and R 39 The carbon atom connected to it forms R 39 and R 40 The carbon atom connected to it forms m1 is 2, R 3aThe two occurrences are independently O and CH2, respectively. When m2 is 0, R 37 、R 36 At least one is not H, and R 36 Not for F;
[0041] R m 、R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of said alkyl groups, heteroalkyl groups, alkoxy groups, cycloalkyl groups, heterocyclyl groups, aryl groups, and heteroaryl groups is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group; in one embodiment, R m 、R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyl group, and an alkyl acyl group; in one embodiment, R m 、R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, hydroxy, C1-C3 alkylacyl, and C1-C3 alkoxy;
[0042] m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6;
[0043] Each occurrence of m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8;
[0044] m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m5 + m6 ≤ 7;
[0045] m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m7+m8≤7;
[0046] m13 and m14 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m13 and m14 are not 0 at the same time, and m13 + m14 ≤ 8;
[0047] m15 and m16 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m15+m16≤7;
[0048] m17 and m18 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6 at each occurrence, and m17+m18≤6; and
[0049] The compound is not
[0050] In one embodiment, the compound is selected from:
[0051] When the compound is of formula IA,
[0052] W 1 and W 2 The same or different, each independently CR a R b 、C(=S)、C(=O)、NR a or SO2, and W 1 and W 2 At least one of them is C(=O);
[0053] G and Z are the same or different and are each independently selected from O, S, and Se. In one embodiment, G and Z are each independently O;
[0054] R 3b and R 3c The carbon atom connected to it forms And R 3a and R 3deach independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of the alkyl groups, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group;
[0055] or R 3c and R 3d The carbon atom connected to it forms And R 3a and R 3b each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of the alkyl groups, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group;
[0056] or R 3a and R 3b The carbon atom connected to it forms And R 3c and R 3dEach of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R 3c and R 3d are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, and a hydroxyl group;
[0057] R d 、R e 、R f 、R g 、R D 、R E 、R F 、R J 、R K 、R L 、R Q 、R W 、R M , and R G Each occurrence is independently C(R m )2、NR m , C(=O), O or S; in one embodiment, R d and R e Each occurrence has at least one O and R D and R E Each time it appears, there is at least one occurrence and at least one of them is O;
[0058] W 3 、W 4 、W 5 and W 6 Each time it appears, it is independently CR m or N; in one embodiment, W 3 、W 4 、W 5 and W 6 Each occurrence is independently CH or N;
[0059] R h and R H Each time it appears, it is NR independently. 1h、C(=O), SO2 or CR 2h R 3h In one embodiment, R h and R H Each occurrence is independently NH, C(═O), C(Cl)H, or C(OH)H;
[0060] m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6;
[0061] Each occurrence of m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8;
[0062] m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m5 + m6 ≤ 7;
[0063] m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m7+m8≤7;
[0064] m13 and m14 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m13 and m14 are not 0 at the same time, and m13 + m14 ≤ 8;
[0065] m15 and m16 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m15+m16≤7;
[0066] m17 and m18 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m17+m18≤6;
[0067] R m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of said alkyl groups, heteroalkyl groups, an alkenyl group, an alkynyl group, an alkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, mEach occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; in one embodiment, R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, and hydroxyl;
[0068] R 1h 、R 2h , and R 3h Each is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group; in one embodiment, R 1h 、R 2h , and R 3h are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, a hydroxyl group, and an alkyl acyl group; in one embodiment, R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, hydroxyl and C1-C3 alkoxy;
[0069] R 1 is selected from H, halogen, a deuterium atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, a cycloalkyl group, a C1-C6 haloalkyl group, and a hydroxyalkyl group, and in one embodiment is selected from H, F, Cl, Br, I, a C1-C3 alkyl group, a C1-C3 alkoxy group, a C3-C6 cycloalkyl group, a C1-C3 haloalkyl group, a hydroxyl group, and a C1-C6 hydroxyalkyl group;
[0070] R 2 、R a , and R b are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, and a C1-C6 alkoxy group; and
[0071] n is 0, 1, 2, or 3;
[0072] When the compound is selected from the structure of formula IB,
[0073] W 11 Selected from CR a R b 、C(=O)、C(=S)、NR a or SO2; in one embodiment W 11 is C(=O);
[0074] G and Z are the same or different and are each independently selected from O, S, and Se;
[0075] R 3b1 and R 3c1 The carbon atom connected to it forms And R N 、R 3a1 and R 3d1 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R N 、R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group;
[0076] or R 3c1 and R 3d1 The carbon atom connected to it forms And R N 、R 3a1 and R 3b1Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R N 、R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group;
[0077] or R 3a1 and R 3b1 The carbon atom connected to it forms And R N 、R 3c1 and R 3d1 Each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxy, hydroxyalkyl, nitro, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl groups; in one embodiment, R N 、R 3c1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group;
[0078] R d1 、R e1 、R f1 、R g1 、R D1 、R E1 、R F1 , and R G1 Each occurrence is independently C(R m )2、NR m, C(=O), O or S; in one embodiment, R d1 , and R e1 Each occurrence has at least one and at least one O, and R D1 , and R E1 Each time it appears, there is at least one and at least one is O;
[0079] W 31 and W 41 Each time it appears, it is independently CR m or N, in one embodiment, W 31 and W 41 Each occurrence is independently CH or N;
[0080] R h1 and R H1 Each time it appears, it is NR independently. 1h 、C(=O), SO2 or CR 2h R 3h In one embodiment, R h1 and R H1 Each occurrence is independently NH, C=O, CHCl or CHOH;
[0081] m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6;
[0082] Each occurrence of m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8;
[0083] m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m5 + m6 ≤ 7;
[0084] m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m7+m8≤7;
[0085] R mEach occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein each of said alkyl groups, heteroalkyl groups, an alkenyl group, an alkynyl group, an alkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group is independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkenyl group, an alkynyl group, m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; in one embodiment, R m , each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxyl and C1-C3 alkoxy;
[0086] R 1h 、R 2h , and R 3h Each is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkoxy group, the cycloalkyl group, the heterocyclyl group, the aryl group, and the heteroaryl group are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group, and a heteroaryl group; in one embodiment, R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, a hydroxyl group, and an alkyl acyl group; in one embodiment, R 1h 、R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxyl and C1-C3 alkoxy;
[0087] R 11is selected from the group consisting of H, halogen, a deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, and hydroxyalkyl, and in one embodiment is H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, and C1-C6 hydroxyalkyl;
[0088] R 21 、R a , and R b are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, and a C1-C6 alkoxy group; and
[0089] n is 0, 1, 2 or 3, in one embodiment 0, 1 or 2;
[0090] When the compound is selected from Formula IC,
[0091] G1 and G2 are each independently selected from O, S, Se; in one embodiment, G1 and G2 are each independently O;
[0092] R 2s Selected from-NR 2A 、-NR 2A CO-, C1-C6 alkylene, and C1-C6 haloalkylene. In one embodiment, R 2s Selected from -NH-CO-, -NH- and -N(CH3)-;
[0093] R3 and R4 form the carbon atom to which they are attached and R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, an alkylamino group , alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; in one embodiment, R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl and an amino group; in another embodiment, R5, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and a hydroxyl group;
[0094] Or R4 and R5 form the carbon atom to which they are connected and R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, an alkylamino group , alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; in one embodiment, R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl and an amino group; in another embodiment, R3, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and a hydroxyl group;
[0095] Or R5 and R6 form the carbon atom to which they are connected and R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group and a heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group , cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; in one embodiment, R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl and an amino group; in another embodiment, R3, R4 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and hydroxyl;
[0096] Or R6 and R7 form the carbon atom to which they are connected and R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclic group, an aryl and a heteroaryl, wherein the alkyl, heteroalkyl, alkenyl, an alkynyl, an alkoxy, a cycloalkyl, a heterocyclic group, an aryl and a heteroaryl are each independently selected from halogen, an alkyl, a heteroalkyl, an alkoxy, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclic group, an alkenyl, an alkynyl, an alkylamino , alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; in one embodiment, R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl and an amino group; in another embodiment, R3, R4 and R5 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and a hydroxyl group;
[0097] R 3a 、R 3b 、R 4a 、R 4b 、R3A 、R 3B 、R 4A 、R 4B Each occurrence is independently selected from C(R 2A )2、NR 2A , C(O), O and S; in one embodiment, R 3A or R 4A Each time it appears, there is at least one O or N, R 3a or R 4a Each time it appears, there is at least one occurrence and at least one of them is O;
[0098] W 3a and W 4a Each time it appears, it is independently CR 2A or N, and W 3a and W 4a At least one of them is a N atom, and Contains at least one O atom or N atom;
[0099] R a and R A Each occurrence is independently C(R 2A )2、NR 2A , or C(O); in one embodiment, R a and R A Each occurrence is independently -NH or -NC(O)CH3;
[0100] m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6;
[0101] m3 and m4 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m3+m4≤8, and m3 and m4 are not both 0;
[0102] m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m5 + m6 ≤ 7;
[0103] m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7, and m7+m8≤7;
[0104] R 2A , and R 1seach occurrence is independently selected from H, halogen, a deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, -C(O)-CH3, and hydroxyalkyl, and in one embodiment is H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, -C(O)-CH3, and C1-C6 hydroxyalkyl;
[0105] When R 2s Selected from-NR 2A CO-, and R4 and R5 form the carbon atom to which they are connected or R5 and R6 form the carbon atom to which they are connected When m1+m2=2, at least one of R3 and R7 is not H, and R7 is not F; and
[0106] The compound is not
[0107] In one embodiment, wherein:
[0108] When the compound is of Formula IA, W 1 and W 2 are the same or different, each independently C(═S), CH2 or C(═O), and W 1 and W 2 At least one of them is C(=O); in one embodiment, W 1 When it is CH2, W 2 C(=O) or W 1 When it is C(=O), W 2 is CH2 or C(=O); in one embodiment, W 1 When it is CH2, W 2 C(=O) or W 1 When it is C(=O), W 2 is CH2; in one embodiment
[0109] G and Z are O; in one embodiment
[0110] R 3b and R 3c The carbon atom connected to it forms And R 3a and R 3d are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group, in one embodiment R 3a and R 3dare each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3a and R 3b The carbon atom connected to it forms And R 3c and R 3d Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3c and R 3d Each is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3c and R 3d are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group, in one embodiment R 3c and R 3d are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; in one embodiment
[0111] R d 、R e 、R f 、R g 、R D 、R E 、R F 、R J 、R K 、R L 、R Q 、R W 、R M , and R G Each occurrence is independently C(R m )2 or O, in one embodiment each independently is CF2, CH2 or O; in one embodiment, R d and R e Each occurrence has at least one O and R D and R E At least one of each occurrence is O; in one embodiment, R d and R e Each time it appears, there is at least one O, and R D and R E Each occurrence has one and at least one value of O; in one embodiment, R d and R e Each time it appears, there is one and only one O, and R D and R E Each occurrence has one and one is O; in one embodiment
[0112] R h and R H NR 1h , C(=O), or CR 2h R 3h ; R 1h 、R 2h , and R 3hEach is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl, and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl; in one embodiment, R 1h 、R 2h , and R 3h Each is independently selected from H, deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl, and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl; in one embodiment R 1h 、R 2h , and R 3hare each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, a hydroxyl group, and a C1-C3 alkoxy group; in one embodiment R 1h 、R 2h , and R 3h are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, a hydroxyl group, and a C1-C3 alkoxy group; in one embodiment, R h and R H is selected from NH, C(=O), C(Cl)H and C(OH)H; in one embodiment
[0113] Each occurrence of m1 and m2 is independently an integer of 0, 1, 2, or 3, and m1+m2≤3; in one embodiment, m1+m2=1, m1+m2=2, or m1+m2=3; in one embodiment,
[0114] Each occurrence of m3 is independently an integer of 0, 1, 2, 3, or 4, m4 is an integer of 1, 2, 3, 4, or 5, and m3+m4≤5, in one embodiment m3+m4=1, m3+m4=2, m3+m4=3, or m3+m4=4; in one embodiment
[0115] Each occurrence of m5 and m6 is independently an integer of 0, 1, 2, 3 or 4, and m5+m6≤4, in one embodiment m5+m6=2 or m5+m6=3; in one embodiment
[0116] Each occurrence of m7 and m8 is independently an integer of 0, 1, 2, 3 or 4, and m7+m8≤4, in one embodiment m7+m8=2 or m7+m8=3; in one embodiment
[0117] Each occurrence of m13 and m14 is independently an integer of 0, 1, 2, 3 or 4, m13 and m14 are not both 0, and m13 + m14 ≤ 5, in one embodiment m13 + m14 = 3 or m13 + m14 = 4; in one embodiment m13 and m14 are both 2; in one embodiment
[0118] Each occurrence of m15 and m16 is independently an integer of 0, 1, 2, 3 or 4, and m15+m16≤4, in one embodiment m15+m16=2 or m15+m16=3; in one embodiment
[0119] Each occurrence of m17 and m18 is independently an integer of 0, 1, 2, 3 or 4, and m15+m16≤3, in one embodiment m15+m16=1 or m15+m16=2; in one embodiment
[0120] R m Each occurrence is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl; in one embodiment R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl; in one embodiment Rm Each occurrence is independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; in one embodiment R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; In one embodiment
[0121] R 1 is selected from H, halogen, C1-C3 alkyl, and hydroxy; in one embodiment R 1 is selected from H, F, Cl, Br, I, C1-C3 alkyl, and hydroxyl; in one embodiment
[0122] R 2 is selected from H, and C1-C3 alkyl; in one embodiment
[0123] n is 0 or 1; or
[0124] When the compound is of formula IB,
[0125] W 11 is selected from CH2, C(=S) or C(=O); in one embodiment, W 11 is C(═O) or C(═S); in one embodiment W 11 is C(=O); in one embodiment
[0126] G and Z are O; in one embodiment
[0127] R N selected from H, deuterium atoms, halogen, C1-C6 alkyl, heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, C1-C6 hydroxyalkyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 is substituted with one or more substituents of heterocyclyl, aryl and heteroaryl, in one embodiment R Nselected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In one embodiment, R N is selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, hydroxyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl and a C4-C8 heterocyclic group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, wherein said C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl and a C4-C8 heterocyclic group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxyl, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in a heteroaryl group;
[0128] In one embodiment
[0129] R 3b1 and R 3c1 The carbon atom connected to it forms And R 3a1 and R 3d1Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 is substituted with one or more substituents of heterocyclyl, aryl and heteroaryl; in one embodiment, R 3a1 and R 3d1 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In one embodiment, R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3c1 and R 3d1 The carbon atom connected to it forms And R 3a1 and R 3b1Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3a1 and R 3b1 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3a1 and R 3b1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3a1 and R3b1 The carbon atom connected to it forms And R 3c1 and R 3d1 Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3c1 and R 3d1 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted with one or more substituents in heteroaryl, in one embodiment R 3c1 and R3d1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; in one embodiment
[0130] R d1 、R e1 、R f1 、R g1 、R D1 、R E1 、R F1 , and R G1 Each occurrence is independently C(R m )2 or O; R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; in one embodiment
[0131] W 31 and W 41 is CH or N; in one embodiment
[0132] Each occurrence of m1 and m2 is independently an integer of 0, 1, 2, or 3, and m1+m2≤3; in one embodiment, m1+m2=1, m1+m2=2, m1+m2=3; in one embodiment,
[0133] Each occurrence of m3 is independently an integer of 0, 1, 2, 3, or 4, m4 is an integer of 1, 2, 3, 4, or 5, and m3+m4≤5, in one embodiment m3+m4=1, m3+m4=2, m3+m4=3, or m3+m4=4; in one embodiment
[0134] Each occurrence of m5 and m6 is independently an integer of 0, 1, 2, 3 or 4, and m5+m6≤4, in one embodiment m5+m6=2 or m5+m6=3; in one embodiment
[0135] Each occurrence of m7 and m8 is independently an integer of 0, 1, 2, 3 or 4, and m7+m8≤4, in one embodiment m7+m8=2 or m7+m8=3; in one embodiment
[0136] R 11 is selected from H, halogen, C1-C3 alkyl, and hydroxyl; R 11 is selected from H, F, Cl, Br, I, C1-C3 alkyl, and hydroxyl; in one embodiment
[0137] R 21 Selected from H, and C1-C3 alkyl; or
[0138] When the compound is of formula IC,
[0139] G1 and G2 are each independently selected from O; in one embodiment
[0140] R 2s Selected from-NR 2A -、-NR 2A CO-;R 2A Each occurrence is independently selected from H and C1-C6 alkyl; in one embodiment, R 2s Selected from -NH-CO-, -NH- and -N(CH3)-;
[0141] In one embodiment
[0142] R3 and R4 form the carbon atom to which they are attached and R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 In one embodiment, R5, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In one embodiment, R5, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; or R4 and R5 are each independently selected from the carbon atom to which they are attached. and R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C6 alkyl group, a C5-C6 alkyl group, a C6-C6 alkyl group, a C7-C6 alkyl group, a C8-C8 alkyl group, a C9-C6 alkyl group, a C1 ...2-C6 alkyl group, a 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 In one embodiment, R3, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In one embodiment, R3, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; or R5 and R6 are each independently selected from the carbon atom to which they are attached. and R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 In one embodiment, R3, R4 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In one embodiment, R3, R4 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; or R6 and R7 are substituted by one or more substituents in a heteroaryl group, in which embodiment R3, R4 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; and R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C1 ... 10 In one embodiment, R3, R4 and R5 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C10 Aryl and C5-C 10 In one embodiment, R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; in one embodiment, R3, R4 and R5 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; in one embodiment,
[0143] R 3a 、R 3b 、R 4a 、R 4b 、R 3A 、R 3B 、R 4A 、R 4B Each occurrence is independently selected from C(R 2A )2、NR 2A and O; in one embodiment
[0144] W 3a and W 4a Each occurrence is independently C(R 2A )2 or N; in one embodiment
[0145] R a and R A Each occurrence is independently NR 2A or CR 2h R 3h In one embodiment, R A and R a is -NH, or -NC(O)CH3; in one embodiment
[0146] R 2A and R 1s Each occurrence is independently selected from H, halogen, a deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, and hydroxyalkyl, and in one embodiment is H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, and C1-C6 hydroxyalkyl.
[0147] In one embodiment, the compound is selected from the following structures:
[0148] in:
[0149] R H1 、RH 、R h 、R f 、R g 、R W 、R M 、W 3 、W 4 、W 5 、W 6 、R d 、R e 、R 3a 、R 3b 、R3 c 、R 3d 、W 1 、W 2 、R F 、R G 、R J 、R K 、R L 、R Q 、R f1 、R g1 、W 31 、W 41 、R d1 、R e1 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、W 11 、m3、m4、R E1 、R D1 、R G1 、R F1 , m2, m5, m6, m8, m13, m14, m15, m16, m17, m18, W 11 、W 31 、W 41 、R N and R h1 As defined above,
[0150] m1, m9 and m10 are each independently an integer of 0, 1, 2, 3, 4, or 5 at each occurrence, and m1+m9+m10≤5; in one embodiment, m1, m9 and m10 are each independently an integer of 0, 1, or 2 at each occurrence, and m1+m9+m10≤2, in one embodiment, m1+m9+m10=1 or m1+m9+m10=0; and
[0151] m7, m11 and m12 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6 at each occurrence, and m7+m11+m12≤6; in one embodiment, m7, m11 and m12 are each independently an integer of 0, 1, 2, or 3 at each occurrence, and m7+m11+m12≤3, in one embodiment, m7+m11+m12=2 or m7+m11+m12=1.
[0152] In one embodiment, the compound is selected from the following structures:
[0153] R H1 、R H 、R h 、R f 、R g 、R W 、R M 、W 3 、W 4 、W 5 、W 6 、R d 、R e 、R 3a 、R 3b 、R 3c 、R 3d 、W 1 、W 2 、R F 、R G 、R J 、R K 、R L 、R Q 、R f1 、R g1 、W 31 、W 41 、R d1 、R e1 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、W 11 、R N , G1, G2, R 1s 、R 2s 、R3、R4、R5、R6、R 3A 、R4 A 、R 3B 、R 4B 、R 3a 、R4a 、R 4b 、R 4a 、R a 、R b , m3, m4, m5, m6, m13, m14, m15, m16, m17, m18 and R h1 As defined above respectively.
[0154] The second aspect of the present invention provides a compound represented by Formula II or its isomers, isotopic derivatives, polymorphs, prodrugs, or pharmaceutically acceptable salts or solvates:
[0155] CLM-L-PTM (Formula II),
[0156] in:
[0157] PTMs are target protein binding moieties;
[0158] L is a bond or chemical linking moiety that covalently links the CLM and the PTM, and
[0159] The CLM is a cerebellum protein E3 ubiquitin ligase binding moiety selected from the following structures:
[0160] in:
[0161] W 11 、W 1 、W 2 , G, Z, R 3a 、R 3b 、R 3c 、R 3d 、R N 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、
[0162] R d 、R e 、R f 、R g 、R D 、R E 、R F 、R G 、R J 、R K 、R L 、R Q 、R W 、R M 、R d1 、R e1 、R f1 、Rg1 、R D1 、R E1 、R F1 、R G1 、W 31 、W 41 、W 3 、W 4 、W 5 、W 6 , m1, m2, m3, m4, m5, m6, m7, m8, m13, m14, m15, m16, m17, m18, R m 、R 1 、R 11 、R 2 、R 21 、n、R 2h , G1, G2, R 1s 、R3、R4、R5、R6、R7、R 3a 、R 4a 、R 3b 、R 4b 、R 3A 、R 4A 、R 3B 、R 4B 、 W 3a 、W 4a , and R 2A As defined above;
[0163] R N1 Each occurrence is independently C(R m )2、NR m , C(=O), O or S;
[0164] R T1 、R t1 、R NT 、R t and R T Each occurrence is N or CR independently 2h ;
[0165] n1 and n2 are each independently an integer of 0, 1, 2, 3, 4, or 5 at each occurrence, and n1+n2≤5; in one embodiment n1+n2=2 or n1+n2=3, in one embodiment n1 is 1 or 2, and n2 is 1;
[0166] R 2m Selected from-NR 2A -、-NR 2A CO-, C1-C6 alkylene, and C1-C6 haloalkylene;
[0167] R aa 、RAA 、R BB , and R bb Each occurrence is independently selected from CR m or N;
[0168] When PTM is CLM is When L is not and
[0169] When PTM is CLM is When L is not
[0170] In one embodiment, the CLM is selected from the following structures:
[0171] W 11 、W 1 、W 2 、R 3a 、R 3b 、R 3c 、R 3d 、R N 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、
[0172] R d 、R e 、R f 、R g 、R D 、R E 、R F 、R G 、R J 、R K 、R L 、R Q 、R W 、R M 、R d1 、R e1 、R f1 、R g1 、R D1 、R E1 、R F1 、R G1 、W 31 、W 41 、W 3 、W 4 、W5 、W 6 , m1, m2, m3, m4, m5, m6, m7, m8, m13, m14, m15, m16, m17, m18, n1, n2, R N1 、R NT 、R t 、R T 、R t1 , and R T1 As defined above.
[0173] In one embodiment, wherein L is a bond or is -(B L ) q -:
[0174] B L Each occurrence is the same or different and is independently selected from: CR L1 R L2 、O、S、SO、SO2、NR L3 、SO2NR L3 ,SONR L3 、CONR L3 NR L3 CONR L4 NR L3 SO2NR L4 , CO, CR L1 =CR L2 、C≡C、SiR L1 R L2 、P(O)R L1 、P(O)OR L1 NR L3 C(=NCN)NR L4 NR L3 C(=NCN),NR L3 C(=CNO2)NR L4 , cycloalkylene, heterocyclylene, arylene, or heteroarylene, wherein the cycloalkylene, heterocyclylene, arylene, and heteroarylene are optionally substituted by 0-6 R L1 In one embodiment, R L2 group substitution;
[0175] R L1 、R L2 、R L3 , and R L4 Each occurrence is independently selected from H, halogen, C 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NH-C 1-8 Alkyl, N(C 1-8 Alkyl)2, C3-11 Cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclic group, OC 3-8 Cycloalkyl, OC 3-11 Heterocyclyl, O-aryl, O-heteroaryl, SC 3-8 Cycloalkyl, NH-C 3-8 Cycloalkyl, N(C 3-8 Cycloalkyl)2, N(C 3-8 Cycloalkyl)(C 1-8 Alkyl), NH-C 3-8 Heterocyclic group, N(C 3-8 Heterocyclic)2, N(C 3-8 Heterocyclic group) (C 1-8 alkyl), NH-aryl, N(aryl)(C 1-8 alkyl), NH-heteroaryl, N(heteroaryl)(C 1-8 alkyl), OH, NH2, SH, SO2P(O)(OC 1-8 Alkyl)(C 1-8 alkyl), P(O)(OC 1-8 Alkyl)2, C≡CC 1-8 Alkyl, C≡CH, CH=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=C(C 1-8 alkyl)2、Si(OH)3、Si(C 1-8 Alkyl)3, Si(OH)(C 1-8 Alkyl)2, CO-C 1-8 Alkyl, CO2H, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NH-C 1-8 Alkyl, SO2N(C 1-8 Alkyl)2, SONH-C 1-8 Alkyl, SON(C 1-8 alkyl)2, CONH-C 1-8 Alkyl, CON(C 1-8 alkyl)2, N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 alkyl)CON(C 1-8 alkyl)2、NHCONH(C 1-8 alkyl), NHCON(C 1-8 alkyl)2、NHCONH2、N(C 1-8 alkyl)SO2NH(C 1-8 alkyl), N(C 1-8alkyl)SO2N(C 1-8 Alkyl)2, NHSO2NH(C 1-8 alkyl), NH SO2 N(C 1-8 alkyl)2, and NH SO2NH2, optionally, the C 1-8 Alkyl, C 3-11 Cycloalkyl, C 3-11 Heterocyclic group, C 6-10 Aryl and C 5-10 The heteroaryl groups are each independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, halocycloalkyl, haloheteroalkyl, alkylamino, aryl, heteroaryl, haloaryl, and haloheteroaryl; and
[0176] q is an integer greater than or equal to 1; in one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
[0177] In one embodiment, wherein B L One or more selected from the following structures: -O-, -S-, -SO-, -SO2-, -CH2-, -CO-, -NH-, -N(CH3)-
[0178] For the connection point.
[0179] In one embodiment, L is selected from the following structures:
[0180] Covalent bond, -(CH2) j -、-(CH2) p -NH-(CH2) s -、-(CH2) y -NH-(CH2) j -NH-(CH2) s -、-(CH2) p -CO-(CH2) s -、-(CH2) p -O-(CH2) s -、-(CH2) y -CO-(CH2) j -CO-(CH2) s -、-(CH2) y -O-(CH2) j -O-(CH2) s -、-(CH2)y -O-(CH2) j -CO-(CH2) s -、-(CH2) y -CO-(CH2) j -O-(CH2) s -、-(CH2) p -NH-(CH2) y -O-(CH2) j -CO-(CH2) s -、-(CH2) y -CO-(CH2) j -O-(CH2) s -NH-(CH2) p -、
[0181] Wherein, j is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0182] k, s, p, and y are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0183] It is the connection point with CLM or PTM;
[0184] In one embodiment, the PTM is a portion that binds to a target protein or polypeptide, wherein the target protein is selected from the group consisting of: structural proteins, receptors, enzymes, cell surface proteins; proteins associated with cellular integration functions, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes, antioxidant activity, proteolysis, and biosynthesis; proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulatory activity, signal transduction activity, structural molecule activity, binding activity, receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, and stimulus response; behavioral proteins; cell adhesion proteins; proteins involved in cell necrosis; and proteins involved in transport, including proteins with protein transport activity, nuclear transport activity, ion transport activity, channel transport activity, carrier activity, permease activity, secretion activity, electron transport activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcriptional regulator activity, extracellular organization and biogenesis activity, and translation regulator activity.
[0185] In one embodiment, the PTM is a moiety that binds to a target protein or polypeptide, wherein the target protein is selected from B7.1 and B7, TNFR2, NADPH oxidase, BclIBax and other partners in the apoptosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDEI I, PDEI II, PDE III, squalene epoxidase, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5HT receptor, dopamine receptor, G protein (i.e., Gq), histamine receptor, 5-lipoxygenase, tryptase-like serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosome, glycogen phosphorylase, carbonic anhydrase, chemokine receptor, JAW STAT, RXR and its analogs, HIV1 protease, HIV1 integrase, influenza neuraminidase, hepatitis B reverse transcriptase, sodium channel, multidrug-resistant bacteria, protein P-glycoprotein, tyrosine kinase, CD23, CD124, tyrosinase p561ck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-αR, ICAM1, Cat+ channel, VCAM, VLA-4 integrin, selectin, CD40 / CD40L, inosine monophosphate dehydrogenase, p38 MAP kinase, Ras1Raf1MEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCVNS3 RNA helicase, glycinamide ribonucleotide formyltransferase, rhinovirus, 3C protease, herpes simplex virus-1 (HSV-1), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin-dependent kinase 4 / 6, vascular endothelial growth factor, oxytocin receptor, inhibitor of microsomal transfer protein, bile acid transport inhibitor, 5-alpha reductase inhibitor, angiotensin 11, glycine receptors, norepinephrine reuptake receptors, endothelin receptors, neuropeptide Y and receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferase, geranylgeranyltransferase, TrkA receptor for NGF, beta-amyloid protein, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neuropil, telomerase inhibition, cytosolic phospholipase A2, EGF receptor tyrosine kinase, ecdysone 20-monooxygenase, GABA-gated chloride channel ion channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel and chloride channel, acetyl-CoA carboxylase, adenylate succinate synthetase, protoporphyrinogen oxidase, enolpyruvylshikimate phosphate synthetase, MYC protein, androgen receptor, estrogen receptor, interleukin-1 receptor-associated kinase-4 (IRAK4), Aurora kinase A, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein, bromodomain protein 4.
[0186] In one embodiment, the PTM is part of the following compounds: Hsp90 inhibitors, kinase inhibitors, phosphatase inhibitors, MDM2 inhibitors, compounds that bind to proteins containing human BET bromodomains, HDAC inhibitors, human lysine methyltransferase inhibitors, compounds that bind to RAF receptors, compounds that bind to FKBP, angiogenesis inhibitors, immunosuppressive compounds, compounds that bind to aryl hydrocarbon receptors, compounds that bind to androgen receptors, compounds that bind to estrogen receptors, compounds that bind to IRAK4, compounds that bind to thyroid hormone receptors, compounds that bind to HIV protease, compounds that bind to HIV Compounds that bind to integrase, compounds that bind to HCV protease, compounds that bind to acyl-protein thioesterase 1 in one embodiment 2, compounds that bind to c-MYC protein, compounds that bind to aurora kinase A, compounds that bind to Bcr-Abl protein, compounds that bind to bromodomain protein 4 (BRD4), compounds that bind to anaplastic lymphoma kinase (ALK), compounds that bind to Bruton's tyrosine kinase (BTK), compounds that bind to cyclin-dependent kinase 4 / 6 (CDK4 / 6), compounds that bind to SMARCA2 / 4 (BRM / BRG1), or compounds that bind to epidermal growth factor receptor.
[0187] In one embodiment, the PTM is a moiety that binds to an androgen receptor. In one embodiment, the PTM is selected from the following structures:
[0188] Among them, F6, F 16 and F 21Each occurrence is independently selected from a single bond, NH, SO, S, O, SO2, alkylene, haloalkylene, heteroalkylene, alkyleneoxy, heteroalkoxy, alkenylene, alkynylene, C(=O), OC(=O), C(=O)O, C(=O)NH, and NHC(=O); wherein the alkylene, alkyleneoxy, alkenylene is optionally substituted with 0, 1, 2, 3, 4, 5, or 6 Rc; in one embodiment, F6, F 16 and F 21 Each occurrence is independently selected from a single bond, NH, SO, S, O, SO2, C(=O), OC(=O), and NHC(=O);
[0189] F A1 , and F A3 Each is independently a 6-10 membered aryl or a 6-10 membered heteroaryl; the aryl or heteroaryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da In one embodiment, F A1 is phenyl, which is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da Replace; F A3 is phenyl or a 6-membered heteroaryl group containing 1, 2, or 3 N, O, or S heteroatoms, optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R da replace;
[0190] F A2 is 3-15 membered cycloalkylene, 5-15 membered spirocycloalkylene, 3-15 membered heterocycloalkylene or 5-15 membered spiroheterocycloalkylene, and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca In one embodiment, F A2 is a 4-6 membered cycloalkylene, a 7-11 membered spirocycloalkylene, a 4-6 membered heterocyclylene, a 7-11 membered heterospirocyclylene, and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca In one embodiment, F A2 is a 4-, 5- or 6-membered cycloalkylene group, a 10-membered heterospirocyclylene group containing 1, 2 or 3 N atoms; and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca replace;
[0191] F A4 is a 6-10 membered aryl-fused 7-15 membered heterospirocyclic group, which is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da In one embodiment, F A4is a phenyl-fused 7-15 membered heterospirocyclic ring containing 1, 2, 3, or 4 N, O, or S, which is optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R da replace;
[0192] R da Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, OH, NH2, CN and NO2, in one embodiment H, F, Cl, Br, I, CH3, OCH3, CF3, OH, NH2, CN and NO2;
[0193] R ca Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, oxo (═O), thioxo (═S), OH, NH 2 , CN, and NO 2 , and in one embodiment H, F, Cl, Br, I, CH 3 , OCH 3 , CF 3 , OH, NH 2 , CN, and NO 2 ;
[0194] In one embodiment, the PTM is selected from: In one embodiment, the PTM is selected from
[0195] In one embodiment, the PTM is a moiety that binds to an estrogen receptor. In one embodiment, the PTM is selected from the following structures:
[0196] R ea Selected from CR e1a and N;
[0197] R e1a 、R e2 and R e3Each occurrence is independently selected from H, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxy, nitro, cyano, and amino. In one embodiment, R e1a and R e2 Each occurrence is independently selected from hydroxy, H, F, Cl, Br, I, and C1-C3 alkyl;
[0198] Each occurrence of e is independently selected from 0, 1, 2, 3, and 4;
[0199] R e4 is selected from 6-10 membered aryl, 6-10 membered heteroaryl, C1-C6 alkyl, C1-C6 haloalkyl, wherein the 6-10 membered aryl and 6-10 membered heteroaryl may be optionally substituted by 0, 1, 2, 3, 4, or 5 R e1a Substituted; in one embodiment, R e4 is selected from phenyl, and difluoroethyl, wherein the phenyl group may be optionally substituted by 0, 1, 2, 3, 4, or 5 R e1 replace;
[0200] In one embodiment, the PTM is selected from:
[0201] In one embodiment, the PTM is a compound that binds to SMARCA2 / 4. In one embodiment, the PTM is selected from the following structures:
[0202] R s1 is selected from a single bond, NH, SO, S, O, SO2, alkylene, haloalkylene, heteroalkylene, alkyleneoxy, heteroalkoxy, alkenylene, alkynylene, C(=O), OC(=O), C(=O)O, C(=O)NH, and NHC(=O); in one embodiment R s1 Selected from single bond, C 2-6 Alkenylene, C 2-6 Alkynylidene;
[0203] R s2 is selected from 6-10 membered arylene, 6-10 membered heteroarylene, 3-15 membered cycloalkylene, 3-15 membered heterocyclylene, 5-15 membered spirocyclylene, wherein the 6-10 membered arylene, 6-10 membered heteroarylene, 3-15 membered cycloalkylene, 5-15 membered spirocyclylene may be optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R s5 Substituted; in one embodiment, R s2is selected from 5-8 membered heteroaryl groups containing 1, 2, or 3 N, O, or S heteroatoms, 4-6 membered heterocyclyl groups containing 1, 2, or 3 N, O, or S heteroatoms, and 7-11 membered spirocyclyl groups, wherein the 5-8 membered heteroaryl groups containing 1, 2, or 3 N, O, or S heteroatoms, 4-6 membered heterocyclyl groups containing 1, 2, or 3 N, O, or S heteroatoms, and 7-11 membered spirocyclyl groups may be optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R s5 Substituted; in one embodiment, R s2 is selected from pyrazolylene, 4-membered heterocyclylene containing 1 N atom, and 8-membered spirocyclylene;
[0204] R s3 、R s4 、R s5 , and R s6 Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, OH, NH2, CN and NO2, in one embodiment H, F, Cl, Br, I, CH3, OCH3, CF3, OH, NH2, CN or NO2; in one embodiment, R s3 OH, R s4 is NH2; and
[0205] s1 is selected from 0, 1, 2, 3 and 4;
[0206] In one embodiment, the PTM is selected from the following structures:
[0207] The third aspect of the present invention provides a pharmaceutical composition comprising the compound described above and a pharmaceutically acceptable excipient.
[0208] The fourth aspect of the present invention provides the use of the above-mentioned compounds and pharmaceutical compositions in the preparation of a medicament for treating or preventing a disease treated by degrading a target protein bound to a target protein ligand, wherein the target protein in one embodiment is cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, IRAK4, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
[0209] The fifth aspect of the present invention provides use of the aforementioned compound or pharmaceutical composition in the preparation of a medicament for treating or preventing a disease that is treated by binding to cerebellin in vivo.
[0210] In a sixth aspect, the present invention provides the use of the compound or pharmaceutical composition described above in the treatment or prevention of a disease associated with the accumulation, in one embodiment, aggregation, of a target protein, wherein the target protein is, in one embodiment, cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
[0211] The seventh aspect of the present invention provides the compound or pharmaceutical composition described above for treating or preventing a disease treated by degrading a target protein bound to a target protein ligand, wherein the target protein, in one embodiment, is cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
[0212] In an eighth aspect, the present invention provides the compound or pharmaceutical composition as described above for use in treating or preventing a disease that can be treated by binding to cerebellum protein in vivo.
[0213] The ninth aspect of the present invention provides the compound or pharmaceutical composition described above for treating or preventing a disease associated with the accumulation, in one embodiment, aggregation, of a target protein, wherein the target protein is, in one embodiment, cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
[0214] The tenth aspect of the present invention provides a method for treating or preventing a disease by degrading a target protein bound to a target protein ligand, comprising administering a therapeutically effective amount of the compound or pharmaceutical composition described above to a subject in need thereof, wherein the target protein, in one embodiment, is cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, IRAK4, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
[0215] A method for treating or preventing a disorder that is treated by binding to cerebellin in vivo comprises administering to a subject in need thereof a therapeutically effective amount of the compounds and pharmaceutical compositions described above.
[0216] A method for treating or preventing a disorder associated with accumulation, in one embodiment, aggregation, of a target protein, comprising administering to a subject in need thereof a compound or pharmaceutical composition as described above, wherein the target protein, in one embodiment, is cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein, or bromodomain protein 4.
[0217] In one embodiment, the disease is a tumor or cancer.
[0218] The present invention also provides a method for inducing degradation of a target protein in a cell, comprising administering an effective amount of the compound or pharmaceutical composition as described above, wherein the target protein, in one embodiment, is cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4. DETAILED DESCRIPTION
[0219] definition
[0220] The term "alkyl" as contemplated herein refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing from 1 to 20 carbon atoms, and in one embodiment an alkyl group containing from 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, and in one embodiment an alkyl group containing from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. In yet another embodiment, lower alkyl groups having 1 to 6 carbon atoms include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. In one embodiment, the substituent is independently selected from one or more substituents selected from H atoms, D atoms, halogen, alkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.The term "heteroalkyl" refers to an alkyl group in which one or more -CH2- are replaced by heteroatoms selected from NH, O and S or one or more -CH- are replaced by N atoms; wherein the alkyl group is as defined above; the heteroalkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, wherein the substituent is independently selected from one or more substituents selected from H atoms, D atoms, halogen, alkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl. The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is as described herein. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy. Alkoxy groups may be optionally substituted or unsubstituted. When substituted, the substituents are, in one embodiment, one or more of the following groups independently selected from H atoms, D atoms, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0221] The term "alkenyl" refers to an alkyl compound containing a carbon-carbon double bond in the molecule, wherein alkyl is as defined above. Alkenyl groups may be substituted or unsubstituted. When substituted, the substituents are, in one embodiment, one or more groups independently selected from hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0222] The term "alkynyl" refers to an alkyl compound containing a carbon-carbon triple bond, wherein alkyl is as defined above. Alkynyl groups may be substituted or unsubstituted. When substituted, the substituents are, in one embodiment, one or more groups independently selected from hydrogen, alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0223] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, in one embodiment 3 to 12 carbon atoms, more in one embodiment 3 to 8 (e.g., 3, 4, 5, 6, 7, and 8) carbon atoms, and more in one embodiment 4 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.
[0224] The cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. In one embodiment, the substituent is independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0225] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is a heteroatom selected from nitrogen, oxygen, or S(O)m (wherein m is an integer from 0 to 2), but excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. In one embodiment, it contains 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) ring atoms, of which 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; in another embodiment, it contains 3 to 8 ring atoms, of which 1-3 are heteroatoms; in another embodiment, it contains 3 to 6 ring atoms, of which 1-3 are heteroatoms; and in another embodiment, it contains 5 or 6 ring atoms, of which 1-3 are heteroatoms. Non-limiting examples of monocyclic heterocyclyls include pyrrolidinyl, tetrahydropyranyl, 1,2.3.6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like.
[0226] The heterocyclic group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment, and the substituent is independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl. The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic is a ring that shares adjacent carbon atoms) group with a conjugated π electron system, in one embodiment 6 to 10 members, such as phenyl and naphthyl. The aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is the aryl ring. The aryl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. In one embodiment, the substituent is independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0227] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 (e.g., 1, 2, 3, and 4) heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. In one embodiment, the heteroaryl group is 5 to 10 members (e.g., 5, 6, 7, 8, 9, or 10 members), and in one embodiment, is 5 or 6 members, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, and the like. The heteroaryl ring includes a heteroaryl group as described above fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the heteroaryl ring. Heteroaryl groups may be substituted or unsubstituted. When substituted, the substituents may be substituted at any available point of attachment, wherein the substituents are independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl. The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0228] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0229] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0230] The term "amino" refers to -NH2.
[0231] The term "cyano" refers to -CN.
[0232] The term "nitro" refers to -NO2.
[0233] The term "ubiquitin ligase" refers to a family of proteins that facilitate the transfer of ubiquitin to specific substrate proteins, targeting them for degradation. For example, cerebellin is an E3 ubiquitin ligase protein that, alone or in combination with an E2 ubiquitin conjugating enzyme, attaches ubiquitin to a lysine on a target protein and subsequently targets the specific protein substrate for degradation via the proteasome. Thus, E3 ubiquitin ligases, alone or in complex with an E2 ubiquitin conjugating enzyme, are responsible for the transfer of ubiquitin to target proteins. Generally speaking, ubiquitin ligases participate in polyubiquitination, where a second ubiquitin is attached to a first ubiquitin, a third ubiquitin to a second ubiquitin, and so on. Polyubiquitination marks proteins for degradation via the proteasome. However, some ubiquitination events are limited to monoubiquitination, in which only a single ubiquitin is added to a substrate molecule by a ubiquitin ligase. Monoubiquitinated proteins are not targeted to the proteasome for degradation but may instead alter their cellular location or function, for example, through binding to other proteins with domains capable of binding ubiquitin. To complicate matters further, different lysines on ubiquitin can be targeted by the E3 for chain preparation. The most common lysine is Lys48 in the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
[0234] The term "target protein" refers to proteins and peptides with any biological function or activity, including structural, regulatory, hormonal, enzymatic, genetic, immune, contractile, storage, transport, and signal transduction. In some embodiments, target proteins include structural proteins, receptors, enzymes, cell surface proteins, proteins associated with the integral functions of the cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, stimulus response, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transport activity, nuclear transport, ion transport activity, channel transport activity, carrier activity), permease activity, secretion activity, electron transport activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Such proteins include proteins from eukaryotic and prokaryotic organisms, including microorganisms, viruses, fungi and parasites, among many others, including humans, microorganisms, viruses, fungi and parasites that are targets for drug therapy, other animals including domestic animals, microorganisms that are targets for testing antibiotics and other antimicrobials and plants and even viruses, among many others.
[0235] The term "isomer" refers to compounds of the present invention that may have asymmetric centers and may occur as racemates, racemic mixtures, and individual diastereomers, all of which are encompassed by the present invention, including stereoisomers and geometric isomers. In the present invention, when a compound or salt thereof exists in stereoisomeric forms (e.g., containing one or more asymmetric carbon atoms), the individual stereoisomers (enantiomers and diastereomers) and their mixtures are encompassed by the present invention. The present invention also encompasses individual isomers of the compound or salt, as well as mixtures of isomers in which one or more chiral centers are inverted. The scope of the present invention includes mixtures of stereoisomers, as well as purified enantiomers or enantiomerically / diastereomerically enriched mixtures. The present invention encompasses mixtures of stereoisomers in all possible combinations of all enantiomers and diastereomers. The present invention encompasses all combinations and subsets of stereoisomers for all specific groups defined above. The present invention also encompasses geometric isomers of the compound or salt thereof, including cis- and trans-isomers.
[0236] The term "isotopic derivative" refers to a compound that differs in structure only in the presence of one or more isotopically enriched atoms. For example, a compound having a structure disclosed herein except that "deuterium" or "tritium" is substituted for hydrogen, or "tritium" is substituted for hydrogen. 18 F-fluorine labeling ( 18 F isotope) instead of fluorine, or with 11 C-, 13 C- or 14 C-enriched carbon ( 11 C-, 13 C-, or 14 C-carbon labeling; 11 C-, 13C- or 14 Compounds in which a carbon atom is replaced by a C-isotope) are within the scope of the present disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays, or as in vivo diagnostic imaging tracers for disease, or as tracers for pharmacodynamic, pharmacokinetic, or receptor studies.
[0237] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not. For example, "optionally substituted cyclopropyl" means that the cyclopropyl group may but need not be substituted, and that the description includes instances where the cyclopropyl group is substituted and instances where the cyclopropyl group is not substituted.
[0238] "Substituted" means that one or more hydrogen atoms, in one embodiment up to 5, and in one embodiment 1 to 3 hydrogen atoms in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort.
[0239] "Pharmaceutically acceptable salts" or "pharmaceutically acceptable salts" refer to salts of the compounds of the present disclosure that are safe and effective when used in mammals and have the desired biological activity.
[0240] EXAMPLES The following examples are offered by way of illustration and not limitation.
[0241] The abbreviations used in this article are as follows:
[0242] MeOH is methanol;
[0243] H2SO2 is concentrated sulfuric acid;
[0244] NIS is N-iodosuccinimide;
[0245] TFA is trifluoroacetic acid;
[0246] Pd is palladium;
[0247] Sn is tin;
[0248] Pyrrolidine is a tetrahydropyrrole;
[0249] OH is hydroxyl group;
[0250] Boc is tert-butyloxycarbonyl;
[0251] NaBH4 is sodium borohydride;
[0252] Et3SiH is triethylsilane;
[0253] H2 is hydrogen;
[0254] LiOH is lithium hydroxide;
[0255] NaOAc is sodium acetate;
[0256] AcOH is acetic acid;
[0257] PE is petroleum ether;
[0258] EA is ethyl acetate;
[0259] CDCl3 is deuterated chloroform;
[0260] HNO3 is nitric acid;
[0261] HBF4 is tetrafluoroboric acid;
[0262] NaNO2 is sodium nitrite;
[0263] NBS is N-bromosuccinimide;
[0264] KOtBu is potassium tert-butoxide;
[0265] NaH is sodium hydride;
[0266] B2pin2 is pinacol borate;
[0267] Oxone is potassium peroxymonosulfonate;
[0268] Cbz is benzyloxycarbonyl;
[0269] PPh3 is triphenylphosphine;
[0270] CBr4 is carbon tetrabromide;
[0271] Zn is zinc;
[0272] NH4Cl is ammonium chloride;
[0273] B is boron;
[0274] Br is bromine;
[0275] (TMS)3SiH is tris(trimethylsilyl)silane;
[0276] AlBN is azobisisobutyronitrile;
[0277] DMF is N,N-dimethylformamide;
[0278] K2CO3 is potassium carbonate;
[0279] TBAB is tetrabutylammonium bromide;
[0280] Bn is benzyl;
[0281] LiAlH4 is lithium aluminum hydride;
[0282] BH3 is borane;
[0283] THF is tetrahydrofuran;
[0284] H2O2 is hydrogen peroxide;
[0285] DMP is Dess-Martin periodinane;
[0286] PBr3 is phosphorus tribromide;
[0287] Pd(OAc)2 is palladium acetate;
[0288] BF3Et2O is boron trifluoride etherate;
[0289] S is sulfur;
[0290] MsCl is methanesulfonyl chloride;
[0291] TEA is triethylamine;
[0292] DBU is 1,8-diazabicyclo[5.4.0]undec-7-ene;
[0293] NaHCO3 is sodium bicarbonate;
[0294] Malonic acid is malonic acid;
[0295] PPA is polyphosphoric acid;
[0296] HBr is hydrogen bromide;
[0297] Tf2O is trifluoromethanesulfonic anhydride;
[0298] Pd / C is palladium on carbon;
[0299] DMSO is dimethyl sulfoxide;
[0300] UPLC is ultra-performance liquid chromatography;
[0301] MgCl2 is magnesium chloride;
[0302] NADPH is a pyridine nucleotide triphosphate;
[0303] NaS2O3 is sodium thiosulfate;
[0304] Pd(dppf)Cl2 or PdCl2(dppf) is [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride;
[0305] Boc2O is di-tert-butyl carbonate;
[0306] AIBN is azobisisobutyronitrile;
[0307] DIPEA or DIEA is N,N-diisopropylethylamine;
[0308] TsOH is p-toluenesulfonic acid;
[0309] CCl4 is carbon tetrachloride;
[0310] CAN is cerium ammonium nitrate;
[0311] IBX is 2-iodoacylbenzoic acid;
[0312] HATU is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
[0313] The following examples are directed to the intermediate compounds and final products identified in the specification and synthesis schemes. The following examples are used to describe the preparation of the compounds of the present invention in detail, but the chemical reactions described are disclosed based on their general applicability to the preparation of the compounds of the present invention. Sometimes, the reactions may not be applicable to each compound within the scope of the present invention as described. Those skilled in the art will readily recognize compounds for which this will occur. In these cases, the reactions can be successfully carried out by conventional modifications known to those skilled in the art. In all preparation methods, all starting materials are known or can be readily prepared using known starting materials.
[0314] The starting materials, chemical reagents, and solvents used in this disclosure are all commercially available and were purchased from companies such as Anage Chemical, Shanghai Bid Pharmaceutical, Beijing Inocare, Jiangsu Aikon, Sinopharm Group, Beijing Bailingwei, and Yunnan Xinlanjing.
[0315] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and, in one embodiment, mass spectrometry (MS). NMR measurements were performed using a Bruker AVANCE-400 / 600 NMR spectrometer. Deuterated solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard. Mass spectrometry (MS) measurements were performed using a Waters Acquity Plus equipment. High-performance liquid chromatography was performed using a Waters 2489 instrument. Medium-pressure flash chromatography was performed using a COMBIFLASH NEXTGEN 300+ instrument. Thin-layer chromatography silica gel plates used were Silica gel 60 thin-layer chromatography silica gel plates (aluminum plates, with fluorescence). Silica gel used for silica gel thin-layer chromatography (100-200 mesh, 200-300 mesh) was purchased from Inotech.
[0316] The reaction progress in the examples was detected by thin layer chromatography (TLC), and the developing solvent used for monitoring the reaction and the eluent used for purifying the compound by column chromatography included: petroleum ether / ethyl acetate system and dichloromethane / methanol system.
[0317] Example 1
[0318] Synthesis of compound A1
[0319] (S)-N-(2,6-dioxopiperidin-3-yl)-7-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide
[0320] Synthesis scheme
[0321] Step 1: tert-Butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A1-2)
[0322] Compound A1-1 (10.0 g, 46.9 mmol, 1.0 eq) was dissolved in toluene (100 mL) and aluminum isopropoxide (12.5 g, 61.0 mmol, 1.3 eq) was added. The reaction was allowed to react at 120°C for 24 hours. The reaction system was cooled to room temperature, and dilute hydrochloric acid (1.0 mol / L, 200 mL) was added. The mixture was extracted three times with ethyl acetate, and the organic phase was collected. The organic phase was concentrated to obtain a crude product, which was purified by column chromatography to afford Compound A1-2 (4.7 g, 47%) as a colorless oil.
[0323] 1 H NMR (600MHz, Chloroform-d) δ5.67(s,1H),4.07(s,2H),3.98–3.92(m,2H),3.54(dd,J=8.2,4.0Hz,2H),2.15(d,J=6.8Hz,2H),1.49(s,9H).
[0324] LCMS(ESI):[M-tBu+H] + =158.20
[0325] Step 2: Methyl 2-fluoro-3-hydroxybenzoate (Compound A1-4)
[0326] Compound A1-3 (5.0 g, 26.2 mmol, 1.0 eq) and triethylamine (8.0 g, 78.5 mmol, 3.0 eq) were dissolved in methanol (50 mL). 1,1-Bis(diphenylphosphino)diphenylferric palladium chloride (2.9 g, 3.9 mmol, 0.15 eq) was added and reacted at 70°C under carbon monoxide pressure for 24 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to obtain Compound A1-4 (2.4 g, 54%) as a white solid.
[0327] 1 H NMR (600MHz, DMSO-d6) δ10.24(s,1H),7.27–7.23(m,1H),7.22–7.18(m,1H),7.12–7.07(m,1H),3.84(s,3H).
[0328] LCMS(ESI):[M+H] - =169.23.
[0329] Step 3: 4,6-dibromo-2-fluoro-3-hydroxybenzoic acid methyl ester (Compound A1-5)
[0330] Compound A1-4 (2.0 g, 11.8 mmol, 1.0 eq) was dissolved in acetonitrile (20 mL). Trifluoroacetic acid (10 mL) was added with stirring at room temperature, followed by N-bromosuccinimide (4.2 g, 23.5 mmol, 2.0 eq). The reaction system was allowed to react at 50°C for 12 hours. The organic phase was concentrated to obtain a crude product, which was purified by column chromatography to afford Compound A1-5 (2.5 g, 65%) as a yellow oil.
[0331] 1 H NMR (600MHz, DMSO-d6) δ11.37 (s, 1H), 7.78 (d, J = 2.0Hz, 1H), 3.90 (s, 3H).
[0332] LCMS(ESI):[M+H] - =327.06.
[0333] Step 4: tert-Butyl 4-((4,6-dibromo-2-fluoro-3-(methoxycarbonyl)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A1-6)
[0334] Compound A1-5 (2.0 g, 6.1 mmol, 1.0 eq), compound A1-2 (1.69 g, 7.9 mmol, 1.3 eq), and triphenylphosphine (3.2 g, 12.2 mmol, 2.0 eq) were dissolved in tetrahydrofuran (20 mL). The mixture was stirred at 0°C under nitrogen for 15 minutes. Diethyl azodicarboxylate (2.1 g, 12.2 mmol, 2.0 eq) was slowly added dropwise to the reaction system. The reaction system was allowed to react at room temperature for 15 hours. The reaction system was concentrated, and the crude product was purified by column chromatography to obtain compound A1-6 (2.8 g, 88%) as a colorless oil. 1 H NMR(600MHz,DMSO-d6)δ7.94(d,J=1.7Hz,1H),5.82(s,1H),5.75–5.73(m,2H) ,4.54(s,2H),3.92(s,3H),3.89–3.80(m,2H),2.25–2.19(m,2H),1.40(s,9H).
[0335] LCMS(ESI):[M-Boc+H] + =424.09.
[0336] Step 5: 1'-(tert-Butyl)6-methyl7-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1',6-dicarboxylate (Compound A1-7): Compound A1-6 (2.0 g, 3.8 mmol, 1.0 eq) was dissolved in toluene (20 mL). Azobisisobutyronitrile (952 mg, 5.7 mmol, 1.5 eq) and tributyltin hydride (3.3 g, 11.5 mmol, 3.0 eq) were added at room temperature and reacted at 110°C for 2 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to obtain Compound A1-7 (1.1 g, 79%) as a colorless oil.
[0337] 1 H NMR (600MHz, DMSO-d6) δ7.37 (ddd, J=7.5, 5.7, 1.4Hz, 1H), 7.22 (dd, J=7.9, 1.3Hz, 1H), 4.03 (qd, J= 7.2,1.3Hz,2H),3.96–3.88(m,2H),3.83(s,3H),2.99–2.81(m,2H),1.80–1.67(m,4H),1.42(s,9H).
[0338] LCMS(ESI):[M-tBu+H] + =310.28.
[0339] Step 6: 1'-(tert-Butoxycarbonyl)-7-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxylic acid (Compound A1-8)
[0340] Compound A1-7 (500 mg, 1.4 mmol, 1.0 eq) was dissolved in tetrahydrofuran:water (3:1) (8 mL). Lithium hydroxide (287 mg, 6.8 mmol, 5.0 eq) was added and the reaction mixture was allowed to react at room temperature for 4 hours. 1N dilute hydrochloric acid was added to the reaction mixture to a pH of 5-6. The mixture was then extracted three times with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. Concentration afforded the crude product, Compound A1-8 (300 mg), as a white solid.
[0341] LCMS(ESI):[M-Boc+H] + =252.27.
[0342] Step 7: (S)-6-((2,6-dioxopiperidin-3-yl)carbamoyl)-7-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A1-9)
[0343] Compound A1-8 (300 mg, 0.9 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL). (S)-3-aminopiperidine-2,6-dione hydrochloride (211 mg, 1.3 mmol, 1.5 eq), N,N-diisopropylethylamine (552 mg, 4.5 mmol, 5.0 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (390 mg, 1.0 mmol, 1.1 eq) were added with stirring at room temperature. The reaction was allowed to react at room temperature for 1 hour. The reaction system was purified by reverse-phase column chromatography to obtain compound A1-9 (300 mg, 76%) as a blue solid.
[0344] 1H NMR(600MHz,DMSO-d6)δ10.86(s,1H),8.55(dd,J=8.3,1.8Hz,1H),7.20(d,J=7.7Hz,1H),7.1 1(dd,J=7.8,5.6Hz,1H),4.74(ddd,J=12.3,8.3,5.4Hz,1H),4.61(s,2H),3.97–3.88(m,2H), 3.02–2.85(m,2H),2.78(ddd,J=17.3,13.2,5.6Hz,1H),2.56–2.52(m,1H),2.07(qd,J=12.9, 4.5Hz,1H),2.03–1.97(m,1H),1.77(td,J=12.8,4.5Hz,2H),1.73–1.67(m,2H),1.43(s,9H).
[0345] LCMS(ESI):[M-Boc+H] + =362.29.
[0346] Step 8: (S)-N-(2,6-dioxopiperidin-3-yl)-7-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide (Compound A1): Compound A1-9 (200 mg, 0.4 mmol, 1.0 eq) was dissolved in a 10:1 ratio of dichloromethane to trifluoroacetic acid (1 mL) and reacted at room temperature for 2 hours. The reaction mixture was concentrated, and the crude product was purified by reverse-phase column chromatography to afford Compound A1 (100 mg, 64%) as a white solid.
[0347] 1 H NMR(600MHz,DMSO-d6)δ10.87(s,1H),8.78–8.76(m,1H),8.57(d,J=8.3Hz,1H), 7.18(ddd,J=7.4,5.6,1.4Hz,1H),7.08(dd,J=7.8,1.5Hz,1H),4.74(dt,J=13.1, 6.8Hz,1H),4.68(s,2H),3.38–3.32(m,2H),3.03(q,J=12.1Hz,2H),2.79(ddd,J= 17.9,13.0,5.6Hz,1H),2.57–2.52(m,1H),2.13–1.97(m,4H),1.94–1.88(m,2H).
[0348] LCMS(ESI):[M+H] + =362.39
[0349] Example 2
[0350] Synthesis of compound A2
[0351] (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-7-carboxamide
[0352] Synthesis scheme
[0353] Step 1: Methyl 3-bromo-6-fluoro-2-hydroxybenzoate (Compound A2-2)
[0354] Compound A2-1 (2.0 g, 11.8 mmol, 1.0 eq) was dissolved in 50 mL of methanol. N-bromosuccinimide (2.2 g, 12.3 mmol, 1.04 eq) was added at room temperature. 10 mL of trifluoroacetic acid was added to the reaction system. The reaction mixture was heated to 40°C and allowed to react at this temperature for 12 hours. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase column chromatography to yield A2-2 (1.78 g, 61%) as a white solid.
[0355] 1 H NMR (400MHz, DMSO-d6) δ11.08(s,1H),7.77(dd,J=8.9,5.9Hz,1H),6.84–6.80(m,1H),3.89(s,3H).
[0356] LCMS(ESI):[MH] - =247.06.
[0357] Step 2: tert-Butyl 4-((6-bromo-3-fluoro-2-(methoxycarbonyl)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A2-3)
[0358] Compound A2-2 (1.68 g, 6.8 mmol, 1.0 eq), compound A1-2 (1.73 g, 8.1 mmol, 1.2 eq), and triphenylphosphine (3.54 g, 13.5 mmol, 2.0 eq) were dissolved in tetrahydrofuran (50 mL) and stirred at 0°C under nitrogen for 15 minutes. Diethyl azodicarboxylate (2.3 g, 13.5 mmol, 2.0 eq) was slowly added dropwise to the reaction system. The reaction system was allowed to react at room temperature for 16 hours. The reaction system was concentrated, and the crude product was purified by column chromatography to obtain compound A2-3 (809 mg, 27%) as a colorless oil.
[0359] LCMS(ESI):[M-Boc+H] + =344.19.
[0360] Step 3: 1'-(tert-Butyl)7-methyl-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1',7-dicarboxylate (Compound A2-4): Compound A2-3 (809 mg, 1.8 mmol, 1.0 eq) was dissolved in toluene (20 mL). Azobisisobutyronitrile (448 mg, 2.7 mmol, 2.0 eq) and tributyltin hydride (1.59 g, 5.5 mmol, 3.0 eq) were added at room temperature and reacted at 110°C for 2 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to obtain Compound A2-4 (588 mg, 54%) as a colorless oil.
[0361] 1 H NMR (400MHz, DMSO-d6) δ7.44(dd,J=8.3,5.4Hz,1H),6.76(dd,J=10.8,8.3Hz,1H),4.58(s,2H ),3.94(m,2H),3.81(s,3H),2.89(s,2H),1.76-1.73(m,2H),1.67–1.62(m,2H),1.41(s,9H).
[0362] LCMS(ESI):[M-Boc+H] + =266.37.
[0363] Step 4: 1'-(tert-Butoxycarbonyl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-7-carboxylic acid (Compound A2-5)
[0364] Compound A2-4 (588 mg, 1.6 mmol, 1.0 eq) was dissolved in tetrahydrofuran:water (3:1) (18 mL). Lithium hydroxide (338 mg, 8.0 mmol, 5.0 eq) was added and the reaction mixture was allowed to react at 50°C for 7 hours. 1N dilute hydrochloric acid was added to the reaction mixture to a pH of 5-6. The mixture was then extracted three times with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. Concentration afforded the crude product, Compound A2-5 (393 mg, 70%), as a white solid.
[0365] 1 H NMR (400MHz, DMSO-d6) δ7.36 (dd, J=8.2, 5.4Hz, 1H), 6.71 (dd, J=10.5, 8.3Hz, 1H), 4.55 (s, 2H) ,3.90(s,2H),2.87(s,2H),1.72(dd,J=12.6,3.7Hz,2H),1.64(d,J=12.8Hz,2H),1.41(s,9H).
[0366] LCMS(ESI):[M-Boc+H] + =252.27.
[0367] Step 5: (S)-7-((2,6-dioxopiperidin-3-yl)carbamoyl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A2-6)
[0368] Compound A2-5 (393 mg, 1.1 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (15 mL). (S)-3-aminopiperidine-2,6-dione hydrochloride (276 mg, 1.7 mmol, 1.5 eq), N,N-diisopropylethylamine (723 mg, 5.6 mmol, 5.0 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (512 mg, 1.3 mmol, 1.2 eq) were added with stirring at room temperature. The reaction was allowed to react at room temperature for 1 hour. The reaction system was quenched with water and extracted three times with ethyl acetate. The organic phase was washed four times with saturated sodium chloride solution. The organic phases were combined and dried over anhydrous sodium sulfate. The crude product was purified by column chromatography to obtain compound A2-6 (355.0 mg, 69%) as a white solid.
[0369] 1 H NMR (400MHz, DMSO-d6) δ10.83(s,1H),8.63(d,J=8.1Hz,1H),7.33(dd,J=8.2,5.4Hz,1H),6.72(dd,J=10.1,8.3Hz,1H),4.72(dd,J=17.4,8.1Hz,1H),4.5 5(s,2H),3.90(s,2H),2.88(s,2H),2.79–2.71(m,1H),2.56–2.51(m,1H),2. 04–1.96(m,2H),1.74(t,J=12.6Hz,2H),1.65(d,J=13.2Hz,2H),1.42(s,9H).
[0370] LCMS(ESI):[M-Boc+H] + =362.37.
[0371] Step 6: (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-7-carboxamide (Compound A2): Compound A2-6 (353 mg, 0.8 mmol, 1.0 eq) was dissolved in 18 mL of a 5:1 dichloromethane:trifluoroacetic acid ratio and allowed to react at room temperature for 1 hour. The reaction mixture was concentrated, and the crude product was purified by reverse-phase column chromatography to afford Compound A2 (257.0 mg, 93%) as a white solid.
[0372] 1 H NMR (400MHz, DMSO-d6) δ10.85(s,1H),8.66(d,J=8.1Hz,2H),8.44(d,J=9.4Hz,1H ),7.21(dd,J=8.3,5.3Hz,1H),6.79(dd,J=10.0,8.3Hz,1H),4.73(dd,J=17.4,8. 1Hz,1H),4.61(s,2H),3.33(d,J=13.0Hz,2H),3.00(dd,J=23.4,10.9Hz,2H),2.8 0–2.71(m,1H),2.54(t,J=3.7Hz,1H),2.03–1.93(m,4H),1.85(d,J=14.0Hz,2H).
[0373] LCMS(ESI):[M+H] + =362.25
[0374] Example 3
[0375] Synthesis of compound A3
[0376] (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxamide
[0377] Synthesis scheme
[0378] Step 1: Methyl 2-fluoro-4-hydroxybenzoate (Compound A3-2)
[0379] Compound A3-1 (5.0 g, 32.0 mmol, 1.0 eq) was dissolved in 80 mL of methanol. 6 mL of concentrated sulfuric acid was added dropwise to the reaction system. The reaction solution was heated to 70°C and allowed to react at this temperature for 24 hours. The resulting reaction system was concentrated under reduced pressure. The crude product was slurried with an appropriate amount of water and filtered to obtain white crystals of A3-2 (5.38 g, 99%).
[0380] LCMS(ESI):[MH] -=169.23.
[0381] Step 2: 2-Fluoro-4-hydroxy-5-iodobenzoic acid methyl ester (Compound A3-3)
[0382] Compound A3-2 (2.5 g, 14.7 mmol, 1.0 eq) and N-iodosuccinimide (3.47 g, 15.4 mmol, 1.04 eq) were dissolved in 70 mL of methanol and reacted at room temperature for 19 hours. The reaction solution was concentrated under reduced pressure and purified by reverse-phase column chromatography to yield compound A3-3 (566 mg, 13%) as a white solid.
[0383] 1 H NMR (400MHz, DMSO-d6) δ11.79(s,1H),8.16(d,J=8.3Hz,1H),6.73(d,J=12.6Hz,1H),3.80(s,3H).
[0384] LCMS(ESI):[MH] - =295.08.
[0385] Step 3: tert-Butyl 4-((5-fluoro-2-iodo-4-(methoxycarbonyl)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A3-4)
[0386] Compound A3-3 (566 mg, 1.9 mmol, 1.0 eq), A1-2 (734 mg, 3.4 mmol, 1.8 eq), and triphenylphosphine (1.5 g, 5.7 mmol, 3.0 eq) were dissolved in 30 mL of dry tetrahydrofuran. Diethyl azodicarboxylate (999 mg, 5.7 mmol, 3.0 eq) was slowly added dropwise at 0°C under nitrogen. After the addition was complete, the mixture was allowed to warm to room temperature and react for 10 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain A3-4 (876 mg, 93%) as a colorless, transparent oil.
[0387] 1 H NMR(600MHz,DMSO-d6)δ8.22(d,J=8.2Hz,1H),7.10(d,J=13.0Hz,1H),5.89(s,1H ),4.66(s,2H),3.88(s,2H),3.82(s,3H),3.46(s,2H),2.16(s,2H),1.41(s,9H).
[0388] LCMS(ESI):[M-Boc+H] + =392.19.
[0389] Step 4: 1'-(tert-Butyl)-5-methyl-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1',5-dicarboxylate (Compound A3-5): Compound A3-4 (876 mg, 1.8 mmol, 1.0 eq), tri-n-butyltin hydroxide (1.56 g, 5.4 mmol, 3.0 eq), and azobisisobutyronitrile (439 mg, 2.7 mmol, 1.5 eq) were dissolved in 30 mL of toluene and reacted at 110°C for 11 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and purified by column chromatography to obtain A3-5 (569 mg, 87%) as a colorless, transparent oil. 1 H NMR (400MHz, DMSO-d6) δ7.73(d,J=7.4Hz,1H),6.84(d,J=11.6Hz,1H),4.61(s,2H),3.92(s,2H ),3.80(s,3H),2.86(s,2H),1.77(td,J=12.9,4.4Hz,2H),1.66(d,J=13.0Hz,2H),1.43(s,9H).
[0390] Step 5: 1'-(tert-Butoxycarbonyl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxylic acid (Compound A3-6)
[0391] Compound A3-5 (569 mg, 1.6 mmol, 1.0 eq) was dissolved in 25 mL of a mixture of tetrahydrofuran and water (v / v = 4 / 1). Lithium hydroxide monohydrate (327 mg, 7.8 mmol, 5.0 eq) was added and the reaction was incubated at 50°C for 7 hours. The reaction solution was concentrated under reduced pressure and then diluted with 50 mL of water. The pH was adjusted to 5-6 with 1 M HCl. The resulting aqueous solution was extracted three times with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to yield a pale yellow solid crude product A3-6 (617 mg). This crude product was directly used in the next reaction without further purification.
[0392] 1 H NMR(600MHz,Methanol-d4)δ7.68(d,J=7.2Hz,1H),6.56(d,J=11.2Hz,1H),4.57(s,2H),4. 03(d,J=13.8Hz,2H),3.01(s,2H),1.84–1.78(m,2H),1.74(d,J=13.0Hz,2H),1.49(s,9H).
[0393] LCMS(ESI):[MH] - =350.38.
[0394] Step 6: (S)-5-((2,6-dioxopiperidin-3-yl)carbamoyl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A3-7)
[0395] Compound A3-6 (617 mg, 1.7 mmol, 1.0 eq), (S)-3-amino-2,6-piperidinedione hydrochloride (434 mg, 2.6 mmol, 1.5 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (801 mg, 2.1 mmol, 1.2 eq) were dissolved in N,N-dimethylformamide (20 mL). N,N-diisopropylethylamine (1.53 mL, 8.8 mmol, 5.0 eq) was added and the reaction mixture was allowed to react at room temperature for 15 hours. The reaction mixture was diluted with 100 mL of ethyl acetate and washed five times with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by column chromatography to afford A3-7 (630 mg, 78%) as a light blue solid.
[0396] 1 H NMR(400MHz, DMSO-d6)δ10.86(s,1H),8.29(dd,J=7.9,3.9Hz,1H),7.56(d,J=7.5 Hz,1H),6.81(d,J=11.5Hz,1H),4.80–4.70(m,1H),4.58(s,2H),3.92(s,2H),2.8 9(s,2H),2.77–2.73(m,1H),2.56–2.52(m,1H),2.10(tt,J=12.8,6.5Hz,1H),2.0 4–2.00(m,1H),1.76(td,J=12.9,4.3Hz,2H),1.67(d,J=13.0Hz,2H),1.43(s,9H).
[0397] LCMS(ESI):[MH] - =460.39.
[0398] Step 7: (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxamide (Compound A3): Compound A3-7 (625 mg, 1.4 mmol, 1.0 eq) was dissolved in 10 mL of dichloromethane, and 2.5 mL of trifluoroacetic acid was added. The reaction was allowed to react at room temperature for 12 hours. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by reverse-phase column chromatography to afford Compound 3 (65.3 mg, 13%) as a white solid.
[0399] 1H NMR(400MHz,DMSO-d6)δ10.87(s,1H),8.75(s,1H),8.34(dd,J=8.0,4.8Hz,1H ),7.50(d,J=7.4Hz,1H),6.88(d,J=11.5Hz,1H),4.80–4.72(m,1H),4.65(s,2H ),3.35(s,2H),3.01(s,2H),2.79(ddd,J=18.6,13.5,5.5Hz,1H),2.56–2.52(m ,1H),2.12(qd,J=12.9,4.4Hz,1H),2.06–1.98(m,3H),1.88(d,J=14.1Hz,2H).
[0400] LCMS(ESI):[M+H] + =362.39
[0401] Example 4
[0402] Synthesis of compound A4
[0403] (S)-N-(2,6-dioxopiperidin-3-yl)-5-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide
[0404] Synthesis scheme
[0405] Step 1: Methyl 2-fluoro-5-hydroxybenzoate (Compound A4-2)
[0406] Compound A4-1 (1.0 g, 6.4 mmol, 1.0 eq) was dissolved in 15 mL of methanol. 1 mL of concentrated sulfuric acid was added dropwise to the reaction system. The reaction solution was heated to 70°C and allowed to react at this temperature for 17 hours. The reaction system was concentrated under reduced pressure, and the crude product was purified by column chromatography to afford A4-2 (992 mg, 91%) as a white solid.
[0407] LCMS(ESI):[MH] - =169.33.
[0408] Step 2: Methyl 2-fluoro-5-hydroxy-4-iodobenzoate (Compound A4-3)
[0409] Compound A4-2 (955 mg, 5.6 mmol, 1.0 eq) and N-iodosuccinimide (1.33 g, 5.9 mmol, 1.05 eq) were dissolved in 30 mL of methanol and reacted at room temperature for 7 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain compound A4-3 (205 mg, 12%) as a light yellow solid.
[0410] 1 H NMR (400MHz, DMSO-d6) δ10.66(s,1H),7.73(d,J=10.0Hz,1H),7.31(d,J=6.3Hz,1H),3.83(s,3H).
[0411] LCMS(ESI):[MH] - =294.98.
[0412] Step 3: tert-Butyl 4-((4-fluoro-2-iodo-5-(methoxycarbonyl)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A4-4)
[0413] Compound A4-3 (155 mg, 0.5 mmol, 1.0 eq), A1-2 (134 mg, 0.3 mmol, 0.6 eq), and triphenylphosphine (274 mg, 1.0 mmol, 2.0 eq) were dissolved in 15 mL of dry tetrahydrofuran. Diethyl azodicarboxylate (182 mg, 1.0 mmol, 2.0 eq) was slowly added dropwise at 0°C under nitrogen. After the addition was complete, the mixture was allowed to warm to room temperature and react for 10 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to obtain A4-4 (133 mg, 52%) as a colorless, transparent oil.
[0414] 1 H NMR(400MHz, Methanol-d4)δ7.69(d,J=9.6Hz,1H),7.36(d,J=6.0Hz,1H),5.91(s,1H),4.55 (s,2H),3.95(s,2H),3.90(s,3H),3.56(t,J=5.4Hz,2H),2.26(d,J=1.6Hz,2H),1.47(s,9H).
[0415] LCMS(ESI):[M-Boc+H] + =392.19.
[0416] Step 4: 1'-(tert-Butoxycarbonyl)-5-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxylic acid (Compound A4-5)
[0417] Compound A4-4 (183 mg, 0.4 mmol, 1.0 eq), tri-n-butyltin hydroxide (325 mg, 1.1 mmol, 2.75 eq), and azobisisobutyronitrile (92 mg, 0.6 mmol, 1.5 eq) were dissolved in 6 mL of toluene and reacted at 110°C for 11 hours. The reaction solution was concentrated under reduced pressure and then diluted with 50 mL of water. The pH was adjusted to 5-6 with 1N hydrochloric acid. The resulting aqueous solution was extracted three times with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to obtain A4-5 (172.3 mg) as a light yellow oil. The crude product was directly used in the next reaction without further purification.
[0418] 1 H NMR (600MHz, DMSO-d6) δ7.13(d,J=9.8Hz,1H),6.95(d,J=5.6Hz,1H),4.44(s,2H),3.90( s,2H),2.96–2.77(m,2H),1.75(td,J=13.0,4.4Hz,2H),1.69–1.63(m,2H),1.42(s,9H).
[0419] LCMS(ESI):[M-Boc+H] + =252.27.
[0420] Step 5: (S)-6-((2,6-dioxopiperidin-3-yl)carbamoyl)-5-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A4-6)
[0421] Compound A4-5 (172 mg, 0.5 mmol, 1.0 eq), (S)-3-amino-2,6-piperidinedione hydrochloride (121 mg, 0.7 mmol, 1.4 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (224 mg, 0.6 mmol, 1.2 eq) were dissolved in 6 mL of N,N-dimethylformamide. N,N-diisopropylethylamine (0.43 mL, 2.5 mmol, 5.0 eq) was added and the reaction was allowed to proceed at room temperature for 12 hours. The reaction solution was diluted with 50 mL of ethyl acetate and washed five times with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by column chromatography to afford A4-6 (74 mg, 33%) as a light blue solid.
[0422] 1H NMR (600MHz, DMSO-d6) δ10.85(s,1H),8.46(dd,J=8.1,3.3Hz,1H),7.34(d,J=1 0.0Hz,1H),6.97(d,J=5.4Hz,1H),4.79–4.68(m,1H),4.50(s,2H),3.92(d,J=12 .0Hz,2H),2.89(s,2H),2.83–2.70(m,1H),2.55(t,J=3.3Hz,1H),2.14–2.01(m ,2H),1.85(ddd,J=48.3,16.6,4.1Hz,2H),1.66(d,J=13.0Hz,2H),1.43(s,9H).
[0423] LCMS(ESI):[MH] - =459.79.
[0424] Step 6: (S)-N-(2,6-dioxopiperidin-3-yl)-5-fluoro-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide (Compound A4): Compound A4-6 (74 mg, 0.16 mmol, 1.0 eq) was dissolved in 3.0 mL of dichloromethane. 1 mL of trifluoroacetic acid was added and the reaction was allowed to proceed at room temperature for 4 hours. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by reverse-phase column chromatography to afford A4 (33.8 mg, 58%) as a white solid.
[0425] 1 H NMR (400MHz, DMSO-d6) δ10.87(s,1H),8.49(dd,J=8.0,2.3Hz,1H),7.19(d,J =9.5Hz,1H),7.00(d,J=5.3Hz,1H),4.76–4.70(m,1H),4.54(s,2H),3.25(d, J=11.8Hz,2H),2.94–2.88(m,2H),2.82–2.73(m,1H),2.57–2.52(m,1H),2.0 8(ddd,J=25.6,12.8,4.4Hz,1H),2.03–1.90(m,3H),1.81(d,J=13.0Hz,2H).
[0426] LCMS(ESI):[M+H] + =362.29.
[0427] Example 5
[0428] Synthesis of compound A5
[0429] (S)-N-(2,6-dioxopiperidin-3-yl)-7-fluorospiro[2,4'-piperidine]-6-carboxamide
[0430] Synthesis scheme
[0431] Step 1: tert-Butyl 6-bromo-7-fluoro-4-oxospiro[thia-2,4'-piperidine]-1'-carboxylate (Compound A5-2)
[0432] Compound A5-1 (10.0 g, 42.9 mmol, 1.0 eq) was dissolved in methanol (100 mL), and N-tert-butyloxycarbonyl-4-piperidone (8.6 g, 42.9 mmol, 1.0 eq) and tetrahydropyrrole (3.1 g, 42.9 mmol, 1.0 eq) were added to the reaction system. The mixture was reacted at room temperature for 2 hours. The reaction system was concentrated under reduced pressure, and the crude product obtained was purified by column chromatography to obtain a light yellow solid compound A5-2 (15.8 g, 88.8%).
[0433] 1 H NMR (600MHz, DMSO-d6) δ7.94(dt,J=8.0,1.7Hz,1H),7.23(dt,J=9.9,2.3Hz,1H),3.72(d,J=13.1Hz ,2H),3.19–3.09(m,2H),2.88(s,2H),1.90–1.87(m,2H),1.69–1.58(m,2H),1.40(d,J=1.6Hz,9H).
[0434] LCMS(ESI):[M-Boc+H] + =316.18
[0435] Step 2: tert-Butyl 6-bromo-7-fluoro-4-hydroxyspiro[chromo-2,4'-piperidine]-1'-carboxylate (Compound A5-3)
[0436] Compound A5-2 (13.2 g, 31.9 mmol, 1.0 eq) was dissolved in methanol (150 mL), cooled to 0°C, and sodium borohydride (1.5 g, 38.2 mmol, 1.2 eq) was slowly added. After the addition was complete, the mixture was returned to room temperature and reacted for 2 hours. Water was added to the reaction solution, and the reaction solution was concentrated under reduced pressure, extracted three times with ethyl acetate, washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was concentrated to obtain a crude product A5-3 (13.0 g). The crude product was directly subjected to the next reaction without further purification.
[0437] LCMS(ESI):[M-Boc+H] + =316.28
[0438] Step 3: 6-bromo-7-fluorospiro[dichloro-2,4'-piperidine] (Compound A5-4)
[0439] Compound A5-3 (13.0 g, 31.2 mmol, 1.0 eq) was dissolved in toluene (150 mL), and p-toluenesulfonic acid (6.5 g, 34.4 mmol, 1.1 eq) was added. The reaction system was heated to 110°C and reacted for 12 hours. After cooling the reaction system to room temperature, it was concentrated under reduced pressure to obtain the crude product A5-4 (11.0 g). This crude product was directly used in the next reaction without further purification.
[0440] LCMS(ESI):[M+H] + =298.18.
[0441] Step 4: tert-Butyl 6-bromo-7-fluorospiro[stilbene-2,4'-piperidine]-1'-carboxylate (Compound A5-5)
[0442] Compound A5-4 (11.0 g, 34.8 mmol, 1.0 eq) was dissolved in dichloromethane (150 mL). Di-tert-butyl dicarbonate (9.1 g, 41.8 mmol, 1.2 eq) and triethylamine (10.6 g, 104.4 mmol, 3.0 eq) were added to the reaction system. The reaction solution was reacted at room temperature for 2 hours. The resulting reaction system was concentrated under reduced pressure, and the crude product was purified by reverse-phase column chromatography to obtain compound A5-5 (10.0 g, 72.2%) as a yellow oil.
[0443] 1 H NMR (600MHz, DMSO-d6) δ7.45(d,J=8.0Hz,1H),6.95(d,J=9.8Hz,1H),6.48(d,J=9.9Hz,1H),5.81(d,J=9.9Hz,1 H),3.69(d,J=13.0Hz,2H),3.19(brs,2H),1.92–1.73(m,2H),1.63(ddd,J=13.7,11.3,4.7Hz,2H),1.40(s,9H).
[0444] LCMS(ESI):[M-Boc+H] + =298.08
[0445] Step 5: 1'-tert-butyl-6-methyl-7-fluorospiro[stilbene-2,4'-piperidine]-1',6-dicarboxylate (Compound A5-6)
[0446] Compound A5-5 (10.0 g, 25.1 mmol, 1.0 eq) was dissolved in methanol (150 mL), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (2.7 g, 3.8 mmol, 0.15 eq) and triethylamine (7.6 g, 75.3 mmol, 3.0 eq) were added. After three carbon monoxide replacements, the reaction system was heated to 110°C and reacted for 12 hours. After cooling to room temperature, the reaction system was filtered, and the filter cake was washed three times with methanol (30 mL). The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain compound A5-6 (7.6 g, 80.2%) as a clear oil.
[0447] 1 H NMR (400MHz, DMSO-d6) δ7.67(d,J=8.3Hz,1H),6.84(d,J=12.1Hz,1H),6.58(d,J=10.0Hz,1H),5.83(d,J=9. 9Hz,1H),3.81(s,3H),3.75–3.63(m,2H),3.22(brs,2H),1.86–1.74(m,2H),1.70–1.53(m,2H),1.41(s,9H).
[0448] LCMS(ESI):[M-Boc+H] + =278.25
[0449] Step 6: 1'-tert-butyl-6-methyl-7-fluorospiro[chromato-2,4'-piperidine]-1',6-dicarboxylate (Compound A5-7)
[0450] Compound A5-6 (7.5 g, 19.9 mmol, 1.0 eq) was dissolved in methanol (100 mL), and palladium on carbon (394 mg) was added. After hydrogen substitution three times, the reaction was allowed to proceed at room temperature for 12 hours. The reaction system was filtered, and the filter cake was washed three times with methanol. The filtrate was concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography to afford compound A5-7 (6.7 g, 88.9%) as a clear oil.
[0451] 1 H NMR (600MHz, DMSO-d6) δ7.67(d,J=8.3Hz,1H),6.74(d,J=12.2Hz,1H),3.80(s,3H),3.70(d,J=13.0Hz,2H),3. 13(brs,2H),2.75(t,J=6.8Hz,2H),1.83(t,J=6.8Hz,2H),1.71–1.62(m,2H),1.59–1.54(m,2H),1.41(s,9H).
[0452] LCMS(ESI):[M-Boc+H] + =280.28
[0453] Step 7: 1'-tert-butyl-6-methyl-7-fluorospiro[chromato-2,4'-piperidine]-1',6-dicarboxylate (Compound A5-8)
[0454] Compound A5-7 (6.6 g, 17.4 mmol, 1.0 eq) was dissolved in tetrahydrofuran (60 mL). Lithium hydroxide (3.65 g, 86.9 mmol, 5.0 eq) and water (60 mL) were added to the reaction mixture and allowed to react at room temperature for 10 hours. 1N hydrochloric acid was added to the reaction mixture to adjust the pH to 5. The mixture was extracted three times with ethyl acetate, washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to yield the crude product, Compound A5-8 (6.0 g, 94.4%), as a white solid. This crude product was carried on to the next step without further purification.
[0455] LCMS(ESI):[M-Boc+H] + =266.27
[0456] Step 8: (S)-6-(2,6-dioxopiperidin-3-yl)carbamoyl)-7-fluorospiro[chromato-2,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A5-9)
[0457] Compound A5-8 (6.0 g, 16.4 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (60 mL). (S)-3-amino-3-methylpiperidine-2,6-dione hydrochloride (4.1 g, 22.9 mmol, 1.4 eq), N,N-diisopropylethylamine (8.5 g, 65.7 mmol, 4.0 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (7.5 g, 19.7 mmol, 1.5 eq) were added sequentially to the reaction mixture. The mixture was allowed to react at room temperature for 2 hours. Water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by reverse-phase column chromatography to obtain Compound A5-9 (7.0 g, 89.7%) as a blue solid.
[0458] 1H NMR(600MHz,DMSO-d6)δ10.85(s,1H),8.24(dd,J=8.1,4.8Hz,1H),7.96(s,1H),7.52(d,J=8.5Hz, 1H),6.73(d,J=12.2Hz,1H),4.75(ddd,J=12.9,8.0,5.4Hz,1H),3.71(d,J=13.2Hz,2H),3.15(dd, J=7.2,4.2Hz,2H),2.82–2.74(m,3H),2.11(qd,J=12.9,4.5Hz,1H),2.01(ddt,J=12.4,5.5,2.8Hz ,1H),1.83(t,J=6.8Hz,2H),1.74–1.62(m,2H),1.56(ddt,J=13.7,11.3,4.6Hz,2H),1.41(s,9H).
[0459] LCMS(ESI):[M-Boc+H] + =376.29
[0460] Step 9: (S)-N-(2,6-dioxopiperidin-3-yl)-7-fluorospiro[2,4'-piperidine]-6-carboxamide (Compound A5)
[0461] Compound A5-9 (7.0 g, 14.7 mmol, 1.0 eq) was added to a dioxane hydrochloride solution (50 mL) and reacted at room temperature for 10 hours. The reaction solution was filtered and the filter cake was air-dried to obtain a white solid compound A5 (5.0 g, 82.5%).
[0462] 1 H NMR(600MHz,DMSO-d6)δ10.85(s,1H),9.03–9.00(m,1H),8.28(dd,J=8.1,4.5Hz,1H),7.53 (d,J=8.4Hz,1H),6.81(d,J=12.1Hz,1H),4.74(ddd,J=12.8,8.0,5.3Hz,1H),3.20(dt,J=1 3.2,3.5Hz,2H),3.08(dq,J=15.9,7.0,3.9Hz,2H),2.84–2.72(m,3H),2.54(q,J=3.2,2.7H z,1H),2.11(qd,J=12.9,4.5Hz,1H),2.00(dtd,J=13.0,5.5,2.7Hz,1H),1.95–1.82(m,6H).
[0463] LCMS(ESI):[M+H] + =376.30
[0464] Example 6
[0465] Synthesis of compound A6
[0466] (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluorospiro[chroman-2,4'-piperidine]-7-carboxamide
[0467] Synthesis scheme
[0468] Step 1: 1-(4-bromo-5-fluoro-2-hydroxyphenyl)ethan-1-one (Compound A6-2)
[0469] Compound A6-1 (20.0 g, 104.7 mmol, 1.0 eq) was dissolved in acetyl chloride (41.4 g, 523.6 mmol, 5.0 eq). The reaction mixture was heated to 60°C and allowed to react for 1.5 hours. The reaction mixture was cooled to 0°C and aluminum chloride (21 g, 157.1 mmol, 1.5 eq) was added. The reaction mixture was heated to 120°C and allowed to react for 4 hours. After cooling the reaction mixture to room temperature, it was added to water and extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phases was purified by column chromatography to obtain Compound A6-2 (20.0 g, 91.9%) as a yellow solid.
[0470] 1 H NMR (600MHz, Chloroform-d) δ12.02 (d, J = 1.2Hz, 1H), 7.48–7.42 (m, 1H), 7.25–7.20 (m, 1H), 2.65–2.59 (m, 3H).
[0471] LCMS(ESI):[M+Na] + =255.27.
[0472] Step 2: tert-Butyl 7-bromo-6-fluoro-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound A6-3)
[0473] Compound A6-2 (10 g, 42.9 mmol, 1.0 eq), tert-butyl 4-oxopiperidine-1-carboxylate (8.55 g, 42.9 mmol, 1.0 eq), and tetrahydropyrrole (3.05 g, 42.9 mmol, 1.0 eq) were dissolved in methanol (150 mL) and the mixture was heated to 50°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by column chromatography to obtain compound A6-3 (14.0 g, 78.75%) as a yellow solid.
[0474] 1 H NMR(400MHz,Chloroform-d)δ7.58(d,J=7.9Hz,1H),7.29(d,J=5.4Hz,1H),3.90(s,2H),3. 17–3.12(t,J=12.4Hz,2H),2.73(s,2H),2.09–1.97(m,2H),1.69–1.57(m,2H),1.48(s,9H).
[0475] LCMS(ESI):[M-Boc+H] + =314.08.
[0476] Step 3: tert-Butyl 7-bromo-6-fluoro-4-hydroxyspiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound A6-4)
[0477] Dissolve compound A6-3 (400 mg, 1.0 mmol, 1.0 eq) in methanol (4 mL). Cool the reaction system to 0°C and add sodium borohydride (54 mg, 1.5 mmol, 1.5 eq). Allow the reaction to proceed overnight at room temperature. Concentrate under reduced pressure, add water, and extract three times with ethyl acetate. Wash with saturated brine, combine the organic phases, and dry over anhydrous sodium sulfate. Concentrate the organic phase to obtain the crude product, compound A6-4, as a white solid.
[0478] LCMS(ESI):[M-Boc+H] + =316.18.
[0479] Step 4: 7-Bromo-6-fluorospiro[diphenyl-2,4'-piperidine] (Compound A6-5)
[0480] Compound A6-4 (45.0 g, 108.1 mmol, 1.0 eq) and p-toluenesulfonic acid (20.5 g, 118.9 mmol, 1.1 eq) were dissolved in toluene (400 mL) and the mixture was heated to 110°C and reacted overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain crude compound A6-5 (5.0 g).
[0481] LCMS(ESI):[M+H] + =298.18.
[0482] Step 5: tert-Butyl 7-bromo-6-fluorospiro[stilbene-2,4'-piperidine]-1'-carboxylate (Compound A6-6)
[0483] Compound A6-5 (5.0 g, 16.7 mmol, 1.0 eq) was dissolved in dichloromethane (50 mL). The reaction system was cooled to 0°C and triethylamine (5.06 g, 50.0 mmol, 3.0 eq) and di-tert-butyl dicarbonate (4.36 g, 20.0 mmol, 1.2 eq) were added. The reaction was allowed to react overnight at room temperature. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound A6-6 (1.8 g, 27.0%) as a white solid.
[0484] LCMS(ESI):[M-Boc+H] + =300.18.
[0485] Step 6: 1'-tert-butyl-7-methyl-6-fluorospiro[stilbene-2,4'-piperidine]-1',7-dicarboxylate (Compound A6-7)
[0486] Compound A6-6 (1.8 g, 4.5 mmol, 1.0 eq), 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (493 mg, 0.7 mmol, 0.15 eq), and triethylamine (1.37 g, 13.5 mmol, 3.0 eq) were dissolved in methanol (30 mL). After carbon monoxide was replaced three times, the system was heated to 70°C and reacted overnight. After cooling the reaction system to room temperature, it was concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain Compound A6-7 (900 mg, 52.75%) as a yellow oil.
[0487] 1 H NMR(600MHz,Chloroform-d)δ7.35–7.40(m,1H),6.75–6.81(m,1H),6.40–6.34(m,1H),5.77–5.71(m ,1H),3.93–3.91(m,5H),3.32–3.28(m,2H),1.98(d,J=13.8Hz,2H),1.66–1.60(m,2H),1.49(s,9H).
[0488] LCMS(ESI):[M-Boc+H] + =278.18.
[0489] Step 7: 1'-tert-butyl-7-methyl-6-fluorospiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A6-8)
[0490] Compound A6-7 (4.1 g, 10.9 mmol, 1.0 eq) was dissolved in methanol (40 mL) and palladium on carbon (900 mg) was added. The mixture was purged with hydrogen three times and allowed to react at room temperature for 12 hours. The reaction mixture was filtered, and the filter cake was washed three times with methanol (10 mL). The mixture was concentrated under reduced pressure to give a crude product, compound A6-8 (4 g).
[0491] 1 H NMR(600MHz,Chloroform-d)δ7.39(d,J=6.2Hz,1H),6.85(d,J=10.7Hz,1H),3.91(s,4H),3.20(s, 2H),2.85–2.77(m,2H),1.86–1.70(m,5H),1.58–1.50(m,2H),1.48(s,9H).LCMS(ESI):[M-Boc+H] + =280.38.
[0492] Step 8: 1-tert-Butyloxycarbonyl-6-fluorospiro[chroman-2,4'-piperidine]-7-carboxylic acid (Compound A6-9)
[0493] Compound A6-8 (800 mg, 2.1 mmol, 1.0 eq) and lithium hydroxide monohydrate (442 mg, 10.5 mmol, 5.0 eq) were dissolved in methanol (10 mL), tetrahydrofuran (2 mL), and water (2 mL). The system was allowed to react overnight at room temperature. After concentration under reduced pressure, water was added and the mixture was extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain the crude product, Compound A6-9 (770 mg), as a white solid.
[0494] LCMS(ESI):[M-Boc+H] + =266.27.
[0495] Step 9: (S)-7-(2,6-dioxopiperidin-3-yl)carbamoyl)-6-fluorospiro[chroman-2,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A6-10)
[0496] Compound A6-9 (770 mg, 3.1 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (451 mg, 2.5 mmol, 0.8 eq), and N,N-diisopropylethylamine (462 mg, 6.3 mmol, 2.0 eq) were dissolved in N,N-dimethylformamide (10 mL). The reaction mixture was allowed to react at room temperature for 15 minutes. (S)-3-Aminopiperidine-2,6-dione hydrochloride (881 mg, 2.3 mmol, 0.7 eq) was added. The reaction mixture was allowed to react overnight at room temperature, then added to water and extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phases was purified by column chromatography to obtain Compound A6-10 (850 mg, 84.83%) as a blue solid.
[0497] LCMS(ESI):[M-Boc+H] + =376.49.
[0498] Step 10: (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluorospiro[chroman-2,4'-piperidine]-7-carboxamide (Compound A6)
[0499] Compound A6-10 (3.0 g, 6.3 mmol, 1.0 eq) was dissolved in 1,4-dioxane hydrochloric acid solution (10 mL). The reaction mixture was allowed to react at room temperature overnight. The reaction mixture was filtered, and the filter cake was washed three times with acetonitrile (10 mL) to obtain Compound A6 (1.75 g, 73.89%) as a white solid.
[0500] 1 H NMR(600MHz,DMSO-d6)δ10.86(s,1H),8.52–8.40(m,1H),7.16–7.12(m,1H),7.11–7.07(m,1H),4.78–4.70(m,1H),3.20–3.12(m,2H), 3.11–3.04(m,2H),2.83–2.72(m,3H),2.57–2.51(m,1H),2.16–2.05(m,1H),2.03–1.96(m,1H),1.94–1.86(m,5H),1.85–1.80(m,2H).
[0501] LCMS(ESI):[M+H] + =376.39.
[0502] Example 7
[0503] Synthesis of compound A7
[0504] (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluorospiro-azetidine-3,2-dihydropyridine-7-carboxamide
[0505] Synthesis scheme
[0506] Step 1: tert-Butyl 7'-bromo-6'-fluoro-4'-oxospiro[azetidine-3,2'-chroman]-1-carboxylate (Compound A7-1)
[0507] Compound A6-2 (10.0 g, 42.9 mmol, 1.0 eq), tert-butyl 3-oxoazetidine-1-carboxylate (7.35 g, 42.9 mmol, 1.0 eq), and tetrahydropyrrole (3.05 g, 42.9 mmol, 1.0 eq) were dissolved in methanol (150 mL) and the mixture was heated to 70°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain Compound A7-1 (8.0 g, 48.27%) as a yellow solid.
[0508] 1 H NMR (400MHz, Chloroform-d) δ7.59(d,J=7.8Hz,1H),7.36(d,J=5.3Hz,1H),4.08(d,J=9.6Hz,2H),3.97(d,J=9.6Hz,2H),3.05(s,2H),1.46(s,9H).
[0509] LCMS(ESI):[M-Boc+H] + =286.08.
[0510] Step 2: tert-Butyl 7'-bromo-6'-fluoro-4'-hydroxyspiro[azetidine-3,2'-chroman]-1-carboxylate (Compound A7-2)
[0511] Compound A7-1 (5.0 g, 12.1 mmol, 1.0 eq) was dissolved in methanol (50 mL). The reaction system was cooled to 0°C and sodium borohydride (654 mg, 18.1 mmol, 1.5 eq) was added. The reaction was allowed to react overnight at room temperature. After concentration under reduced pressure, water was added and the mixture was extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain the crude product, Compound A7-2 (4.5 g), as a white solid.
[0512] LCMS(ESI):[M-Boc+H] + =288.28.
[0513] Step 3: 7-bromo-6-fluorospiro[azetidine-3,2'-stilbene] (Compound A7-3)
[0514] Compound A7-2 (4.5 g, 10.8 mmol, 1.0 eq) and p-toluenesulfonic acid (2.05 g, 11.9 mmol, 1.1 eq) were dissolved in toluene (40 mL) and the mixture was heated to 110°C and reacted overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain crude compound A7-3 (4.0 g).
[0515] LCMS(ESI):[M+H] + =270.17.
[0516] Step 4: tert-Butyl 7'-bromo-6'-fluorospiro[azetidine-3,2'-benzopyridine]-1-carboxylate (Compound A7-4)
[0517] Compound A7-3 (4.0 g, 13.3 mmol, 1.0 eq) was dissolved in dichloromethane (40 mL). The reaction system was cooled to 0°C and triethylamine (4.05 g, 39.9 mmol, 3.0 eq) and di-tert-butyl dicarbonate (3.49 g, 16.0 mmol, 1.2 eq) were added. The reaction was allowed to react overnight at room temperature. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound A7-4 (2.7 g, 69.36%) as a white solid.
[0518] LCMS(ESI):[M-Boc+H] + =270.17.
[0519] Step 5: 1-tert-Butyl 7'-methyl-6-fluorospiro[azetidine-3,2'-dimethylbenzene]-1,7'-dicarboxylate (Compound A7-5): Compound A7-4 (3.7 g, 9.2 mmol, 1.0 eq), 1,1-bis(diphenylphosphino)dibenzoylmethanepalladium chloride (1.01 g, 1.4 mmol, 0.15 eq), and triethylamine (2.81 g, 27.7 mmol, 3.0 eq) were dissolved in methanol (40 mL). After carbon monoxide was replaced three times, the reaction mixture was heated to 70°C and allowed to react overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain Compound A7-5 (1.8 g, 51.32%) as a yellow oil.
[0520] 1H NMR(600MHz,Chloroform-d)δ7.42–7.38(m,1H),6.79(d,J=10.2Hz,1H),6.45(d,J=9.8Hz, 1H), 6.13 (d, J = 9.8Hz, 1H), 4.26–4.21 (m, 2H), 4.03–3.98 (m, 2H), 3.92 (s, 3H), 1.47 (s, 9H).
[0521] LCMS(ESI):[M-tBu+H] + =294.28.
[0522] Step 6: 1-tert-butyl-7'-methyl-6'-fluorospiro[azetidine-3,2'-chromocyclic]-1,7'-dicarboxylate (Compound A7-6) Compound A7-5 (1.8 g, 4.8 mmol, 1.0 eq) was dissolved in methanol (20 mL) and palladium carbon (360 mg) was added to the system. After hydrogen replacement 3 times, the reaction was carried out at room temperature for 12 hours. The reaction system was filtered, the filter cake was washed three times with methanol (10 mL), and concentrated under reduced pressure to obtain crude compound A7-6 (1.8 g).
[0523] 1 H NMR(600MHz,Chloroform-d)δ7.42(d,J=6.2Hz,1H),6.91–6.80(m,1H),4.04(d,J= 9.4Hz,2H),3.96–3.95(m,5H),2.90–2.82(m,2H),2.18–2.09(m,2H),1.47(s,9H).
[0524] LCMS(ESI):[M-Boc+H] + =252.37.
[0525] Step 7: 1-tert-Butyloxycarbonyl-6'-fluorospiro[azetidine-3,2'-chromohydro]-7'-carboxylic acid (Compound A7-7)
[0526] Compound A7-6 (1.8 g, 4.7 mmol, 1.0 eq) and lithium hydroxide monohydrate (995 mg, 23.7 mmol, 5.0 eq) were dissolved in methanol (20 mL) and water (4 mL). The system was reacted at room temperature overnight, concentrated under reduced pressure, and then water was added. The mixture was extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain the crude product, Compound A7-7 (1.7 g), as a white solid.
[0527] 1H NMR(600MHz,Chloroform-d)δ7.49(d,J=6.3Hz,1H),6.87(d,J=10.6Hz,1H),4.05(d,J=9 .3Hz,2H),3.91(d,J=9.3Hz,2H),2.91–2.81(m,2H),2.14(d,J=7.0Hz,2H),1.47(s,9H).
[0528] LCMS(ESI):[M-Boc+H] + =238.26.
[0529] Step 8: (S)-7'-((2,6-dioxopiperidin-3-yl)carbamoyl)-6-fluorospiro[azetidine-3,2'-chrometidine]-1-carboxylic acid tert-butyl ester (Compound A7-8)
[0530] Compound A7-7 (1.7 g, 4.7 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.95 g, 5.1 mmol, 1.1 eq), and N,N-diisopropylethylamine (1.02 g, 14.0 mmol, 3.0 eq) were dissolved in N,N-dimethylformamide (10 mL). The reaction mixture was allowed to react at room temperature for 15 minutes. (S)-3-Aminopiperidine-2,6-dione hydrochloride (997 mg, 5.6 mmol, 1.2 eq) was added. The reaction mixture was allowed to react overnight at room temperature, then added to water and extracted three times with ethyl acetate. The mixture was washed with saturated brine (20 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phases was purified by column chromatography to obtain Compound A7-8 (1.5 g, 67.80%) as a blue solid.
[0531] 1 H NMR(600MHz,Chloroform-d)δ10.86(s,1H),8.48–8.42(m,1H),7.96(s,1H),7.12–7.07(m,2H),4.78–4.69(m,1H),3.97–3. 92(m,2H),3.83(d,J=9.2Hz,2H),2.75–2.86(m,2H),2.57–2.50(m,1H),2.14–2.04(m,3H),2.04–1.97(m,1H),1.40(s,9H).
[0532] LCMS(ESI):[M-Boc+H] + =348.39.
[0533] Step 9: (S)-N-(2,6-dioxopiperidin-3-yl)-6-fluorospiro-azetidine-3,2-dihydropyridine-7-carboxamide (Compound A7)
[0534] Compound A7-8 (50 mg, 0.1 mmol, 1.0 eq) was dissolved in 1,4-dioxane hydrochloric acid (2 mL, 4 N). The reaction mixture was allowed to react overnight at room temperature. The reaction mixture was filtered, and the filter cake was washed three times with acetonitrile (2 mL) to obtain Compound A7 (13.0 mg, 33.49%) as a white solid.
[0535] 1 H NMR(600MHz,DMSO-d6)δ10.87(s,1H),9.64(brs,1H),8.52–8.46(m,1H),7.16–7.10(m,2H),4.79–4.69(m,1H),4.06(d,J=11.4Hz,2H),4.0 2(d,J=11.3Hz,2H),2.88–2.82(m,2H),2.82–2.73(m,1H),2.57–2.50(m,1H),2.21(t,J=6.5Hz,2H),2.15–2.05(m,1H),2.03–1.96(m,1H).
[0536] LCMS(ESI):[M+H] + =348.39.
[0537] Example 8
[0538] Synthesis of compound A8
[0539] (S)-N-(2,6-dioxohesperidin-3-yl)-7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide
[0540] Synthesis scheme
[0541] Step 1: tert-Butyl 4-((2-bromo-6-methoxyphenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A8-2) Compound A8-1 (3.0 g, 14.78 mmol, 1.0 eq), A1-2 (3.78 g, 17.73 mmol, 1.2 eq), and triphenylphosphine (7.75 g, 29.55 mmol, 2 eq) were dissolved in tetrahydrofuran (60 mL). The temperature was cooled to 0°C and diethyl azodicarboxylate (5.56 g, 28.38 mmol, 2.5 eq) was added. After the addition was complete, the mixture was returned to room temperature and reacted for 12 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added to the system. The mixture was extracted with ethyl acetate (100 mL*3 times), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by reverse phase column chromatography to obtain white solid compound A8-2 (5.50 g, 93.46%).
[0542] LCMS(ESI):[M-Boc+H] + =298.38.
[0543] Step 2: tert-Butyl 7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate (Compound A8-3)
[0544] Compound A8-2 (1.0 g, 2.51 mmol, 1.0 eq), tri-n-butyltin hydroxide (1.10 g, 3.77 mmol, 1.5 eq), and azobisisobutyronitrile (412 mg, 2.51 mmol, 1.0 eq) were dissolved in toluene (200 mL) and reacted at 110°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to obtain compound A8-3 (800 mg, 99.7%) as a yellow solid.
[0545] LCMS(ESI):[M-Boc+H] + =220.36.
[0546] Step 3: 6-bromo-7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A8-4)
[0547] Compound A8-3 (500 mg, 1.57 mmol, 1.0 eq) was dissolved in acetonitrile (50 mL). N-bromosuccinimide (306.49 g, 1.72 mmol, 1.1 eq) and thiourea (11.92 mg, 156.54 μmol, 0.1 eq) were added to the reaction system. The reaction solution was allowed to react at room temperature for 1 hour. The resulting reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound A8-4 (600 mg, 96.23%) as a pale yellow solid.
[0548] LCMS(ESI):[M-Boc+H] + =298.28
[0549] Step 4: 1'-(tert-butyl)6-methyl7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1',6-dicarboxylate (Compound A8-5)
[0550] Compound A8-4 (500 mg, 1.26 mmol, 1.0 eq) was dissolved in methanol (10 mL), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (91.8 mg, 0.13 mmol, 0.1 eq) and triethylamine (381 mg, 3.77 mmol, 3 eq) were added sequentially. The mixture was allowed to react at 80°C under a carbon monoxide atmosphere for 16 hours. The resulting reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to afford compound A8-5 (220 mg, 46.43%) as a white solid.
[0551] LCMS(ESI)[M-Boc+H] + =278.37.
[0552] Step 5: 1'-(tert-Butoxycarbonyl)-7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxylic acid (Compound A8-6): Compound A8-5 (200 mg, 529.89 μmol, 1.0 eq) was dissolved in a 3:1:1 mixture of tetrahydrofuran / methanol / water (2 mL). Sodium hydroxide (63.89 mg, 1.59 mmol, 3 eq) was added and the mixture was allowed to react at room temperature for 2 hours. Acetic acid was added to adjust the pH to 7. The reaction system was concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography to afford Compound A8-6 (170 mg, 88.28%) as a white solid.
[0553] LCMS(ESI)[M-Boc+H] + =264.37.
[0554] Step 6: (S)-6-((2,6-dioxohesperidin-3-yl)carbamoyl)-7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A8-7)
[0555] Compound A8-6 (160 mg, 440.27 μmol, 1.0 eq), (S)-3-aminopiperidine-2,6-dione (440.27 μmol, 1.0 eq), EDCI (162 mg, 880.55 μmol, 2.0 eq), and HOBT (119 mg, 880.55 μmol, 2.0 eq) were dissolved in DMF (5 mL). DIEA (227.62 mg, 1.76 μmol, 4.0 eq) was added to the reaction system and allowed to react at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by reverse-phase column chromatography to obtain compound A8-7 (200 mg, 95.93%) as a white solid.
[0556] LCMS(ESI)[M-56] + =418.39
[0557] Step 7: (S)-N-(2,6-dioxohesperidin-3-yl)-7-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide (Compound A8)
[0558] Compound A8-7 (500 mg, 1.12 mmol, 1.0 eq) was dissolved in dichloromethane (25 mL) and trifluoroacetic acid (5 mL) was added. The reaction was allowed to react at room temperature for 1 hour. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by reverse-phase column chromatography to yield Compound A8 (268 mg, 67.97%) as a white solid.
[0559] 1 H NMR (400MHz, CD3OD) δ7.48–7.43(m,2H),4.87(dd,J=10.0,8.1Hz,1H),4.65(s,2H),3.93(s,3H),3.54–3.44(m,2H),3.18(td, J=13.0,3.4Hz,2H),2.86(ddd,J=17.6,10.6,8.8Hz,1H),2.74(dt,J=17.6,3.8Hz,1H),2.28–2.10(m,4H),2.08–1.98(m,2H).
[0560] LCMS (ESI) [M+H] + =356.39
[0561] Example 9
[0562] Synthesis of compound A9
[0563] (S)-N-(2,6-dioxopiperidin-3-yl)-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxamide
[0564] Synthesis scheme
[0565] Step 1: 1'-benzyl-5-bromo-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine] (Compound A9-2)
[0566] Compound A9-1 (2.9 g, 9.370 mmol, 1.0 eq) was dissolved in acetonitrile (30 mL). N-bromosuccinimide (1.67 g, 9.370 mmol, 1.0 eq) and thiourea (71.34 mg, 937.3 μmol, 0.1 eq) were added to the reaction system. The reaction was allowed to react at room temperature for 2 hours. The resulting reaction system was concentrated under reduced pressure, and the resulting crude product was purified by normal phase column chromatography to obtain compound A9-2 (2.58 g, 70.89%) as a light yellow oil.
[0567] 1H NMR(600MHz,Methanol-d4)δ7.40–7.34(m,5H),7.32–7.28(m,1H),7.26(s,1H),6.52(s,1H),4.42(s,2H),3.82(s,3H ),3.60(s,2H),2.92(dt,J=12.5,3.7Hz,2H),2.15(t,J=12.1Hz,2H),1.94(td,J=13.0,4.0Hz,2H),1.74–1.69(m,2H).
[0568] LCMS(ESI):[M+H] + =389.39.
[0569] Step 2: 1'-benzyl-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxylic acid methyl ester (Compound A9-3)
[0570] Compound A9-2 (2.58 g, 6.64 mmol, 1.0 eq), 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (538.58 mg, 664.43 μmol, 0.1 eq), and triethylamine (2.02 g, 19.93 mmol, 3.0 eq) were dissolved in methanol (30 mL). The mixture was heated to 70°C under carbon monoxide and allowed to react for 12 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added. The mixture was extracted with ethyl acetate (100 mL x 3), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by reverse phase column chromatography to yield compound A9-3 (1.69 g, 69.22%) as a yellow oil.
[0571] LCMS(ESI):[M+H] + =368.39.
[0572] Step 3: 1'-benzyl-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxylic acid (Compound A9-4)
[0573] Compound A9-3 (1.20 g, 3.27 mmol, 1.0 eq) and lithium hydroxide (782.06 mg, 32.66 mmol, 10.0 eq) were dissolved in methanol / tetrahydrofuran / water (8 mL / 8 mL / 2 mL) and reacted at 50°C under nitrogen for 2 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to obtain compound A9-4 (1.01 g, 87.51%) as a yellow solid.
[0574] LCMS(ESI):[M+H] + =354.29.
[0575] Step 4: (S)-1'-benzyl-N-(2,6-dioxopiperidin-3-yl)-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxamide (Compound A9-5)
[0576] Compound A9-4 (1.01 g, 2.86 mmol, 1 eq), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (2.17 g, 5.72 mmol, 2.0 eq), and N,N-diisopropylethylamine (1.48 g, 11.43 mmol, 4.0 eq) were added to the reaction mixture. The mixture was reacted at room temperature for 30 minutes. (S)-3-aminopiperidine-2,6-dione (549.26 mg, 4.29 mmol, 1.5 eq) was then added to the reaction mixture. After the addition was complete, the mixture was reacted at room temperature for 2 hours. Water (50 mL) was added to the reaction system, and the mixture was extracted with dichloromethane (50 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain compound A9-5 (749 mg, 56.62%) as a reddish-brown oil.
[0577] LCMS (ESI) [M+H] + =464.49.
[0578] Step 5: (S)-N-(2,6-dioxopiperidin-3-yl)-6-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-5-carboxamide (Compound A9)
[0579] LCMS (ESI) [M+H] + =407.69.
[0580] Compound A9-5 (750 mg, 1.62 mmol, 1.0 eq) was dissolved in methanol (15 mL), and palladium (10%) on carbon (172.19 mg, 161.80 μmol, 0.1 eq) was added. After hydrogen substitution three times, the mixture was allowed to react at room temperature for 12 hours. The reaction mixture was filtered, and the filter cake was washed three times with methanol (15 mL). The filtrate was concentrated under reduced pressure, and the crude product was purified by reverse-phase column chromatography to yield Compound A9 (474 mg, 78.45%) as a white solid.
[0581] 1H NMR(600MHz,DMSO-d6)δ10.90(s,1H),8.53(d,1H),7.74(s,1H),6.66(s,1H),4 .64(dd,J=11.7,6.2Hz,1H),4.55(s,2H),3.87(s,4H),3.30(d,J=12.9Hz,2H), 2.95(td,J=13.4,3.1Hz,2H),2.73(ddd,J=17.3,12.7,6.5Hz,1H),2.57–2.53( m,1H),2.09(dt,J=9.4,3.4Hz,2H),2.02–1.94(m,2H),1.83(d,J=14.2Hz,2H).
[0582] LCMS (ESI) [M+H] + =374.39
[0583] Example 10
[0584] Synthesis of compound A10
[0585] (S)-N-(2,6-dioxohesperidin-3-yl)-5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide
[0586] Synthesis scheme
[0587] Step 1: tert-Butyl 4-((2-bromo-4-methoxyphenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound A10-2) Compound A10-1 (5.0 g, 24.63 mmol, 1.0 eq), Compound A1-2 (6.3 g, 29.55 mmol, 1.2 eq), and triphenylphosphine (12.9 g, 49.25 mmol, 2.50 eq) were dissolved in tetrahydrofuran (200 mL). The temperature was cooled to 0°C and diethyl azodicarboxylate (9.3 g, 49.25 mmol, 2.0 eq) was added. After the addition was complete, the mixture was returned to room temperature and reacted for 12 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added to the system. The mixture was extracted with ethyl acetate (100 mL*3 times), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by a forward column to obtain white solid compound A10-2 (7.3 g, 74.42%).
[0588] LCMS(ESI):[M-100+H] + =398.0;400.0.
[0589] Step 2: tert-Butyl 5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate (Compound A10-3)
[0590] Compound A10-2 (7.3 g, 18.33 mmol, 1.0 eq), tri-n-butyltin hydroxide (11.9 g, 36.66 mmol, 2.0 eq), and azobisisobutyronitrile (7.5 g, 45.82 mmol, 2.5 eq) were dissolved in toluene (100 mL) and reacted at 110°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to obtain compound A10-3 (4.8 g, 82.2%) as a yellow solid.
[0591] LCMS (ESI): [M-56+H] + =264.27.
[0592] Step 3: tert-Butyl 6-bromo-5-methoxy-2H-pyro[benzofuran-3,4'-piperidine]-1'-carboxylate (Compound A10-4)
[0593] Compound A10-3 (4.0 g, 12.52 mmol, 1.0 eq) was dissolved in acetonitrile (40 mL). N-bromosuccinimide (1.8 g, 10.02 mmol, 0.8 eq) and thiourea (95.3 mg, 1.25 mmol, 0.1 eq) were added to the reaction system. The reaction mixture was allowed to react at room temperature for 12 hours. The resulting reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound A10-4 (3.0 g, 60.14%) as a pale yellow solid.
[0594] 1H NMR(600MHz,DMSO-d6)δ7.13(s,1H),7.02(s,1H),4.43(s,2H),3.92(d,J=27.6Hz,2H), 3.78(s,3H),1.80(tt,J=20.1,10.2Hz,2H),1.69–1.57(m,2H),1.42(d,J=2.2Hz,11H).
[0595] LCMS (ESI) [M+H] + =298.18;300.18.
[0596] Step 4: 1'-(tert-butyl)6-methyl-5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1',6-dicarboxylate (Compound A10-5)
[0597] Compound A10-4 (2.6 g, 6.53 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide:methanol (20:10 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (477.6 mg, 0.65 mmol, 0.1 eq) and triethylamine (2.0 g, 19.58 mmol, 3.0 eq) were added. The system was reacted overnight at 80°C under a carbon monoxide atmosphere. The reaction system was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography to afford Compound A10-5 (1.5 g, 60.88%) as a pale yellow solid.
[0598] LCMS (ESI) [M-56+H] + =322.28.
[0599] Step 5: 1'-(tert-Butoxycarbonyl)-5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxylic acid (Compound A10-6): Compound A10-5 (1.5 g, 3.97 mmol, 1.0 eq) was dissolved in tetrahydrofuran:methanol:water (12 mL + 12 mL + 3 mL), and sodium hydroxide (795 mg, 19.89 mmol, 5.0 eq) was added. The mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain Compound A10-6 (1.2 g, 83.0%) as a white solid.
[0600] LCMS (ESI) [M+H] + =364.35.
[0601] Step 6: (S)-6-((2,6-dioxyhesperidin-3-yl)carbamoyl)-5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A10-7)
[0602] Compound A10-6 (1.2 g, 3.30 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (10 mL), and N,N-diisopropylethylamine (2.1 g, 16.5 mmol, 5.0 eq) was added. 3-Aminopiperidine-2,6-dione (634.0 mg, 4.95 mmol, 1.5 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 g, 6.6 mmol, 2.0 eq), and 1-hydroxybenzotriazole (893 mg, 6.6 mmol, 2.0 eq) were then added. The reaction was allowed to react at room temperature for 2 hours. The reaction system was concentrated under reduced pressure, and the crude product was purified by column chromatography to afford Compound A10-7 (900 mg, 57.6%) as a white solid.
[0603] LCMS (ESI) [M+H] + =474.49
[0604] Step 7: (S)-N-(2,6-dioxohesperidin-3-yl)-5-methoxy-2H-spiro[benzofuran-3,4'-piperidine]-6-carboxamide (Compound A10)
[0605] Compound A10-7 (900 mg, 1.90 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (5 mL) was added. The mixture was allowed to react at room temperature for 2 hours. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by reverse-phase column chromatography to afford Compound A10 (580 mg, 81.7%) as a white solid.
[0606] 1H NMR (600MHz, DMSO-d6) δ10.91(s,1H),8.67(d,J=7.3Hz,1H),7.23(s,1H),6.97(s,1H),4.80–4.68(m,1H),4.51(s,2H),3.90(s,3H),3.35(d,J= 12.9Hz,2H),3.12–2.98(m,2H),2.77(dtd,J=12.1,9.1,7.2Hz,1H),2.5 4(d,J=3.7Hz,2H),2.09(qd,J=9.8,8.4,4.2Hz,4H),1.93–1.76(m,2H).
[0607] LCMS (ESI) [M+H] + =374.30
[0608] Example 11
[0609] Synthesis of compound A11
[0610] (S)-N-(2,6-dioxohesperidin-3-yl)-7-methoxyspiro[chroman-2,4'-piperidine]-6-carboxamide
[0611] Synthesis scheme
[0612] Step 1: 1-(5-bromo-2-hydroxy-4-methoxyphenyl)ethan-1-one (Compound A11-2)
[0613] Compound A11-1 (10.0 g, 60.18 mmol, 1.0 eq) was dissolved in acetonitrile (300 mL). N-bromosuccinimide (10.65 g, 60.18 mmol, 1.0 eq) and thiourea (458.05 mg, 6.02 mmol, 0.1 eq) were added to the reaction system. The reaction was allowed to react at room temperature for 0.5 hours. The resulting reaction system was concentrated under reduced pressure, and the crude product was washed with methanol to obtain Compound A11-2 (11.3 g, 76.62%) as a white solid.
[0614] 1 H NMR (600MHz, DMSO-d6) δ12.54(s,1H),8.06(s,1H),6.65(s,1H),3.90(s,3H),2.58(s,3H).
[0615] LCMS(ESI):[M+H] + =245.17.
[0616] Step 2: 5-acetyl-4-hydroxy-2-methoxybenzoic acid methyl ester (Compound A11-3)
[0617] Compound A11-2 (11.30 g, 46.11 mmol, 1.0 eq), DPPF palladium dichloride (3.37 g, 4.61 mmol, 0.1 eq), and triethylamine (14.00 g, 138.33 mmol, 3 eq) were dissolved in methanol (100 mL) and N,N-dimethylformamide (100 mL) and reacted at 70°C for 12 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added to the system. The system was extracted with ethyl acetate (100 mL*3 times), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phase was purified by normal column chromatography to obtain compound A11-3 (10 g, 96.73%) as a white solid.
[0618] LCMS(ESI):[M+H] + =225.26.
[0619] Step 3: 1'-(tert-butyl)6-methyl7-methoxy-4-oxospiro[chroman-2,4'-piperidine]-1',6-dicarboxylate (Compound A11-4)
[0620] Compound A11-3 (10.0 g, 44.60 mmol, 1.0 eq), tert-butyl 4-oxopiperidine-1-carboxylate (10.66 g, 53.52 mmol, 1.2 eq), and pyrrolidine (3.81 g, 53.52 mmol, 1.2 eq) were dissolved in methanol (200 mL) and reacted at 70°C for 4 hours. After cooling the reaction system to room temperature, the mixture was purified by column chromatography to obtain compound A11-4 (12.0 g, 66.36%) as a white solid.
[0621] 1 H NMR(600MHz,DMSO-d6)δ8.12(s,1H),6.80(s,1H),3.89(s,3H),3.77(s,5H),3.29–
[0622] 3.05(m,2H),2.83(s,2H),1.92–1.85(m,2H),1.65(ddd,J=13.8,11.6,4.7Hz,2H),1.40(s,9H).
[0623] LCMS(ESI):[M+H] + =406.39.
[0624] Step 4: 1'-(tert-butyl)6-methyl-4-hydroxy-7-methoxyspiro[chroman-2,4'-piperidine]-1',6-dicarboxylate (Compound A11-5)
[0625] Compound A11-4 (5.0 g, 12.33 mmol, 1.0 eq) was dissolved in methanol (100 mL). The reaction system was cooled to 0°C and sodium borohydride (933.09 mg, 24.66 mmol, 2.0 eq) was slowly added to the system. The reaction was allowed to react at room temperature for 2 hours. Aqueous solution (50 mL) was added to the reaction system and extracted with ethyl acetate (50 mL x 3). The mixture was washed with saturated brine (100 mL). The combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound A11-5 (5 g, 99.51%) as a white solid.
[0626] LCMS (ESI) [M+H] + =408.49.
[0627] Step 5: 7-methoxyspiro[chromene-2,4'-piperidine]-6-carboxylic acid methyl ester (Compound A11-6)
[0628] Compound A11-5 (7.0 g, 17.18 mmol, 1.0 eq) was dissolved in toluene (100 mL), and p-toluenesulfonic acid (3.25 g, 18.90 mmol, 1.1 eq) was added. The reaction was continued at 110°C for 2 hours. The reaction system was concentrated under reduced pressure to obtain a crude product A11-6 (7 g). The crude product was directly used for the next reaction without further purification.
[0629] LCMS (ESI) [M+H] + =290.28.
[0630] Step 6: 1'-(tert-butyl)6-methyl7-methoxyspiro[chromene-2,4'-piperidine]-1',6-dicarboxylate (Compound A11-7)
[0631] Compound A11-6 (7.0 g, 24.19 mmol, 1.0 eq), di-tert-butyl dicarbonate (7.92 g, 36.29 mmol, 1.5 eq) and triethylamine (7.34 g, 72.58 mmol, 3 eq) were dissolved in dichloromethane (100 mL) and reacted at room temperature for 2 hours. The reaction system was concentrated under reduced pressure to obtain a crude product A11-7 (10 g). The crude product was directly used for the next reaction without further purification.
[0632] LCMS (ESI) [M+H] + =390.39.
[0633] Step 7: 1'-(tert-butyl)6-methyl7-methoxyspiro[chroman-2,4'-piperidine]-1',6-dicarboxylate (Compound A11-8)
[0634] Compound A11-7 (10 g, 25.68 mmol, 1.0 eq) was dissolved in tetrahydrofuran (100 mL) and palladium / carbon (5 g) was added. After hydrogen substitution three times, the reaction was continued at 50°C for 12 hours. The reaction system was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product A11-8 (10 g). This crude product was directly used in the next reaction without further purification.
[0635] LCMS (ESI) [M+H] + =392.49
[0636] Step 8: 1'-(tert-Butoxycarbonyl)-7-methoxyspiro[chroman-2,4'-piperidine]-6-carboxylic acid (Compound A11-9)
[0637] Compound A11-8 (10 g, 25.55 mmol, 1.0 eq) was dissolved in methanol (80 mL), tetrahydrofuran (80 mL), and water (40 mL). Sodium hydroxide (5.11 g, 127.73 mmol, 5.0 eq) was added to the mixture and allowed to react at 50°C for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse-phase column chromatography to afford compound A11-9 (4 g, 41.49%) as a white solid.
[0638] LCMS (ESI) [M+H] + =378.38
[0639] Step 9: (S)-6-((2,6-dioxopiperidin-3-yl)carbamoyl)-7-methoxyspiro[chroman-2,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A11-10)
[0640] Compound A11-9 (3.0 g, 7.95 mmol, 1.0 eq), (S)-3-aminopiperidine-2,6-dione (1.22 g, 9.54 mmol, 1.2 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.28 g, 11.92 mmol, 1.5 eq), and 1-hydroxybenzotriazole (1.61 g, 11.92 mmol, 1.5 eq) were dissolved in N,N-dimethylformamide (50 mL). N,N-diisopropylethylamine (3.08 g, 23.85 mmol, 3.0 eq) was added to the mixture and allowed to react at room temperature for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse phase column chromatography to afford compound A11-10 (2 g, 51.61%) as a white solid.
[0641] LCMS (ESI) [M+H] + =488.39
[0642] Step 10: (S)-N-(2,6-dioxohesperidin-3-yl)-7-methoxyspiro[chroman-2,4'-piperidine]-6-carboxamide (Compound A11): Compound A11-10 (7.0 g, 14.36 mmol, 1.0 eq) was dissolved in dichloromethane (50 mL). Trifluoroacetic acid (20 mL) was added and the mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated to obtain a crude product which was purified by reverse-phase column chromatography to afford Compound A11 (5.1 g, 91.68%) as a white solid.
[0643] 1H NMR (400MHz, DMSO-d6) δ10.90(s,1H),9.06(d,J=10.9Hz,1H),8.49(d,J=7.2Hz,1H) ,7.69(s,1H),6.61(s,1H),4.72(dt,J=11.1,7.0Hz,1H),3.87(s,3H),3.24(d,J=12 .5Hz,2H),3.20–3.07(m,2H),2.74(dt,J=25.5,6.2Hz,3H),2.52–2.44(m,1H),2.08 (ddt,J=12.3,8.9,3.9Hz,2H),1.90(d,J=14.4Hz,2H),1.83(q,J=12.1,9.2Hz,4H).
[0644] LCMS (ESI) [M+H] + =388.49
[0645] Example 12
[0646] Synthesis of compound A12
[0647] (S)-N-(2,6-dioxohesperidin-3-yl)-6-methoxyspiro[chroman-2,4'-piperidine]-7-carboxamide
[0648] Synthesis scheme
[0649] Step 1: 1-(4-bromo-2,5-dihydroxyphenyl)ethan-1-one (Compound A12-2)
[0650] Compound A12-1 (1.0 g, 4.93 mmol, 1.0 eq) and acetyl chloride (1.93 g, 24.63 mmol, 5.0 eq) were reacted at 60°C for 0.5 hours. The temperature was then cooled to room temperature. Aluminum trichloride (1.31 g, 9.85 mmol, 2.0 eq) was added to the reaction system and the reaction was continued at 160°C for 6 hours. After cooling to room temperature, water (50 mL) was added to the system, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by normal column chromatography to obtain Compound A12-2 (230 mg, 20.21%) as a white solid.
[0651] 1 H NMR (600MHz, DMSO-d6) δ11.16(s,1H),9.97(s,1H),7.32(s,1H),7.16(s,1H),2.56(s,3H).
[0652] LCMS(ESI):[M+H] + =231.16.
[0653] Step 2: Methyl 4-acetyl-2,5-dihydroxybenzoate (Compound A12-3)
[0654] Compound A12-2 (300 mg, 1.30 mmol, 1.0 eq), DPPF palladium dichloride (89.64 mg, 0.13 mmol, 0.1 eq), and triethylamine (394.18 mg, 3.90 mmol, 3 eq) were dissolved in methanol (5 mL) and reacted at 70°C for 12 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added to the system. The system was extracted with ethyl acetate (100 mL*3 times), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phase was purified by normal column chromatography to obtain Compound A12-3 (150 mg, 50.96%) as a yellow solid.
[0655] 1 H NMR (600MHz, DMSO-d6) δ10.74(s,1H),9.81(s,1H),7.30(s,2H),3.88(s,3H),2.61(s,3H).
[0656] LCMS(ESI):[M+H] - =209.35.
[0657] Step 3: 1'-(tert-Butyl)7-methyl-6-hydroxy-4-oxospiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A12-4): Compound A12-3 (150.0 mg, 713.66 umol, 1.0 eq), tert-butyl 4-oxopiperidine-1-carboxylate (170.64 g, 856.39 umol, 1.2 eq), and pyrrolidine (60.91 g, 856.39 umol, 1.2 eq) were dissolved in methanol (5 mL) and reacted at 70°C for 4 hours. The reaction system was cooled to room temperature and purified by column chromatography to obtain Compound A12-4 (220 mg, 78.76%) as a yellow solid.
[0658] LCMS(ESI):[M+H] + =392.38.
[0659] Step 4: 1'-(tert-butyl)7-methyl-6-methoxy-4-oxospiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A12-5)
[0660] Compound A12-4 (220.0 mg, 562.06 μmol, 1.0 eq), iodomethane (239.33 mg, 1.69 mmol, 3.0 eq), and potassium carbonate (233.04 g, 1.69 mmol, 3.0 eq) were dissolved in N,N-dimethylformamide (5 mL) and reacted at room temperature for 4 hours. After cooling the reaction system to room temperature, the product was purified by column chromatography to obtain compound A12-5 (220 mg, 96.54%) as a yellow solid.
[0661] LCMS(ESI):[M+H] + =406.38.
[0662] Step 5: 1'-(tert-butyl)7-methyl-4-hydroxy-6-methoxyspiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A12-6)
[0663] Compound A12-5 (220 mg, 542.61 μmol, 1.0 eq) was dissolved in methanol (3 mL). The reaction system was cooled to 0°C and sodium borohydride (41.06 mg, 1.09 mmol, 2.0 eq) was slowly added to the system. The reaction was allowed to react at room temperature for 2 hours. Aqueous solution (5 mL) was added to the reaction system and extracted with ethyl acetate (5 mL x 3). The mixture was washed with saturated brine (10 mL). The combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound A12-6 (170.0 mg, 76.89%) as a white solid.
[0664] LCMS (ESI) [M+H] + =408.38.
[0665] Step 6: 6-methoxyspiro[chromene-2,4'-piperidine]-7-carboxylic acid methyl ester (Compound A12-7)
[0666] Compound A12-6 (170 mg, 417.22 mmol, 1.0 eq) was dissolved in toluene (5 mL), and p-toluenesulfonic acid (93.40 mg, 542.38 mmol, 1.3 eq) was added. The reaction was allowed to react at 110°C for 2 hours. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase column chromatography to obtain compound A12-7 (120 mg, 99.41%) as a colorless oil.
[0667] LCMS (ESI) [M+H] + =290.38.
[0668] Step 7: 1'-(tert-Butyl)7-methyl-6-methoxyspiro[chromene-2,4'-piperidin]-1',7-dicarboxylate (Compound A12-8): Compound A12-7 (120 mg, 414.75 umol, 1.0 eq), di-tert-butyl dicarbonate (135.7 mg, 622.12 umol, 1.5 eq), and triethylamine (125.91 mg, 1.24 mmol, 3 eq) were dissolved in dichloromethane (2 mL) and reacted at room temperature for 2 hours. The reaction system was concentrated under reduced pressure and purified by reverse phase column chromatography to obtain Compound A12-8 (150 mg, 92.87%) as a yellow oil. LCMS (ESI) [M+H] + =390.38.
[0669] Step 8: 1'-(tert-Butyl)7-methyl-6-methoxyspiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A12-9) Compound A12-8 (150 mg, 385.16 umol, 1.0 eq) was dissolved in tetrahydrofuran (5 mL) and palladium / carbon (20 mg) was added to the system. After hydrogen substitution three times, the reaction was carried out at 50°C for 12 hours. The reaction system was filtered and the filtrate was concentrated under reduced pressure to obtain the crude product A12-9 (120 mg). The crude product was directly used in the next step without further purification.
[0670] LCMS (ESI) [M+H] + =392.28
[0671] Step 9: 1'-(tert-butyl)7-methyl-6-hydroxyspiro[chroman-2,4'-piperidine]-1',7-dicarboxylate (Compound A12-10)
[0672] Compound A12-9 (120 mg, 306.54 mmol, 1.0 eq) was dissolved in methanol (4 mL), tetrahydrofuran (4 mL), and water (2 mL). Sodium hydroxide (61.30 mg, 1.53 mmol, 5.0 eq) was added to the mixture and allowed to react at 50°C for 2 hours. The reaction mixture was concentrated to obtain a crude product which was purified by reverse-phase column chromatography to afford Compound A12-10 (50 mg, 43.22%) as a white solid.
[0673] LCMS (ESI) [M+H] + =378.38
[0674] Step 10: ((S)-7-((2,6-dioxohesperidin-3-yl)carbamoyl)-6-methoxyspiro[chroman-2,4'-piperidine]-1'-carboxylic acid tert-butyl ester (Compound A12-11)
[0675] Compound A12-10 (40 mg, 105.98 umol, 1.0 eq), (S)-3-aminopiperidine-2,6-dione (16.29 mg, 127.17 umol, 1.2 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30.48 mg, 158.97 umol, 1.5 eq), and 1-hydroxybenzotriazole (21.44 mg, 158.97 umol, 1.5 eq) were dissolved in N,N-dimethylformamide (1 mL). N,N-diisopropylethylamine (41.09 mg, 317.93 mmol, 3.0 eq) was added to the mixture and allowed to react at room temperature for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse phase column chromatography to afford compound A12-11 (30 mg, 58.06%) as a white solid.
[0676] LCMS (ESI) [M+H] + =488.39
[0677] Step 11: (SO-N-(2,6-dioxohesperidin-3-yl)-6-methoxyspiro[chroman-2,4'-piperidine]-7-carboxamide (Compound A12)
[0678] Compound A12-11 (20 mg, 41.02 μmol, 1.0 eq) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (1 mL) was added to the mixture. The mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse-phase column chromatography to afford Compound A12 (15 mg, 94.38%) as a white solid.
[0679] 1 H NMR (400MHz, DMSO-d6) δ10.91 (s, 1H), 8.64 (d, J = 7.2Hz, 2H), 7.37 (s, 1H), 6.9 5(s,1H),4.74(dt,J=11.1,7.0Hz,1H),3.86(s,3H),3.20(d,J=12.4Hz,2H),3 .13(q,J=11.8Hz,2H),2.82(t,J=6.7Hz,2H),2.80–2.72(m,1H),2.54(t,J=3. 6Hz,1H),2.09(tq,J=12.5,4.7Hz,2H),1.92–1.80(m,4H),1.80–1.71(m,2H).
[0680] LCMS (ESI) [M+H] + =388.39
[0681] Example 13
[0682] Synthesis of compound B1
[0683] (S)-N-((S)-2,6-dioxopiperidin-3-yl)-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazin-8-yl)carboxamide
[0684] Synthesis scheme
[0685] Step 1: (S)-tert-Butyl 4-(2-bromo-4-nitrophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate (Compound B1-2)
[0686] Compound B1-1 (2.1 g, 9.71 mmol, 1.0 eq), 2-bromo-1-iodo-4-nitrobenzene (3.34 g, 10.20 mmol, 1.05 eq), ethylene glycol (1.21 g, 19.42 mmol, 2 eq), cuprous iodide (462.30 mg, 2.43 mmol, 0.25 eq), and potassium phosphate (4.12 g, 19.42 mmol, 2 eq) were dissolved in isopropanol (30 ml) and reacted at 100°C under nitrogen for 12 h. The reaction solution was filtered and concentrated to obtain the crude product, which was then purified by column chromatography to afford B1-2 (1.25 g, 30.9%) as a yellow oil.
[0687] 1 H NMR (600MHz, DMSO-d6) δ8.37(d,J=2.7Hz,1H),8.17(dd,J=9.0,2.7Hz,1H),7.32(d,J=9.0Hz,1H),4.62(t,J=5.2Hz, 1H),3.92-3.84(m,2H),3.84-3.81(m,1H),3.48-3.40(m,2H),3.39-3.34(m,1H),3.10(brs,1H),3.03–2.96(m,1H).
[0688] LCMS(ESI):[M-Boc+H] + =360.29.
[0689] Step 2: (S) tert-Butyl 8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylate (Compound B1-3)
[0690] Compound B1-2 (1.24 g, 2.98 mmol, 1.0 eq), 2-(di-tert-butylphosphino)-1,1'-binaphthyl (237.43 mg, 0.59 mmol, 0.2 eq), palladium acetate (66.9 mg, 0.29 mmol, 0.1 eq), and cesium carbonate (1.94 g, 5.96 mmol, 2 eq) were dissolved in toluene and reacted at 100°C under nitrogen for 12 h. The reaction solution was concentrated to obtain a crude product which was purified by column chromatography to afford B1-3 (0.74 g, 74.1%) as a yellow solid.
[0691] 1 H NMR (600MHz, DMSO-d6) δ7.77(dd,J=9.1,2.6Hz,1H),7.52(d,J=2.6Hz,1H),7.05(d,J=9.2Hz,1H),4.42(dd, J=11.2,3.2Hz,1H),4.03-3.93(m,4H),3.40-3.35(m,1H),2.99(brs,1H),2.95-2.88(m,1H),2.67(brs,1H).
[0692] LCMS(ESI):[M-Boc+H] + =279.98.
[0693] Step 3: (S) tert-butyl 8-amino-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylate (Compound B1-4)
[0694] Compound B1-3 (0.74 g, 2.21 mmol, 1.0 eq) was dissolved in methanol (20 ml) and palladium (10%) / carbon (150 mg, 10%) was added to the system. The hydrogen atmosphere was replaced three times and the reaction was allowed to proceed at room temperature for 12 h. The organic phase was filtered and concentrated to obtain a purple solid compound B1-4 (0.63 g, 93.5%). The crude product was directly used in the next reaction without further purification.
[0695] LCMS(ESI):[M+H] + =306.28.
[0696] Step 4: (S) tert-Butyl 8-iodo-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylate (Compound B1-5): Compound B1-4 (2.1 g, 6.88 mmol, 1.0 eq) was dissolved in diiodomethane (45 ml). Isoamyl nitrite (1.61 g, 13.75 mmol, 2 eq) and potassium iodide (3.42 g, 20.63 mmol, 3 eq) were added to the mixture. The mixture was reacted at 80°C under nitrogen for 12 h. The mixture was filtered, and the organic phase was concentrated under reduced pressure. The resulting crude product was purified by column chromatography to afford Compound B1-5 (1.53 g, 53.4%) as a yellow oil.
[0697] 1 H NMR(600MHz,Chloroform-d)δ7.15(dd,J=8.5,2.1Hz,1H),7.11(d,J=2.0Hz,1H),6.55(d,J=8.6Hz,1H),4.23(dd,J=10.8,2.8Hz,1H),4.20–4.08(m,2 H),3.97(dd,J=10.8,8.5Hz,1H),3.64(d,J=12.0Hz,1H),3.13-3.07(m,1H) ,3.03(brs,1H),2.72(td,J=12.1,3.5Hz,1H),2.62(brs,1H),1.50(s,9H).
[0698] LCMS(ESI):[M-tBu+H] + =361.19.
[0699] Step 5: 3-(tert-Butyl)8-methyl-(S)-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-dicarboxylate (Compound B1-6)
[0700] B1-5 (0.12 g, 0.29 mmol, 1 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (35.3 mg, 43.2 μmol, 0.15 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (19.7 mg, 86.5 μmol, μmol, 0.3 eq), and triethylamine (35.3 mg, 0.86 mmol, 3 eq) were dissolved in a mixed solvent of ultra-dry N,N-dimethylformamide (6 ml) and methanol (3 ml). The system was purged with carbon monoxide three times and reacted at 90°C for 12 h. The reaction solution was concentrated under reduced pressure to remove methanol, and the solution was extracted with ethyl acetate and water. The organic phase was dried over anhydrous sodium sulfate, and the resulting crude product was purified by column chromatography to obtain compound B1-6 (45 mg, 44.8%) as a yellow solid.
[0701] 1 H NMR(600MHz,Chloroform-d)δ7.59(dd,J=8.6,2.0Hz,1H),7.47(d,J=2.0Hz,1H),6.80(d,J=8.6Hz,1H),4.28(dd,J=10.9,2.9Hz,1H),4.24–4.06(m,2H),3.9 9(dd,J=10.9,8.2Hz,1H),3.88(s,3H),3.78(d,J=12.1Hz,1H),3.28-3.22(m, 1H),3.04(brs,1H),2.87(td,J=12.1,3.5Hz,1H),2.66(brs,1H),1.51(s,9H).
[0702] LCMS(ESI)[M-tBu+H] + =293.28.
[0703] Step 6: (S)-3-(tert-Butyloxycarbonyl)-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxylic acid (Compound B1-7) Compound B1-6 (40 mg, 0.11 mmol, 1.0 eq) was dissolved in tetrahydrofuran (1 mL) and a 1 mL aqueous solution of lithium hydroxide (27.5 mg, 1.15 mmol, 10 eq) was added. The reaction was allowed to react at 50°C for 10 h. The reaction mixture was adjusted to pH = 2 with dilute hydrochloric acid and extracted with ethyl acetate and water. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford Compound B1-7 (32 mg, 83.4%) as a white solid. The crude product was used directly in the next step without further purification.
[0704] LCMS(ESI)[M-tBu+H] + =279.38
[0705] Step 7: (S)-8-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B1-8)
[0706] Compound B1-7 (32 mg, 95.7 μmol, 1.0 eq) was dissolved in ultra-dry N,N-dimethylformamide (1 ml). 2-(7-Azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (43.7 mg, 114.8 μmol, 1.2 eq), (S)-3-amino-2,6-piperidinedione hydrochloride (18.9 mg, 114.8 μmol, 1.2 eq), and N,N-diisopropylethylamine (37.1 mg, 287.1 μmol, 3 eq) were added sequentially to the solution. The reaction was allowed to react at room temperature for 1 h. The reaction solution was filtered and purified by preparative liquid chromatography to afford compound B1-8 (35 mg, 82.3%) as a white solid.
[0707] LCMS(ESI)[M-Boc+H] + =345.39
[0708] Step 8: (S)-N-((S)-2,6-dioxopiperidin-3-yl)-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazin-8-yl)carboxamide (Compound B1)
[0709] Compound B1-8 (25 mg, 56.2 μmol, 1.0 eq) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (1 mL) was added. The reaction was allowed to react at room temperature for 1 h. The reaction system was concentrated under reduced pressure and purified by preparative liquid chromatography to afford Compound B1 (15 mg, 77.4%) as a white solid.
[0710] 1 H NMR (600MHz, DMSO-d6) δ10.83(s,1H),9.12-8.95(m,2H),8.51(d,J=8.3Hz,1H),7.44(dd,J=8.5,2.1Hz,1H),7. 32(d,J=2.1Hz,1H),7.04(d,J=8.7Hz,1H),4.76-4.70(m,1H),4.34(dd,J=11.1,2.8Hz,1H),4.14-4.09(m,1H), 4.02(dd,J=11.1,7.5Hz,1H),3.50-3.45(m,1H),3.43(d,J=12.2Hz,1H),3.39(d,J=11.9Hz,1H),3.12-3.03(m, 1H),3.00(td,J=12.9,2.7Hz,1H),2.88–2.75(m,2H),2.57–2.52(m,1H),2.17–2.06(m,1H),1.97-1.93(m,1H).
[0711] LCMS (ESI) [M+H] + =345.39
[0712] Example 14
[0713] Synthesis of compound B2
[0714] (R)-N-((S)-2,6-dioxopiperidin-3-yl)-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazin-8-yl)carboxamide
[0715] Synthesis scheme
[0716] The synthesis method of compound B2 is the same as that of compound B1.
[0717] 1 H NMR (600MHz, DMSO-d6) δ10.84(s,1H),9.02(s,1H),8.96(s,1H),8.52(d,J=8.4Hz,1H),7.44(dd,J=8 .6,2.1Hz,1H),7.32(d,J=2.1Hz,1H),7.04(d,J=8.7Hz,1H),4.76-4.70(m,1H),4.34(dd,J=11.1,2.8 Hz,1H),4.14–4.09(m,1H),4.01(dd,J=11.2,7.5Hz,1H),3.49–3.43(m,3H),3.13–3.03(m,1H),2.99 (td,J=13.0,2.7Hz,1H),2.88–2.74(m,2H),2.58–2.52(m,1H),2.15-2.06(m,1H),1.97-1.91(m,1H).
[0718] LCMS (ESI) [M+H] + =345.30
[0719] Example 15
[0720] Synthesis of compound B3
[0721] (R)-N-((S)-2,6-dioxohesperidin-3-yl)-9-fluoro-1,2,3,4,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0722] Synthesis scheme
[0723] Step 1: (R)-tert-Butyl 4-(4-bromo-2,5-difluorophenyl)-3-(hydroxymethyl)piperazine-1-carboxylate (Compound B3-2)
[0724] Compound B3-1 (3.0 g, 13.87 mmol, 1.0 eq) was dissolved in isopropanol (30 mL). Compound B2-1 (4.87 g, 15.26 mmol, 1.2 eq), ethylene glycol (1.72 g, 27.74 mmol, 2.0 eq), cuprous iodide (660 mg, 3.47 mmol, 0.25 eq), and potassium phosphate (5.9 g, 27.74 mmol, 2.0 eq) were added to the reaction system. The reaction solution was heated to 100°C and reacted at this temperature for 12 hours under nitrogen. The resulting reaction system was concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography to afford Compound B3-2 (1 g, 17.7%) as a pale yellow solid.
[0725] LCMS(ESI):[M+H] + =351.29.
[0726] Step 2: (R)-8-bromo-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B3-3)
[0727] Compound B3-2 (1.0 g, 2.46 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (10 mL). The temperature was lowered to 0°C, and sodium hydride (89 mg, 3.68 mmol, 1.5 eq) was added. After the addition was complete, the temperature was gradually raised to 110°C and the reaction was allowed to proceed for 3 hours. The reaction solution was concentrated under reduced pressure, and water (50 mL) was added to the system. The system was extracted with ethyl acetate (100 mL*3 times), washed with saturated brine (100 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phase was purified by reverse phase column chromatography to obtain compound B3-3 (880 mg, 84.13%) as a yellow oil.
[0728] LCMS(ESI):[M+H] + =331.19.
[0729] Step 3: 3-(tert-Butyl)8-methyl(R)-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3,8(4H)-dicarboxylate (Compound B3-4)
[0730] Compound B3-3 (600 mg, 1.55 mmol, 1.0 eq), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (222 mg, 0.465 mmol, 0.30 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (253 mg, 3.31 mmol, 0.2 eq), and triethylamine (782 mg, 7.75 mmol, 5 eq) were dissolved in a mixture of methanol and N,N-dimethylformamide (30 mL) and reacted at 90°C under a carbon monoxide atmosphere for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain yellow solid compound B3-4 (422 mg, 74.34%).
[0731] LCMS(ESI):[M+H] + =311.18.
[0732] Step 4: (R)-3-(tert-Butyloxycarbonyl)-9-fluoro-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxylic acid (Compound B3-5)
[0733] Compound B3-4 (412 mg, 1.12 mmol, 1.0 eq) was dissolved in a mixture of methanol, tetrahydrofuran, and water (9 mL). The reaction mixture was heated to 50°C and allowed to react for 3 hours. The resulting reaction system was cooled to 0°C, and acetic acid was added dropwise to the reaction mixture until the pH reached 6. The mixture was extracted with ethyl acetate (50 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain compound B3-5 (335 mg, 84.55%) as a brown solid.
[0734] LCMS (ESI) [M+H] + =388.29.
[0735] Step 5: (R)-8-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B3-6)
[0736] Compound B3-5 (325 mg, 0.922 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (3 mL). (S)-3-aminopiperidine-2,6-dione (227.71 mg, 1.38 mmol, 1.5 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (526.06 mg, 1.38 mmol, 1.5 eq), and N,N-diisopropylethylamine (357.63 mg, 2.77 mmol, 3.0 eq) were added. The reaction was allowed to react at room temperature for 2 hours. Water (50 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by reverse phase column chromatography to obtain white solid compound B3-6 (322 mg, 75.49%).
[0737] LCMS (ESI) [M+H] + =407.39.
[0738] Step 6: (R)-N-((S)-2,6-dioxohesperidin-3-yl)-9-fluoro-1,2,3,4,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide (Compound B3)
[0739] Compound B3-6 (322 mg, 0.696 mmol, 1.0 eq) and trifluoroacetic acid (0.5 ml) were dissolved in dichloromethane (1.5 mL). The mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to obtain compound B3 (240 mg, 95.31%) as a white solid.
[0740] 1 H NMR (600MHz, DMSO) δ10.86(s,1H),7.95(s,1H),7.10(d,J=7.2Hz,1H),6.96(d,J=1 3.7Hz,1H),4.75–4.67(m,2H),4.31(dd,J=11.2,2.7Hz,1H),4.09(d,J=10.2Hz,1H ),3.99(dd,J=11.2,7.2Hz,1H),3.55–3.47(m,1H),3.44–3.35(m,2H),3.09–2.99( m,2H),2.86–2.75(m,2H),2.56–2.52(m,1H),2.15–2.05(m,1H),2.02–1.94(m,1H).
[0741] LCMS (ESI) [M+H] +=363.49.
[0742] Example 16
[0743] Synthesis of compound B4
[0744] (R)-N-((S)-2,6-dioxohesperidin-3-yl 0-9-methoxy-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0745] Synthesis scheme
[0746] Step 1: (R)-tert-Butyl 4-(2-fluoro-5-methoxy-4-nitrophenyl)-3-(hydroxymethyl)piperazine-1-carboxylate (Compound B4-2). Compound B4-1 (3.90 g, 18.03 mmol, 1.0 eq) and Compound B2-1 (3.41 g, 18.03 mmol, 1.0 eq) were dissolved in dimethyl sulfoxide (20 mL). The reaction solution was heated to 100°C and reacted at this temperature for 12 hours. Water (50 mL) was added to the system, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by normal column chromatography to obtain Compound B4-2 (4.20 g, 60.44%) as a yellow solid.
[0747] 1 H NMR (600MHz, DMSO-d6) δ7.82(d,J=13.7Hz,1H),6.69(d,J=7.5Hz,1H),4.76(t,J=5.3Hz,1H),4.02–3.85(m,6H),3.50 (hept,J=6.3,5.8Hz,2H),3.37(dt,J=12.1,3.1Hz,1H),3.32(dd,J=12.6,3.4Hz,1H),3.27–2.92(m,2H),1.42(s,9H).
[0748] LCMS(ESI):[M+H] + =386.28.
[0749] Step 2: (R)-9-methoxy-8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B4-3)
[0750] Compound B4-2 (3.0 g, 7.78 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (10 mL). Sodium hydroxide (373.61 mg, 9.34 mmol, 1.2 eq) was added in three portions. The reaction mixture was heated to 110°C and allowed to react at this temperature for 2 hours. Water (50 mL) was added to the system, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by reverse phase column chromatography to yield compound B4-3 (2.50 g, 87.90%) as a yellow solid.
[0751] LCMS(ESI):[M+H] + =366.28.
[0752] Step 3: (R)-8-amino-9-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B4-4)
[0753] Compound B4-3 (2.50 g, 6.84 mmol, 1.0 eq) was dissolved in methanol (60 mL), and palladium / carbon (500 mg) was added. After hydrogen substitution three times, the reaction was allowed to proceed at room temperature for 12 hours. The reaction system was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product B4-4 (1.9 g, 82.79%). This crude product was directly used in the next step without further purification.
[0754] LCMS(ESI):[M+H] + =335.39.
[0755] Step 4: (R)-8-iodo-9-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B4-5)
[0756] Compound B4-4 (1.30 g, 3.88 mmol, 1.0 eq) was dissolved in diiodomethane (10 mL), and isoamyl nitrite (908.11 mg, 7.75 mmol, 2.0 eq) and potassium iodide (1.93 g, 11.63 mmol, 3.0 eq) were added dropwise. The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated to obtain a crude product which was purified by normal phase column chromatography to afford compound B4-5 (750 mg, 43.36%) as a yellow oil.
[0757] LCMS (ESI) [M+H] + =446.29.
[0758] Step 5: 3-(tert-Butyl)8-methyl(R)-9-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3,8(4H)-dicarboxylate (Compound B4-6)
[0759] Compound B4-5 (500 mg, 1.12 mmol, 1.0 eq), DPPF palladium dichloride (81.90 mg, 0.11 mmol, 0.1 eq), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (106.82 mg, 0.22 mmol, 0.2 eq) and triethylamine (566.86 mg, 5.60 mmol, 5 eq) were dissolved in methanol (10 mL) and N,N-dimethylformamide (5 mL) and reacted at 80°C for 12 hours. The reaction solution was concentrated under reduced pressure, and water (20 mL) was added to the system. The mixture was extracted with ethyl acetate (40 mL * 3 times), washed with saturated brine (40 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by reverse phase column chromatography to obtain a brown solid compound B4-6 (350 mg, 82.55%).
[0760] LCMS (ESI) [M+H] + =379.39.
[0761] Step 6: (R)-3-(tert-Butoxycarbonyl)-9-methoxy-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxylic acid (Compound B4-7)
[0762] Compound B4-6 (300 mg, 792.76 μmol, 1.0 eq) and sodium hydroxide (158.54 mg, 3.96 mmol, 5.0 eq) were dissolved in methanol (2 mL), tetrahydrofuran (2 mL), and water (1 mL) and reacted at room temperature for 2 hours. The reaction solution was concentrated, and the resulting crude product was purified via reverse-phase column chromatography to obtain compound B4-7 (250 mg, 86.54%) as a brown solid.
[0763] LCMS (ESI) [M+H] + =365.49.
[0764] Step 7: (R)-8-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-9-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B4-8)
[0765] Compound B4-7 (200 mg, 548.85 umol, 1.0 eq), (S)-3-aminopiperidine-2,6-dione (84.39 mg, 658.62 umol, 1.2 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (157.82 mg, 828.27 umol, 1.5 eq), and 1-hydroxybenzotriazole (111.20 mg, 828.27 umol, 1.5 eq) were dissolved in N,N-dimethylformamide (2 mL). N,N-diisopropylethylamine (212.81 mg, 1.65 mmol, 3.0 eq) was added to the mixture and reacted at room temperature for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse phase column chromatography to afford compound B4-8 (250 mg, 95.99%) as a white solid.
[0766] LCMS (ESI) [M+H] + =475.49
[0767] Step 8: (R)-tert-Butyl 4-(2-fluoro-5-methoxy-4-nitrophenyl)-3-(hydroxymethyl)piperazine-1-carboxylate (Compound B4): Compound B4-8 (250 mg, 526.85 μmol, 1.0 eq) was dissolved in dichloromethane (4 mL). Trifluoroacetic acid (2 mL) was added to the mixture and allowed to react at room temperature for 2 hours. The reaction solution was concentrated to obtain a crude product which was purified by reverse phase column chromatography to afford Compound B4 (180 mg, 91.25%) as a white solid.
[0768] 1 H NMR(400MHz,DMSO-d6)δ10.90(s,1H),9.10(s,1H),8.55–8.48(m,1H),7.29(s, 1H),6.68(s,1H),4.70(dt,J=12.5,6.3Hz,1H),4.26(ddd,J=20.9,10.7,2.3Hz ,2H),3.95(dd,J=11.2,7.3Hz,1H),3.90(s,3H),3.53–3.48(m,1H),3.45–3.36 (m,2H),3.11–3.02(m,2H),2.86–2.73(m,2H),2.53(s,1H),2.14–2.03(m,2H).
[0769] LCMS (ESI) [M+H] + =375.39
[0770] Example 17
[0771] Synthesis of compound B5
[0772] (R)-N-((S)-2,6-dioxohesperidin-3-yl)-7-fluoro-1,2,3,4,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0773] Synthesis scheme
[0774] The synthesis method of compound B5 is the same as that of compound B3.
[0775] 1 H NMR (600MHz, CD3OD) δ7.40 (dd, J=8.9, 7.6Hz, 1H), 6.88 (dd, J=9.1, 1.4Hz, 1H), 4.82 (dd, J=12 .7,5.3Hz,1H),4.45(dd,J=11.2,2.9Hz,1H),4.2-4.19(m,1H),4.13(dd,J=11.2,7.3Hz,1H), 3.63–3.58(m,1H),3.56–3.47(m,2H),3.29–3.20(m,1H),3.16(td,J=13.2,2.9Hz,1H),3.02( t,J=12.2Hz,1H),2.87-2.81(m,1H),2.74-2.70(m,1H),2.32-2.28(m,1H),2.22-2.15(m,1H).
[0776] LCMS (ESI) [M+H] + =363.36
[0777] Example 18
[0778] Synthesis of compound B6
[0779] (R)-N-((S)-2,6-dioxohesperidin-3-yl)-7-methoxy-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0780] Synthesis scheme
[0781] Step 1: (R)-7-methoxy-8-nitro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B6-2)
[0782] Compound B6-1 (2.0 g, 13.87 mmol, 1.0 eq) was dissolved in dimethyl sulfoxide (20 mL). Compound B2-1 (1.75 g, 9.25 mmol, 1.0 eq) and cesium carbonate (9.0 g, 27.6 mmol, 3.0 eq) were added to the reaction system. The reaction solution was heated to 110°C under nitrogen and allowed to react at this temperature for 3 hours. Water (50 mL) was added to the system, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B6-2 (1.47 g, 43.51%) as a yellow oil.
[0783] LCMS(ESI):[M+H] + =310.28.
[0784] Step 2: (R)-8-amino-7-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B6-3)
[0785] Compound B6-2 (1.4 g, 3.83 mmol, 1.0 eq) was dissolved in a mixture of isopropanol and water (13 mL). Iron powder (1.07 g, 19.15 mmol, 5.0 eq) and ammonium chloride (2.0 g, 38.3 mmol, 10.0 eq) were added to the reaction system. The temperature was raised to 80°C and the reaction was allowed to proceed for 3 hours. The reaction solution was filtered, and the filter cake was washed three times with ethyl acetate. The organic phase was concentrated to obtain a crude product, which was purified by reverse-phase column chromatography to yield compound B6-3 (565 mg, 43.96%) as a yellow solid.
[0786] LCMS(ESI):[M+H] + =336.39.
[0787] Step 3: (R)-8-iodo-7-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B6-4)
[0788] Compound B6-3 (400 mg, 1.19 mmol, 1.0 eq), isoamyl nitrite (279 mg, 2.38 mmol, 2.0 eq), and potassium iodide (594 mg, 3.58 mmol, 3 eq) were dissolved in diiodomethane (5 mL) and reacted at 80°C under a nitrogen atmosphere for 3 hours. The reaction system was cooled to room temperature, concentrated under reduced pressure, and purified by column chromatography to obtain compound B6-4 (282 mg, 52.98%) as a yellow solid.
[0789] LCMS(ESI):[M+H] + =391.19.
[0790] Step 4: 3-(tert-Butyl)8-methyl(R)-7-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3,8(4H)-dicarboxylate (Compound B6-5)
[0791] Compound B6-4 (262 mg, 0.587 mmol, 1.0 eq) was dissolved in a mixture of methanol and N,N-dimethylformamide (6 mL). 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (84 mg, 0.176 mmol, 0.3 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (95.8 mg, 0.12 mmol, 0.2 eq), and triethylamine (296.46 mg, 2.94 mmol, 5 eq) were added to the reaction system. The reaction solution was heated to 90°C and reacted at 90°C for 12 hours under a carbon monoxide atmosphere. After cooling the reaction system to room temperature, it was concentrated under reduced pressure, added with water (100 mL), and extracted with ethyl acetate (100 mL x 3). The organic phases were washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain yellow solid compound B6-5 (130 mg, 58.52%).
[0792] LCMS (ESI) [M+H] + =323.28.
[0793] Step 5: (R)-3-(tert-Butoxycarbonyl)-7-methoxy-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxylic acid (Compound B6-6)
[0794] Compound B6-5 (120 mg, 0.317 mmol, 1.0 eq) was dissolved in a mixture of methanol, tetrahydrofuran, and water (9 mL). The reaction mixture was heated to 50°C and allowed to react for 3 hours. The resulting reaction system was cooled to 0°C, and acetic acid was added dropwise to the reaction system until the pH reached 6. The mixture was extracted with ethyl acetate (50 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain compound B6-6 (100 mg, 86.54%) as a brown solid.
[0795] LCMS (ESI) [M+H] + =309.20.
[0796] Step 6: (R)-8-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-7-methoxy-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B6-7)
[0797] Compound B6-6 (90 mg, 0.246 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (3 mL). (S)-3-aminopiperidine-2,6-dione (60.98 mg, 0.37 mmol, 1.5 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (187.8 mg, 0.49 mmol, 1.5 eq), and N,N-diisopropylethylamine (159.3 mg, 1.235 mmol, 5.0 eq) were added. The reaction was allowed to proceed at room temperature for 2 hours. Water (50 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by reverse phase column chromatography to obtain white solid compound B6-7 (60 mg, 51.2%).
[0798] LCMS (ESI) [M+H] + =475.33
[0799] Step 7: (R)-N-((S)-2,6-dioxohesperidin-3-yl)-7-methoxy-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide (Compound B6)
[0800] Compound B6-7 (60 mg, 0.126 mmol, 1.0 eq) and trifluoroacetic acid (0.5 ml) were dissolved in dichloromethane (1.5 mL). The mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford compound B6 (18 mg, 38.02%) as a white solid.
[0801] 1 H NMR (600MHz, DMSO) δ10.91(s,1H),8.54(d,J=7.3Hz,1H),7.34(d,J=8.9Hz,1H),6.77(d,J=9.0Hz,1H),4.77–4.72(m,1H),4.35 (dd,J=10.9,2.6Hz,1H),3.94(t,1H),3.87–3.79(m,4H),3.23(s,2H),3.17–3.06(m,3H),2.84–2.73(m,3H),2.15–2.03(m,3H).
[0802] LCMS (ESI) [M+H] + =375.39.
[0803] Example 19
[0804] Synthesis of compound B7
[0805] (R)-N-((S)-2,6-dioxohesperidin-3-yl)-N-methyl-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0806] Synthesis scheme
[0807] The synthesis method of compound B7 is the same as that of compound B1.
[0808] 1 H NMR (400MHz, DMSO-d6) δ10.90(d,J=19.7Hz,1H),7.07–6.72(m,3H),4.33(d,J=11.0Hz,1H),3.51(d,J=10.3Hz,1H),3.39(dd,J =18.3,10.7Hz,2H),3.04(d,J=9.2Hz,2H),2.88(d,J=6.2Hz,2H),2.74(d,J=8.6Hz,3H),2.43–2.32(m,1H),2.01–1.86(m,1H).
[0809] LCMS (ESI) [M+H] + =358.30
[0810] Example 20
[0811] Synthesis of compound B8
[0812] (S)-N-((S)-2,6-dioxohesperidin-3-yl)-9-fluoro-1,2,3,4,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide
[0813] Synthesis scheme
[0814] Step 1: (S)-tert-Butyl 4-(4-bromo-2,5-difluorophenyl)-3-(hydroxymethyl)piperazine-1-carboxylate (Compound B8-2)
[0815] The synthesis method refers to the synthesis of compound B3-2.
[0816] Step 2: (S)-8-bromo-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B8-3)
[0817] Compound B8-2 (2.1 g, 5.16 mmol, 1.0 eq) and KOH (0.868 g, 15.47 mmol, 3.0 eq) were dissolved in DMSO (21 mL) and heated to 40°C for 2 hours. Water (30 mL) was added to the system, and the mixture was extracted with ethyl acetate (60 mL x 3). The mixture was washed with saturated brine (60 mL). The combined organic phases were then dried over anhydrous sodium sulfate. The organic phases were concentrated to yield crude product B8-3 (1.49 g, 74.62%). This crude product was carried on to the next step without further purification.
[0818] LCMS(ESI):[M-Bu+H] + =331.29.
[0819] Step 3: 3-(tert-Butyl)8-methyl(S)-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3,8(4H)-dicarboxylate (Compound B8-4)
[0820] Compound B8-3 (955 mg, 2.47 mmol, 1.0 eq), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (352.7 mg, 0.74 mmol, 0.3 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (302 mg, 0.37 mmol, 0.15 eq), and triethylamine (748.6 mg, 7.40 mmol, 3 eq) were dissolved in a mixture of methanol and N,N-dimethylformamide (10 mL) and reacted at 90°C for 12 hours under a carbon monoxide atmosphere. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain yellow solid compound B8-4 (425 mg, 47.04%).
[0821] LCMS(ESI):[M-Bu+H] + =311.38.
[0822] Step 4: (S)-3-(tert-Butyloxycarbonyl)-9-fluoro-1,2,3,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxylic acid (Compound B8-5)
[0823] Compound B8-4 (400 mg, 1.09 mmol, 1.0 eq) was dissolved in a mixture of methanol, tetrahydrofuran, and water (5 mL). The reaction mixture was heated to 50°C and allowed to react for 2 hours. The resulting reaction system was cooled to 0°C, and 1N HCl was added dropwise to the reaction system until the pH reached 3. The mixture was extracted with ethyl acetate (50 mL x 3). The mixture was washed with saturated brine (100 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated and then purified by reverse phase chromatography to obtain compound B8-5 (252 mg, 65.51%) as a brown solid.
[0824] LCMS (ESI) [M-Bu+H] + =297.28.
[0825] Step 5: (S)-8-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-9-fluoro-1,2,4a,5-tetrahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester (Compound B8-6)
[0826] Compound B8-5 (252 mg, 0.715 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (2 mL). (S)-3-aminopiperidine-2,6-dione (141.3 mg, 0.858 mmol, 1.2 eq), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (205.6 mg, 1.07 mmol, 1.5 eq), 1-hydroxybenzotriazole (145.0 mg, 1.07 mmol, 1.5 eq), and N,N-diisopropylethylamine (277 mg, 2.15 mmol, 3.0 eq) were added and reacted at room temperature for 3 hours. The mixture was concentrated and purified by reverse phase column chromatography to afford compound B8-6 (306 mg, 92.52%) as a white solid.
[0827] LCMS (ESI) [M-Bu+H] + =407.39.
[0828] Step 6: (S)-N-((S)-2,6-dioxohesperidin-3-yl)-9-fluoro-1,2,3,4,4,4a,5-hexahydrobenzo[b]pyrazino[1,2-d][1,4]oxazine-8-carboxamide (Compound B8)
[0829] Compound B8-6 (400 mg, 0.865 mmol, 1.0 eq) and trifluoroacetic acid (0.3 ml) were dissolved in dichloromethane (1.5 mL). The reaction was allowed to proceed at room temperature for 2 hours. The reaction solution was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford compound 2 (300 mg, 95.72%) as a white solid.
[0830] 1 H NMR(600MHz,CD3OD)δ7.64(d,J=8.2Hz,1H),7.49-7.34(m,5H),6.93(d,J=8.2Hz ,1H),5.15(dd,J=13.4,5.2Hz,1H),4.65(dd,J=12.8,5.2Hz,2H),4.60(d,J=5.0 Hz,2H),3.86-3.78(m,2H),3.18-3.13(m,2H),2.99-2.87(m,1H),2.82-2.75(m, 2H),2.70-2.65(m,2H),2.47-2.40(m,2H),2.31-2.23(m,2H),2.18-2.12(m,2H).
[0831] LCMS (ESI) [M+H] + =363.39.
[0832] Example 21
[0833] Synthesis of compound B9
[0834] (S)-N-((S)-2,6-dioxopiperidin-3-yl)-10-methoxy-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxamide
[0835] Synthesis scheme
[0836] Step 1: (S)-tert-Butyl 4-(2-fluoro-5-methoxy-4-nitrophenyl)-3-(2-hydroxyethyl)piperazine-1-carboxylate (Compound B9-1). Compound B4-1 (5.0 g, 26.4 mmol, 1.0 eq) was dissolved in dimethyl sulfoxide (50 mL) and tert-butyl (3S)-3-(2-hydroxyethyl)-1-piperazinecarboxylate (6.1 g, 26.4 mmol, 1.0 eq) was added. The reaction system was reacted at 100°C for 12 hours. After cooling the reaction system to room temperature, water was added, and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain Compound B9-1 (5.9 g, 56.3%) as a yellow oil.1 H NMR(400MHz, DMSO-d6)δ7.84(d,J=13.7Hz,1H),6.77(d,J=7.5Hz,1H),4.69–4.61(m,1H),4.09–3.9 8(m,2H),3.95–3.86(m,4H),3.48–3.37(m,2H),3.32–2.92(m,4H),1.76–1.50(m,2H),1.42(s,9H).
[0837] LCMS(ESI):[M-tBu+H] + =344.39.
[0838] Step 2: (S)-10-methoxy-9-nitro-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B9-2)
[0839] Compound B9-1 (5.0 g, 12.5 mmol, 1.0 eq) was dissolved in dimethyl sulfoxide (50 mL) and potassium hydroxide (1.4 g, 25.0 mmol, 2.0 eq) was added at room temperature. The reaction system was allowed to react at 60°C for 2 hours. After cooling the reaction system to room temperature, water was added and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to yield compound B9-2 (3.5 g, 73.7%) as a yellow solid.
[0840] 1 H NMR(400MHz,DMSO-d6)δ7.43(s,1H),6.59(s,1H),4.25–4.16(m,1H),4.16–4.09(m,1H),3.88(s,3H),3.7 9–3.72(m,1H),3.67–3.58(m,2H),3.56–3.38(m,4H),2.07–1.98(m,1H),1.98–1.87(m,1H),1.43(s,9H).
[0841] LCMS(ESI):[M+H] + =380.35.
[0842] Step 3: (S)-9-amino-10-methoxy-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B9-3)
[0843] Compound B9-2 (3.0 g, 7.9 mmol, 1.0 eq) was dissolved in methanol (30 mL) and palladium / carbon (600 mg) was added. The reaction was allowed to react at room temperature for 12 hours under hydrogen. The reaction system was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product, compound B9-3 (2.2 g).
[0844] LCMS(ESI):[M+H] + =350.39.
[0845] Step 4: (S)-9-iodo-10-methoxy-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B9-4)
[0846] Compound B9-3 (2.0 g, 5.7 mmol, 1.0 eq) was dissolved in diiodomethane (20 mL). Isoamyl nitrite (1.3 g, 11.5 mmol, 2.0 eq) and potassium iodide (2.9 g, 17.2 mmol, 3.0 eq) were added at room temperature and allowed to react for 15 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to afford compound B9-4 (1.4 g, 53.1%) as a yellow oil.
[0847] 1 H NMR(600MHz,DMSO-d6)δ7.13(s,1H),6.57(s,1H),4.19–4.05(m,2H),3.75(s ,3H),3.66–3.45(m,3H),3.30–3.14(m,4H),2.02–1.85(m,2H),1.42(s,9H).
[0848] LCMS(ESI)[M-tBu+H] + =405.29.
[0849] Step 5: 3-(tert-Butyl)-9-methyl(S)-10-methoxy-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3,9-dicarboxylate (Compound B9-5)
[0850] Compound B9-4 (1.1 g, 2.5 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide:methanol (2:1) (20 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (309 mg, 0.38 mmol, 0.15 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (437 mg, 0.76 mmol, 0.30 eq), and triethylamine (765 mg, 7.6 mmol, 3.0 eq) were added. The mixture was reacted at 80°C under carbon monoxide pressure for 12 hours. The reaction system was cooled to room temperature and concentrated. The crude product was purified by reverse-phase column chromatography to obtain compound B9-5 (370 mg, 37.5%) as a colorless oil.
[0851] 1 H NMR(600MHz,DMSO-d6)δ7.15(s,1H),6.55(s,1H),4.18–4.05(m,2H),3.76(s,3H),3.70(s,3 H),3.67–3.50(m,3H),3.42–3.37(m,2H),3.30–3.18(m,2H),2.01–1.85(m,2H),1.43(s,9H).
[0852] LCMS(ESI)[M-tBu+H] + =337.19.
[0853] Step 6: (S)-3-(tert-Butoxycarbonyl)-10-methoxy-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxylic acid (Compound B9-6)
[0854] Compound B9-5 (300 mg, 0.76 mmol, 1.0 eq) was dissolved in tetrahydrofuran:methanol:water (1:1:2) (4 mL). Lithium hydroxide (321 mg, 7.64 mmol, 10.0 eq) was added and allowed to react at room temperature for 12 hours. Dilute hydrochloric acid (1N) was added to the reaction system to adjust the pH to ≤ 5. The mixture was extracted with ethyl acetate, washed with saturated brine, and the combined organic phases were concentrated under reduced pressure to obtain the crude product, Compound B9-6 (280 mg), as a white solid.
[0855] LCMS (ESI) [M+H] + =379.35.
[0856] Step 7: (S)-9-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-10-methoxy-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B9-7)
[0857] Compound B9-6 (200 mg, 0.53 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (4 mL). (S)-3-aminopiperidine-2,6-dione hydrochloride (130 mg, 0.79 mmol, 1.5 eq), N,N-diisopropylethylamine (342 mg, 2.6 mmol, 5.0 eq), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (301 mg, 0.79 mmol, 1.5 eq) were added to the mixture and reacted at room temperature for 1 hour. Water was added to the reaction system, and the mixture was extracted with ethyl acetate and washed with saturated brine. The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B9-7 (220 mg, 85.2%) as a white solid.
[0858] 1 H NMR (600MHz, DMSO-d6) δ10.90(s,1H),8.51(d,J=7.1Hz,1H),7.32(s,1H),6.61(s,1H),4.70(dt,J=12.5,6.4Hz,1H),4.19–4.06(m,2H),3. 89(s,3H),3.70–3.52(m,3H),3.52–3.43(m,2H),3.25–3.15(m,2H),2 .81–2.74(m,1H),2.14–2.03(m,2H),1.99–1.83(m,3H),1.43(s,9H).
[0859] LCMS (ESI) [M+H] + =489.45.
[0860] Step 8: (S)-N-((S)-2,6-dioxopiperidin-3-yl)-10-methoxy-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxamide (Compound B9)
[0861] Compound B9-7 (100 mg, 0.20 mmol, 1.0 eq) was dissolved in dichloromethane (1 mL), and a solution of hydrochloric acid in 1,4-dioxane (1 mL) was added. The mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford compound B9 (50 mg, 62.89%) as a white solid.
[0862] 1 H NMR(600MHz,DMSO-d6)δ10.91(s,1H),8.53(d,J=7.2Hz,1H),7.37(s,1H),6.72(s,1H),4.71 (dt,J=11.1,6.9Hz,1H),4.18–4.12(m,1H),4.09(dt,J=11.3,5.8Hz,1H),3.90(s,3H),3.66 –3.56(m,2H),3.49–3.41(m,1H),3.34–3.27(m,1H),3.27–3.21(m,1H),3.21–3.11(m,1H),3 .03–2.96(m,1H),2.77(ddd,J=17.6,12.1,7.1Hz,1H),2.55–2.52(m,1H),2.13–1.92(m,4H).
[0863] LCMS (ESI) [M+H] + =389.35.
[0864] Example 22
[0865] Synthesis of compound B10
[0866] (R)-N-((S)-2,6-dioxopiperidin-3-yl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxirane-9-amide
[0867] Synthesis scheme
[0868] Step 1: Methyl 2-fluoro-4-methoxy-5-nitrobenzoate (Compound B10-2)
[0869] Compound B10-1 (10.0 g, 46.06 mmol, 1.0 eq) was dissolved in methanol (200 mL). Sodium methoxide methanol solution (5.4 M, 9.4 mL, 50.66 mmol, 1.1 eq) was added to the reaction system at -20°C and allowed to react for 2 hours. The resulting reaction system was filtered, and the filter cake was washed with carbon tetrachloride to obtain compound B10-2 (10.0 g, 94.75%) as a yellow solid.
[0870] 1 H NMR (600MHz, DMSO-d6) δ8.45(d,J=7.5Hz,1H),7.47(d,J=12.7Hz,1H),4.02(s,3H),3.87(s,3H).
[0871] LCMS(ESI):[M+H] + =230.25.
[0872] Step 2: (R)-tert-Butyl 3-(hydroxymethyl)-4-(5-methoxy-2-(methoxycarbonyl)-4-nitrophenyl)piperazine-1-carboxylate (Compound B10-3)
[0873] Compound B10-2 (10.0 g, 43.64 mmol, 1.0 eq) and compound B2-1 (11.33 g, 52.36 mmol, 1.2 eq) were dissolved in dimethyl sulfoxide (100 mL) and reacted at 100°C for 12 hours. Water was added to the system, extracted with ethyl acetate, washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by reverse-phase column chromatography to obtain compound B10-3 (10.0 g, 53.87%) as a yellow solid.
[0874] 1 H NMR (600MHz, DMSO-d6) δ8.32(s,1H),6.69(s,1H),4.65(t,J=5.3Hz,1H),4.02–3.96(m,5H),3.82(s,3H ),3.61(s,1H),3.48–3.43(m,2H),3.34–3.31(m,1H),3.21(d,J=13.1Hz,2H),3.00(s,1H),1.42(s,9H).
[0875] LCMS(ESI):[M+H] + =426.35.
[0876] Step 3: (R)-3-(hydroxymethyl)-4-(2-(hydroxymethyl)-5-methoxy-4-nitrophenyl)piperazine-1-carboxylic acid tert-butyl ester (Compound B10-4)
[0877] Compound B10-3 (10.0 g, 23.51 mmol, 1.0 eq) was dissolved in methanol (200 mL). Sodium borohydride (4.45 g, 117.53 mmol, 5.0 eq) was added at 0°C and allowed to react at 22°C under nitrogen for 5 hours. The reaction system was added to water and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phases was purified by column chromatography to obtain compound B10-4 (7.0 g, 74.93%) as a yellow solid.
[0878] LCMS(ESI):[M+H] + =398.35.
[0879] Step 4: (R)-10-methoxy-9-nitro-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine (Compound B10-5)
[0880] Dissolve B10-4 (10.0 g, 25.16 mmol, 1.0 eq) in toluene (100 mL) and add D-camphorsulfonic acid (11.69 g, 50.32 mmol, 2.0 eq). React at 100°C for 3 hours. Concentrate the reaction mixture under reduced pressure to obtain the crude product B10-5 (7.0 g), which is used directly in the next step.
[0881] LCMS (ESI) [M+H] + =280.25.
[0882] Step 5: (R)-10-methoxy-9-nitro-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-3(4H)-carboxylic acid tert-butyl ester (Compound B10-6)
[0883] Compound B10-5 (7.0 g, 25.06 mmol, 1.0 eq) was dissolved in dichloromethane (100 mL), and triethylamine (7.61 g, 75.19 mmol, 3.0 eq) and di-tert-butyl dicarbonate (8.2 g, 37.59 mmol, 1.5 eq) were added. The reaction was allowed to react at room temperature for 2 hours. The reaction system was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford Compound B10-6 (8.0 g, 84.13%) as a yellow oil.
[0884] 1H NMR (600MHz, DMSO-d6) δ7.87(s,1H),6.62(s,1H),4.77(d,J=12.9Hz,1H),4.56(d,J=12.9Hz,1H),3.94(s,3H), 3.80(d,J=13.2Hz,1H),3.74–3.69(m,2H),3.64(d,J=11.9Hz,1H),3.59–3.43(m,3H),3.31(s,2H),1.43(s,9H).
[0885] LCMS (ESI) [M+H] + =380.30.
[0886] Step 6: (R)-9-amino-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-3(4H)-carboxylic acid tert-butyl ester (Compound B10-7)
[0887] Compound B10-6 (8.0 g, 21.09 mmol, 1.0 eq) was dissolved in methanol (100 mL). Palladium on carbon (1 g) was added to the reaction system and allowed to react at room temperature under hydrogen for 12 hours. The reaction system was filtered, and the filtrate was concentrated under reduced pressure to obtain compound B10-7 (6.8 g, 92.09%) as a light gray solid.
[0888] LCMS (ESI) [M+H] + =350.35.
[0889] Step 7: (R)-9-iodo-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-3(4H)-carboxylic acid tert-butyl ester (Compound B10-8)
[0890] Compound B10-7 (1.0 g, 3.44 mmol, 1.0 eq) was dissolved in diiodomethane (10 mL), and isoamyl nitrite (671 mg, 5.72 mmol, 2.0 eq) and potassium iodide (1.43 g, 8.59 mmol, 3.0 eq) were added. The mixture was allowed to react at room temperature for 16 hours. The reaction mixture was concentrated to obtain a crude product, which was then purified by column chromatography to afford compound B10-8 (860 mg, 65.28%) as a white solid.
[0891] 1H NMR (400MHz, DMSO-d6) δ7.53(s,1H),6.57(s,1H),4.56(d,J=3.2Hz,2H),3.83(s,3H),3.69(qd,J= 11.8,11.3,3.9Hz,3H),3.53(dd,J=13.3,5.5Hz,1H),3.34–3.22(m,4H),2.98(s,1H),1.42(s,9H).
[0892] LCMS (ESI) [M+H] + =461.30.
[0893] Step 8: 3-(tert-Butyl)-9-methyl(R)-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-3,9(4H)-dicarboxylate (Compound B10-9)
[0894] Compound B10-8 (860 mg, 1.87 mmol, 1.0 eq), 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (137 mg, 0.19 mmol, 0.1 eq), and triethylamine (567 mg, 5.6 mmol, 3.0 eq) were dissolved in methanol (10 mL). The mixture was reacted at 70°C under carbon monoxide for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound B10-9 (700 mg, 95.47%) as a yellow solid.
[0895] LCMS (ESI) [M+H] + =393.40.
[0896] Step 9: (R)-3-(tert-Butoxycarbonyl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-9-carboxylic acid (Compound B10-10)
[0897] Compound B10-9 (700 mg, 1.78 mmol, 1.0 eq) was dissolved in tetrahydrofuran (5 mL) and water (1 mL), and lithium hydroxide monohydrate (150 mg, 3.57 mmol, 2.0 eq) was added. The mixture was reacted at room temperature for 12 hours. The pH was adjusted to 6 with 1M hydrochloric acid, and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to obtain a crude yellow solid, Compound B10-10 (670 mg), which was used directly in the next step.
[0898] LCMS (ESI) [M+H] + =379.35.
[0899] Step 10: (R)-9-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-10-methoxy-1,2,4a,5-tetrahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-3(4H)-carboxylic acid tert-butyl ester (Compound B10-11)
[0900] Compound B10-10 (670 mg, 1.77 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (10 mL), along with (S)-3-aminopiperidine-2,6-dione hydrochloride (321 mg, 1.95 mmol, 1.0 eq), N,N-diisopropylethylamine (687 mg, 5.31 mmol, 3.0 eq), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (1.01 g, 2.66 mmol, 1.5 eq). The mixture was reacted at room temperature for 1 hour. The reaction mixture was purified by reverse-phase column chromatography to afford compound B10-11 (500 mg, 57.81%) as a yellow solid.
[0901] LCMS (ESI) [M+H] + =489.40.
[0902] Step 11: (R)-N-((S)-2,6-dioxopiperidin-3-yl)-10-methoxy-1,2,3,4,4a,5-hexahydro-7H-benzo[e]pyrazino[2,1-c][1,4]oxazepine-9-amide (Compound B10)
[0903] Compound B10-11 (500 mg, 1.02 mmol, 1.0 eq) was dissolved in 5 mL of dichloromethane:trifluoroacetic acid (10:1) and allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford compound B10 (297 mg, 68.30%) as a white solid.
[0904] 1H NMR(600MHz,DMSO-d6)δ10.90(s,1H),8.52(d,J=7.2Hz,1H),7.76(s,1H),6.68(s,1H) ,4.82(d,J=11.5Hz,1H),4.73(dt,J=11.4,6.9Hz,1H),4.61(d,J=11.6Hz,1H),3.97(s, 3H),3.71(dd,J=13.7,2.7Hz,1H),3.61(dt,J=13.2,3.2Hz,2H),3.49(t,J=12.3Hz,1H),3.35–3.33(m, 4H), 3.17 (q, J=11.9, 11.1Hz, 2H), 2.78 (ddd, J=17.2, 12.4, 6.8Hz, 1H), 2.53 (s, 1H), 2.16–2.05 (m, 2H).
[0905] LCMS (ESI) [M+H] + =389.30.
[0906] Example 23
[0907] Synthesis of compound B11
[0908] (S)-N-((S)-2,6-Dioxopiperidin-3-yl)-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxamide
[0909] Synthesis scheme
[0910] Step 1: (S)-tert-Butyl 4-(2-fluoro-4-nitrophenyl)-3-(2-hydroxyethyl)piperazine-1-carboxylate (Compound B11-2)
[0911] Compound B11-1 (8.69 g, 37.71 mmol, 1.0 eq) was dissolved in dimethyl sulfoxide (20 mL), and tert-butyl (3S)-3-(2-hydroxyethyl)-1-piperazinecarboxylate (6.0 g, 37.71 mmol, 1.0 eq) was added. The reaction mixture was heated to 100°C and allowed to react at this temperature for 8 hours. After cooling the reaction system to room temperature, it was added to water and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain Compound B11-2 (12.0 g, 86.1%) as a yellow solid.
[0912] LCMS(ESI):[M-Boc+H] + =270.27.
[0913] Step 2: (S)-9-nitro-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B11-3)
[0914] Compound B11-2 (12.0 g, 32.49 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (50 mL), and sodium hydride (1.69 g, 42.23 mmol, 1.3 eq) was added. The reaction was allowed to react at 100°C for 8 hours. The reaction system was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B11-3 (9.0 g, 79.2%) as a yellow solid.
[0915] LCMS(ESI):[M-Boc+H] + =250.37.
[0916] Step 3: (S)-9-amino-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B11-4)
[0917] Compound B11-3 (9.0 g, 25.76 mmol, 1.0 eq) was dissolved in methanol (120 mL), and palladium / carbon (1.9 g) was added to the system. After hydrogen substitution three times, the reaction was allowed to proceed at room temperature for 12 hours. The reaction system was filtered, and the filter cake was washed three times with methanol (100 mL). After concentration under reduced pressure, the crude product, compound B11-4 (4.7 g), was obtained.
[0918] LCMS(ESI)[M-Boc+H] + =320.38.
[0919] Step 4: (S)-9-iodo-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B11-5)
[0920] Compound B11-4 (4.7 g, 14.71 mmol, 1.0 eq) was dissolved in diiodomethane (50 mL), and isoamyl nitrite (3.45 g, 29.43 mmol, 2.0 eq) and potassium iodide (7.33 g, 44.14 mmol, 3.0 eq) were added. The reaction mixture was heated to 80°C under a nitrogen atmosphere and reacted overnight. After cooling the reaction mixture to room temperature, the organic phase was concentrated and the resulting crude product was purified by column chromatography to afford compound B11-5 (3.5 g, 55.2%) as a yellow oil.
[0921] 1 H NMR (400MHz, DMSO-d6) δ7.25–7.19(m,1H),7.11–7.05(m,1H),6.78–6.70(m,1H),4.35–4.24(m,1H),4.18–4.09(m,1H),3.64–3.56(m ,1H),3.55–3.48(m,1H),3.34–3.24(m,1H),3.19–3.11(m,2H),3.11–3.04(m,2H),2.07–1.94(m,1H),1.89–1.80(m,1H),1.41(s,9H).
[0922] Step 5: (S)-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3,9-dicarboxylic acid 3-tert-butyl (Compound B11-6)
[0923] Compound B11-5 (2.1 g, 5.0 mmol, 1.0 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (612 mg, 0.749 mmol, 0.15 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (867 mg, 1.5 mmol, 0.3 eq), and triethylamine (1.52 g, 14.99 mmol, 3.0 eq) were dissolved in methanol (10 mL) and N,N-dimethylformamide (20 mL). After carbon monoxide was replaced three times, the reaction mixture was heated to 90°C and allowed to react overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain compound B11-6 (380 mg, 20.9%) as a yellow oil. 1 H NMR (600MHz, DMSO-d6) δ7.54–7.48(m,1H),7.30(d,J=2.1Hz,1H),6.98(d,J=8.5Hz,1H),4.23–4.19(m,2H),3.78(s,3H),3.58–3.51(m, 2H),3.53–3.47(m,1H),3.43–3.36(m,1H),3.32–3.25(m,3H),2.06–1.97(m,1H),1.93–1.84(m,1H),1.42(s,9H).LCMS(ESI)[M-Boc+H] + =263.37.
[0924] Step 6: (S)-3-(tert-Butyloxycarbonyl)-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxylic acid (Compound B11-7)
[0925] Compound B11-6 (380 mg, 1.05 mmol, 1.0 eq) and lithium hydroxide monohydrate (0.307 g, 7.34 mmol, 7.0 eq) were dissolved in methanol (2 mL), tetrahydrofuran (2 mL), and water (1 mL). The reaction was allowed to react overnight at room temperature. After concentration under reduced pressure, the pH of the reaction system was adjusted to 7 using dilute hydrochloric acid. The reaction system was filtered, and the filter cake was washed three times with water (5 mL). The crude product, compound B11-7 (300 mg), was obtained as a white solid.
[0926] LCMS(ESI)[M-Boc+H] + =249.17.
[0927] Step 7: ((S)-9-(((S)-2,6-dioxopiperidin-3-yl)carbamoyl)-1,2,4,4a,5,6-hexahydro-3H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-3-carboxylic acid tert-butyl ester (Compound B11-8)
[0928] Compound B11-7 (300 mg, 0.861 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (360 mg, 0.947 mmol, 1.1 eq), and N,N-diisopropylethylamine (333 mg, 2.58 mmol, 3.0 eq) were dissolved in N,N-dimethylformamide (10 mL). The reaction mixture was allowed to react at room temperature for 15 minutes. (S)-3-Aminopiperidine-2,6-dione hydrochloride (170 mg, 1.03 mmol, 1.2 eq) was added. The reaction mixture was allowed to react overnight at room temperature, then added to water and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain Compound B11-8 (350 mg, 88.6%) as a blue solid.
[0929] 1H NMR(600MHz,DMSO-d6)δ10.84(s,1H),8.55(d,J=8.4Hz,1H),7.50–7.45(m,1H),7.34(d ,J=2.1Hz,1H),7.00(d,J=8.4Hz,1H),4.77–4.70(m,1H),4.30–4.23(m,1H),4.22–4.16 (m,1H),3.66–3.59(m,1H),3.58–3.53(m,1H),3.43–3.53(m,2H),3.26–3.20(m,2H),2. 83–2.75(m,1H),2.57–2.50(m,1H),2.14–1.98(m,2H),1.95–1.84(m,2H),1.43(s,9H).
[0930] LCMS (ESI) [M+H] + =459.40.
[0931] Step 8: (S)-N-((S)-2,6-dioxopiperidin-3-yl)-2,3,4,4a,5,6-hexahydro-1H-benzo[b]pyrazino[1,2-d][1,4]oxazepine-9-carboxamide (Compound B11)
[0932] Compound B11-8 (100 mg, 0.218 mmol, 1.0 eq) was dissolved in 1,4-dioxane hydrochloric acid (1 mL, 4 N) and dichloromethane (1 mL). The reaction mixture was allowed to react overnight at room temperature. The resulting crude product was concentrated and purified by reverse-phase column chromatography to afford Compound B11 (30 mg, 38.38%) as a white solid.
[0933] 1 H NMR (400MHz, DMSO-d6) δ10.86(s,1H),8.62(d,J=8.4Hz,1H),7.57–7.49(m,1H),7.38(d ,J=2.1Hz,1H),7.09(d,J=8.4Hz,1H),4.79–4.68(m,1H),4.41–4.31(m,1H),4.19–4.09 (m,1H),3.47–3.40(m,1H),3.41–3.30(m,3H),3.27–3.18(m,1H),3.16(s,1H),3.11–2. 98(m,1H),2.85–2.71(m,1H),2.57–2.53(m,1H),2.17–2.00(m,2H),1.98–1.86(m,2H).
[0934] LCMS (ESI) [M+H]+ =359.38.
[0935] Example 24
[0936] Synthesis of compound B12
[0937] (R)-N-((S)-2,6-dioxohesperidin-3-yl)-9-methoxy-6-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline-8-carboxamide
[0938] Synthesis scheme
[0939] The first step: (R)-4-(4-bromo-5-methoxy-2-nitrophenyl)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester (Compound B12-2) was prepared with reference to the first step of Compound B5.
[0940] LCMS(ESI):[M-Boc] + =390.30.
[0941] Step 2: (R)-tert-Butyl 4-(4-bromo-5-methoxy-2-nitrophenyl)-3-(((methylsulfonyl)oxy)methyl)piperazine-1-carboxylate (Compound B12-3)
[0942] Compound B12-2 (2.0 g, 4.48 mmol, 1.0 eq) and triethylamine (907 mg, 8.96 mmol, 2.0 eq) were dissolved in dichloromethane (30 mL). The temperature was lowered to 0°C and methylsulfonyl chloride (770 mg, 6.72 mmol, 1.5 eq) was added dropwise. The mixture was allowed to react at room temperature under nitrogen for 2 hours. Saturated aqueous ammonium chloride (50 mL) was added, and the mixture was extracted with dichloromethane (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B5-3 (2.3 g, 97.88%) as a yellow solid.
[0943] LCMS(ESI):[M-Boc] + =468.38.
[0944] Step 3: (S)-8-bromo-9-methoxy-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylic acid tert-butyl ester (Compound B12-4)
[0945] Compound B12-3 (2.3 g, 4.39 mmol, 1.0 eq) and ammonium chloride (2.35 g, 43.86 mmol, 10 eq) were dissolved in ethanol / water (4:1) (50 mL). Iron powder (1.47 g, 26.32 mmol, 6 eq) was added at room temperature. The reaction was allowed to react overnight at 80°C under nitrogen. The reaction mixture was cooled to room temperature, water (150 mL) was added, and extraction was performed with ethyl acetate (3 times with 100 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B5-3 (800 mg, 45.79%) as a yellow solid.
[0946] LCMS(ESI):[M-Boc] + =342.30
[0947] Step 4: (S)-8-bromo-9-methoxy-6-methyl-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylic acid tert-butyl ester (Compound B12-5)
[0948] Compound B12-4 (800 mg, 2.01 mmol, 1.0 eq) and 37% aqueous formaldehyde solution (245 g, 3.01 mmol, 1.5 eq) were dissolved in methanol (20 mL). Sodium cyanoborohydride (252 mg, 4.02 mmol, 2 eq) was added at room temperature. The reaction mixture was allowed to react for 2 hours at room temperature. Water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound B5-3 (500 mg, 60.37%) as a white solid.
[0949] LCMS(ESI):[M-Boc] + =356.33.
[0950] Step 5: 3-(tert-butyl)8-methyl(S)-9-methoxy-6-methyl-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoline-3,8-dicarboxylate (Compound B12-6)
[0951] Prepared by referring to the fourth step of compound A8.
[0952] LCMS(ESI):[M-Boc] + =335.47.
[0953] Step 6: (S)-3-(tert-Butoxycarbonyl)-9-methoxy-6-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline-8-carboxylic acid (Compound B12-7)
[0954] Prepared according to the fifth step of compound A8
[0955] LCMS(ESI)[M-Boc] + =321.44.
[0956] Step 7: (S)-8-(((S)-2,6-dioxohesperidin-3-yl)carbamoyl)-9-methoxy-6-methyl-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylic acid tert-butyl ester (Compound B12-68)
[0957] Prepared by referring to the sixth step of compound A8.
[0958] LCMS(ESI)[M-Boc] + =431.56.
[0959] Step 8: (R)-N-((S)-2,6-dioxohesperidin-3-yl)-9-methoxy-6-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline-8-carboxamide (Compound B12)
[0960] Prepared according to step 7 of compound A8
[0961] 1 H NMR(400MHz, Methanol-d4)δ7.31(s,1H),6.59(s,1H),4.77(dd,J=12.7,5.2Hz,1H),4.30(s,1H),3.98(s,3H),3.70(s,1H),3.53–3.40(m ,2H),3.45-3.31(m,2H)3.23(s,2H),3.05(t,J=12.0Hz,2H),2.92-2.79(m,3H),2.75-2.69(m,1H),2.48-2.41(m,1H),2.13-2.02(m,1H).
[0962] LCMS (ESI) [M+H] + =332.44
[0963] Example 25
[0964] Synthesis of compound C1
[0965] 3-(2H-spiro[benzofuran-3,4'-piperidin]-6-yl)amino)piperidine-2,6-dione
[0966] Synthesis scheme
[0967] Step 1: tert-Butyl 4-((2-bromo-5-nitrophenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C1-2)
[0968] Compound C1-1 (5.0 g, 22.9 mmol, 1.0 eq), compound A1-2 (6.4 g, 29.8 mmol, 1.3 eq), and triphenylphosphine (12.0 g, 45.9 mmol, 2.0 eq) were dissolved in tetrahydrofuran (50 mL). The mixture was stirred at 0°C under nitrogen for 15 minutes. Diethyl azodicarboxylate (8.0 g, 45.9 mmol, 2.0 eq) was slowly added dropwise to the reaction system. The reaction system was allowed to react at room temperature for 12 hours. The reaction system was concentrated, and the crude product was purified by column chromatography to obtain compound C1-2 (8.0 g, 84.4%) as a colorless oil. 1 H NMR (600MHz, DMSO-d6) δ7.92(d,J=8.6Hz,1H),7.87(d,J=2.5Hz,1H),7.77(dd,J=8.7,2.5Hz,1H),5.91(s ,1H),4.74(d,J=2.1Hz,2H),3.45(d,J=5.9Hz,2H),3.34(s,2H),2.15(tt,J=4.8,2.5Hz,2H),1.41(s,9H).
[0969] LCMS(ESI):[M-Boc+H] + =313.16.
[0970] Step 2: tert-Butyl 4-((5-amino-2-bromophenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C1-3)
[0971] Compound C1-2 (5.0 g, 12.1 mmol, 1.0 eq) was dissolved in ethanol:ammonium chloride solution (5:1) (60 mL). Iron powder (6.8 g, 121.0 mmol, 10.0 eq) was added, and the reaction system was stirred at 80°C for 2 hours. Water was added to the reaction system, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, Compound C1-3 (4.0 g).
[0972] 1H NMR(600MHz,DMSO-d6)δ7.10(d,J=8.5Hz,1H),6.31(d,J=2.4Hz,1H),6.11(dd,J=8.5,2.4Hz,1 H),5.82(s,1H),5.28(s,2H),4.40(s,2H),3.51–3.43(m,2H),2.17–2.10(m,2H),1.41(s,9H).
[0973] LCMS(ESI):[M-Boc+H] + =283.15.
[0974] Step 3: tert-Butyl 4-((2-bromo-5-((2,6-dioxopiperidin-3-yl)amino)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C1-4)
[0975] Compound C1-5 (800 mg, 2.1 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL), and 3-bromopiperidine-2,6-dione (481 mg, 2.5 mmol, 1.2 eq) and sodium bicarbonate (350 mg, 4.2 mmol, 2.0 eq) were added. The mixture was reacted at 80°C for 12 hours. The reaction system was cooled to room temperature, added with water, and extracted with ethyl acetate. The mixture was washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C1-4 (565 mg, 54.7%) as a light green solid.
[0976] 1 H NMR (600MHz, DMSO-d6) δ10.82(s,1H),7.18(d,J=8.7Hz,1H),6.23(dd,J=8.7,2.5Hz,1H),6.08(d,J=7.9Hz,1H),5.84(s,1H),4.45(s,2H),4.37(ddd,J =12.2,7.9,4.9Hz,1H),3.86(s,2H),3.45(s,2H),2.78–2.70(m,1H),2.63– 2.55(m,1H),2.18–2.05(m,3H),1.87(qd,J=12.4,4.7Hz,1H),1.41(s,9H).
[0977] LCMS(ESI):[M-Boc+H] + =396.29.
[0978] Step 4: tert-Butyl 6-((2,6-dioxopiperidin-3-yl)amino)-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate (Compound C1-5)
[0979] Compound C1-4 (565 mg, 1.1 mmol, 1.0 eq) was dissolved in toluene (5 mL). Azobisisobutyronitrile (375 mg, 2.3 mmol, 2.0 eq) and tributyltin hydride (998 mg, 3.4 mmol, 3.0 eq) were added at room temperature and reacted at 110°C for 15 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to obtain compound C1-5 (220 mg, 46.3%) as a white oil.
[0980] 1 H NMR (600MHz, DMSO-d6) δ10.78(s,1H),6.91(d,J=8.1Hz,1H),6.18(dd,J=8.1,2.0Hz,1H),6.14 (d,J=2.0Hz,1H),5.77(d,J=7.6Hz,1H),4.32(s,2H),4.26(ddd,J=12.0,7.6,4.8Hz,1H),3.91– 3.79(m,2H),2.74(ddd,J=17.5,12.1,5.4Hz,1H),2.56(dt,J=17.4,4.2Hz,1H),2.08(dq,J=13. 6,4.8Hz,1H),1.84(qd,J=12.2,4.6Hz,1H),1.69–1.60(m,2H),1.60–1.53(m,2H),1.42(s,9H).
[0981] LCMS (ESI) [M+H] + =416.35.
[0982] Step 5: 3-(2H-spiro[benzofuran-3,4'-piperidin]-6-yl)amino)piperidine-2,6-dione (Compound C1)
[0983] Compound C1-6 (110 mg, 0.26 mmol, 1.0 eq) was dissolved in dichloromethane (1 mL). A solution of hydrochloric acid in 1,4-dioxane (1 mL) was added and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford Compound C1 (90 mg, 96.6%) as a white solid.
[0984] 1H NMR(600MHz,DMSO-d6)δ10.83(s,1H),6.86(dd,J=8.1,1.5Hz,1H),6.32–6 .26(m,1H),6.27–6.21(m,1H),4.39(s,2H),4.37–4.29(m,1H),3.30–3.21( m,2H),3.01–2.88(m,2H),2.73(ddd,J=17.7,12.2,5.4Hz,1H),2.57(dt,J= 17.5,4.2Hz,1H),2.13–2.00(m,3H),1.93–1.82(m,1H),1.79–1.71(m,2H).
[0985] LCMS (ESI) [M+H] + =316.35.
[0986] Example 26
[0987] Synthesis of compound C2
[0988] 3-((2H-spiro[benzofuran-3,4'-piperidin]-5-yl)amino)piperidine-2,6-dione
[0989] Synthesis scheme
[0990] Step 1: tert-Butyl 4-((2-bromo-4-nitrophenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C2-2)
[0991] Compound C2-1 (10.0 g, 45.87 mmol, 1.0 eq), A1-2 (12.72 g, 59.63 mmol, 1.3 eq), and triphenylphosphine (24.06 g, 91.74 mmol, 2.0 eq) were dissolved in tetrahydrofuran (250 mL). The temperature was cooled to 0°C, and diethyl azodicarboxylate (15.98 g, 91.74 mmol, 2.0 eq) was added. After the addition was complete, the mixture was allowed to return to room temperature and react for 12 hours. The reaction solution was concentrated under reduced pressure, and water was added. The mixture was extracted with ethyl acetate, washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to yield compound C2-2 (18.0 g, 94.95%) as a yellow solid.
[0992] 1H NMR(600MHz,DMSO-d6)δ8.41-8.46(m,1H),8.29–8.24(m,1H),7.35(d,J=9.2Hz,1H),5.89 (s,1H),4.75(s,2H),3.87(s,2H),3.45(d,J=5.9Hz,2H),2.17–2.12(m,2H),1.40(s,9H).
[0993] LCMS(ESI):[M-Boc+H] + =313.08.
[0994] Step 2: tert-Butyl 4-((4-amino-2-bromophenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C2-3)
[0995] Compound C2-2 (18.0 g, 43.56 mmol, 1.0 eq), ammonium chloride (11.65 g, 217.78 mmol, 5.0 eq), and iron powder (12.16 g, 217.78 mmol, 5.0 eq) were dissolved in ethanol (100 mL) and water (20 mL). The reaction system was heated to 60°C for 1 hour. The reaction system was filtered and concentrated under reduced pressure. Water was added and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to obtain compound C2-3 (16.0 g, 95.54%) as a yellow oil.
[0996] 1 H NMR(600MHz,DMSO-d6)δ6.83(d,J=8.7Hz,1H),6.80(d,J=2.7Hz,1H),6.53–6.48(m,1H),5.77(s,1H),4 .91(s,2H),4.35(d,J=2.1Hz,2H),3.84(s,2H),3.43(t,J=5.7Hz,2H),2.15–2.10(m,2H),1.41(s,9H).
[0997] LCMS(ESI):[M-Boc+H] + =283.18.
[0998] Step 3: tert-Butyl 4-((2-bromo-4-((2,6-dioxopiperidin-3-yl)amino)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (Compound C2-4)
[0999] Compound C2-3 (10.0 g, 26.09 mmol, 1.0 eq), 3-bromopiperidine-2,6-dione (6.01 g, 31.31 mmol, 1.2 eq), and sodium bicarbonate (4.38 g, 52.18 mmol, 2.0 eq) were dissolved in N,N-dimethylformamide (100 mL) and reacted at 80°C under nitrogen for 16 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water was added and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to obtain compound C2-4 (10.0 g, 77.5%) as a blue oil.
[1000] 1 H NMR (400MHz, DMSO-d6) δ10.78(s,1H),6.94–6.89(m,2H),6.67–6.60(m,1H),5.79(s,1H),5.77–5.74(m,1H),4.39(s,2H),4.32–4.22(m,1 H),3.84(s,2H),3.47–3.40(m,2H),2.79–2.66(m,1H),2.62–2.51(m,1H),2.14(s,2H),2.10–2.01(m,1H),1.92–1.77(m,1H),1.41(s,9H).
[1001] LCMS(ESI):[M-Boc+H] + =394.39.
[1002] Step 4: tert-Butyl 5-((2,6-dioxopiperidin-3-yl)amino)-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate (Compound C2-5)
[1003] Compound C2-4 (10.0 g, 20.23 mmol, 1.0 eq), tri-n-butyltin hydroxide (17.66 g, 60.68 mmol, 3.0 eq), and azobisisobutyronitrile (6.64 g, 40.45 mmol, 2.0 eq) were dissolved in toluene (100 mL) and reacted at 110°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. Water was added and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained from the concentrated organic phases was purified by column chromatography to yield compound C2-5 (4.0 g, 47.6%) as a yellow solid.
[1004] 1H NMR(600MHz,DMSO-d6)δ10.76(s,1H),6.64–6.59(m,1H),6.56–6.51(m,1H) ,6.47–6.43(m,1H),5.37(d,J=7.2Hz,1H),4.30(s,2H),4.25–4.17(m,1H),3 .89(s,2H),3.34(s,2H),2.77–2.68(m,1H),2.61–2.54(m,1H),2.15–2.07(m ,1H),1.87–1.77(m,1H),1.72–1.64(m,2H),1.63–1.57(m,2H),1.42(s,9H).
[1005] LCMS(ESI)[M-Boc+H] + =316.28.
[1006] Step 5: 3-((2H-spiro[benzofuran-3,4'-piperidinyl]-5-yl)amino)piperidine-2,6-dione (Compound C2)
[1007] Compound C2-5 (100 mg, 0.24 mmol, 1.0 eq) was dissolved in 1,4-dioxane hydrochloric acid solution (4N, 1 mL) and dichloromethane (1 mL). The reaction mixture was allowed to react overnight at room temperature. The resulting crude product was concentrated and purified by reverse-phase column chromatography to afford compound C2 (0.07 g, 92.22%) as a white solid.
[1008] 1 H NMR(600MHz,DMSO-d6)δ10.87(s,1H),6.66–6.61(m,2H),6.60–6.57(m,1H),5.40(s,1H),4.39(s,2H),4.27–4.21(m,1H),3.35–3.29(m,2 H),3.04–2.95(m,2H),2.75–2.66(m,1H),2.63–2.56(m,1H),2.12–2.04(m,1H),2.01–1.92(m,2H),1.91–1.83(m,1H),1.82–1.77(m,2H).
[1009] LCMS (ESI) [M+H] + =316.30
[1010] Example 27
[1011] Synthesis of compound C3
[1012] 3-(Spiro[benzopyran-2,4'-piperidin]-6-ylamino)piperidine-2,6-dione
[1013] Synthesis scheme
[1014] Step 1: tert-Butyl 6-bromo-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C3-2)
[1015] The preparation was carried out according to the first step of compound A5.
[1016] Step 2: tert-Butyl 6-bromo-4-hydroxyspiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C3-3)
[1017] Prepared by referring to the second step of compound A5.
[1018] Step 3: 6-bromospiro[chromene-2,4'-piperidine] (Compound C3-4)
[1019] Prepared by referring to the third step of compound A5.
[1020] Step 4: tert-Butyl 6-bromospiro[chromene-2,4'-piperidine]-1'-carboxylate (Compound C3-5)
[1021] Prepared by referring to the fourth step of compound A5.
[1022] Step 5: tert-Butyl 6-(Benzylamino)spiro[chromene-2,4'-piperidine]-1'-carboxylate (Compound C3-6)
[1023] Compound C3-5 (300 mg, 0.78 mmol, 1.0 eq) was dissolved in 1,4-dioxane (10 mL). Benzylamine (168 mg, 1.57 mmol, 2 eq), BrettPhos (84 mg, 0.16 mmol, 0.2 eq), tris(dibenzylideneacetone)dipalladium (144 mg, 0.14 mmol, 0.2 eq), and cesium carbonate (767 mg, 2.35 mmol, 3 eq) were added to the reaction system. The reaction was continued at 100°C under nitrogen for 12 hours. The resulting reaction system was concentrated under reduced pressure, and the resulting crude product was purified by normal phase column chromatography to afford compound C3-6 (178 mg, 55.5%) as a pale yellow liquid.
[1024] LCMS(ESI):[M+H] + =409.54
[1025] Step 6: tert-Butyl 6-aminospiro[benzopyran-2,4'-piperidine]-1'-carboxylate (Compound C3-7)
[1026] Compound C3-6 (178 mg, 0.44 mmol, 1.0 eq) was dissolved in methanol (5 mL), and palladium (20%) / carbon (36 mg, 20%) was added. After hydrogen substitution three times, the reaction was allowed to proceed at room temperature for 12 hours. The reaction system was filtered, and the filter cake was washed three times with methanol (5 mL). The resulting filtrate was concentrated under reduced pressure to obtain a crude yellow liquid of compound C3-7 (121 mg, 87.2%).
[1027] LCMS(ESI):[M+H] + =319.42
[1028] Step 7: tert-Butyl 6-((2,6-dioxopiperidin-3-yl)amino)spiro[chromane-2,4'-piperidine]-1'-carboxylate (Compound C3-8) The crude compound C3-7 (120 mg, 0.37 mmol, 1.0 eq) was dissolved in DMF (5 mL), and 3-bromopiperidine-2,6-dione (88 mg, 0.45 mmol, 1.2 eq) and sodium bicarbonate (63 mg, 0.75 mmol, 2 eq) were added to the system. The mixture was reacted at 80°C under nitrogen protection for 3 hours. After the reaction system was cooled to room temperature, preparative liquid separation was performed to obtain a gray solid compound C3-8) (72 mg, 44.5%).
[1029] LCMS(ESI):[M+H] + =430.52
[1030] Step 8: 3-(Spiro[benzopyran-2,4'-piperidin]-6-ylamino)piperidine-2,6-dione (Compound C3)
[1031] Compound C3-8 (72 mg, 0.17 mmol, 1.0 eq) was dissolved in dichloromethane (20 mL), and 1,4-dioxane hydrochloride solution (12 mg, 0.33 mmol, 2 eq) was added thereto. After the system was reacted at room temperature for 2 hours, white solid compound C3 (5 mg, 9.1%) was obtained by preparative liquid separation.
[1032] LCMS(ESI):[M+H] + =330.38
[1033] 1H NMR(600MHz,DMSO-d6)δ10.89(s,1H),8.91-8.82(m,2H),6.74–6.52(m,3H),4.31-4.23(m,1H),3.22–3.12(m,2H), 3.08–3.02(m,2H),2.76–2.64(m,3H),2.60–2.56(m,1H),2.10–2.00(m,1H),1.90–1.85(m,3H),1.82–1.72(m,4H).
[1034] Example 28
[1035] Synthesis of compound C4
[1036] 3-(Spiro[chroman-2,4'-piperidin]-7-ylamino)piperidine-2,6-dione
[1037] Synthesis scheme
[1038] Step 1: tert-Butyl 7-bromo-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-2)
[1039] Compound C4-1 (25 g, 116.25 mmol, 1.0 eq.), tert-butyl 4-oxopiperidine-1-carboxylate (23.16 g, 116.25 mmol, 1.0 eq.), and tetrahydropyrrole (4.13 g, 58.13 mmol, 0.5 eq.) were dissolved in methanol (250 mL). The reaction mixture was heated to 70°C and reacted for 16 hours. After cooling the reaction mixture to room temperature, the mixture was filtered to obtain compound C4-2 (40 g, 86.83%) as a yellow solid.
[1040] 1 H NMR(400MHz,Chloroform-d)δ7.73(d,J=8.4Hz,1H),7.23(d,J=1.8Hz,1H),7.17(dd,J=8.4,1.8Hz,1H),3.9 0(s,2H),3.21(t,J=12.6Hz,2H),2.73(s,2H),2.02(dd,J=14.4,2.8Hz,2H),1.66–1.58(m,2H),1.48(s,9H).
[1041] LCMS(ESI):[M-tBu+H] + =340.20.
[1042] Step 2: tert-Butyl 7-bromo-4-hydroxyspiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-3)
[1043] Compound C4-2 (40 g, 100.94 mmol, 1.0 eq.) was dissolved in methanol (400 mL). The reaction system was cooled to 0°C and sodium borohydride (5.73 g, 151.41 mmol, 1.5 eq.) was added. The reaction was allowed to react overnight at room temperature. After concentration under reduced pressure, water was added and the mixture was extracted three times with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The organic phases were concentrated to yield the crude product, Compound C4-3 (40 g, 99.49%), as a white solid.
[1044] LCMS(ESI):[M-Boc+H] + =298.20.
[1045] Step 3: 7-bromospiro[chroman-2,4'-piperidine] (Compound C4-4)
[1046] Compound C4-3 (40.0 g, 100.43 mmol, 1.0 eq.) was dissolved in trifluoroacetic acid (200 mL) and triethylsilyl hydrochloride (17.52 g, 150.64 mmol, 1.5 eq.) was added. The system was heated to 50°C and reacted overnight. After cooling the reaction system to room temperature, it was concentrated under reduced pressure to obtain crude compound C4-4 (28.0 g), which was used directly in the next step.
[1047] LCMS(ESI):[M+H] + =282.20.
[1048] Step 4: tert-Butyl 7-bromospiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-5)
[1049] Compound C4-4 (28.0 g, 99.23 mmol, 1.0 eq.) was dissolved in dichloromethane (300 mL). The reaction system was cooled to 0°C and triethylamine (30.12 g, 297.68 mmol, 3.0 eq.) and di-tert-butyl dicarbonate (32.48 g, 148.84 mmol, 1.5 eq.) were added. The reaction was allowed to react overnight at room temperature. The reaction system was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to obtain compound C4-5 (32 g, 84.36%) as a white solid.
[1050] 1H NMR(400MHz,Chloroform-d)δ7.03(d,J=2.0Hz,1H),7.00–6.91(m,2H),3.90(s,2H),3.21 (s,2H),2.74(t,J=6.8Hz,2H),1.80(q,J=7.7,7.3Hz,4H),1.59–1.50(m,2H),1.49(s,9H).
[1051] Step 5: tert-Butyl 7-(benzylamino)spiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-6)
[1052] Compound C4-5 (500 mg, 1.31 mmol, 1.0 eq.), benzylamine (350 mg, 3.27 mmol, 2.5 eq.), tris(dibenzylideneacetone)dipalladium (120 mg, 0.13 mmol, 0.1 eq.), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-tri-1-propyl-11'-biphenyl (140 mg, 0.26 mmol, 0.2 eq.), and cesium carbonate (1.28 g, 3.92 mmol, 3.0 eq.) were added to ultra-dry 1,4-dioxane (10 mL) and reacted at 80°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to afford compound C4-6 (500 mg, 93.58%) as a yellow solid.
[1053] 1 H NMR (400MHz, DMSO-d6) δ7.41–7.27(m,5H),6.72(d,J=8.2Hz,1H),6.14(dd,J=8.2,2.3Hz,1H),5.96(d,J=2.3Hz,1H),4.19(d,J=6.1Hz ,2H),3.65(d,J=13.0Hz,2H),3.10(s,2H),2.54(d,J=6.7Hz,2H),1.73–1.58(m,4H),1.51–1.42(m,2H),1.40(s,9H).LCMS(ESI)[M+H] + =409.45.
[1054] Step 6: tert-Butyl 7-aminospiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-7)
[1055] Compound C4-6 (500 mg, 1.22 mmol, 1.0 eq.) was dissolved in methanol (5 mL) and palladium on carbon (50 mg) was added. The reaction was allowed to proceed at room temperature under hydrogen for 16 hours. The reaction system was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain C4-7 (350 mg, 89.81%) as a yellow solid.
[1056] 1 H NMR (400MHz, DMSO-d6) δ6.68(d,J=8.1Hz,1H),6.08(dd,J=8.0,2.2Hz,1H),5.99(d,J=2.2Hz,1H),4.8 1(s,2H),3.69(d,J=13.0Hz,2H),3.10(s,2H),2.54(d,J=6.8Hz,2H),1.73–1.60(m,4H),1.40(s,11H).
[1057] LCMS (ESI) [M+H] + =319.35.
[1058] Step 7: tert-Butyl 7-((2,6-dioxopiperidin-3-yl)amino)spiro[chroman-2,4'-piperidine]-1'-carboxylate (Compound C4-8)
[1059] Compound C4-7 (350 mg, 1.10 mmol, 1.0 eq.) was dissolved in N,N-dimethylformamide (3.5 mL), and 3-bromopiperidine-2,6-dione (422 mg, 2.20 mmol, 2.0 eq.) and sodium bicarbonate (185 mg, 2.20 mmol, 2.0 eq.) were added. The mixture was reacted at 80°C for 12 hours. The reaction system was cooled to room temperature, added with water, and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to yield compound C4-8 (400 mg, 84.72%) as a light blue solid.
[1060] 1H NMR (600MHz, DMSO-d6) δ10.76(s,1H),7.96(s,1H),6.76(d,J=8.3Hz,1H),6.21(dd,J=8.2,2.3Hz,1 H), 6.10 (d, J = 2.3Hz, 1H), 5.62 (d, J = 7.6Hz, 1H), 4.25 (ddd, J = 12.0, 7.6, 4.8Hz, 1H), 3.68 (d, J = 12. 8Hz,2H),3.14(d,J=30.8Hz,2H),2.57(t,J=6.8Hz,3H),2.10–2.05(m,1H),1.83(dd,J=12.3,4.4Hz ,1H),1.72(t,J=6.8Hz,2H),1.66(d,J=13.6Hz,2H),1.49(dq,J=13.4,5.9,5.4Hz,2H),1.41(s,9H).
[1061] LCMS(ESI)[M-Boc+H] + =374.35.
[1062] Step 8: 3-(Spiro[chromium-2,4'-piperidinyl]-7-ylamino)piperidine-2,6-dione (Compound C4)
[1063] Compound C4-8 (300 mg, 0.70 mmol, 1.0 eq.) was dissolved in dichloromethane (1 mL). A solution of hydrochloric acid in 1,4-dioxane (1 mL) was added and allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford Compound C5 (223 mg, 87.27%) as a blue solid.
[1064] 1 H NMR (600MHz, DMSO-d6) δ10.85(d,J=4.5Hz,1H),9.37(d,J=12.9Hz,1H),9.14(d,J=13 .1Hz,1H),6.85(dd,J=8.4,3.8Hz,1H),6.37(s,1H),6.28(d,J=7.3Hz,1H),4.34(dt,J =11.0,4.9Hz,1H),3.16(d,J=12.5Hz,2H),3.04(t,J=12.3Hz,2H),2.74(ddd,J=17.6, 12.4,5.4Hz,1H),2.66–2.53(m,3H),2.05(dt,J=13.4,4.6Hz,1H),1.94–1.71(m,7H).
[1065] LCMS (ESI) [M+H] +=330.30
[1066] Example 29
[1067] Synthesis of compound C5
[1068] 3-((3H-spiro[benzofuran-2,4'-piperidin]-6-yl)amino)piperidine-2,6-dione
[1069] Synthesis scheme
[1070] Step 1: tert-Butyl 4-(4-bromo-2-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (Compound C5-2)
[1071] Compound C5-1 (5.0 g, 18.7 mmol, 1.0 eq), magnesium (680 mg, 28.0 mmol, 1.5 eq), and iodine (95 mg, 0.37 mmol, 0.02 eq) were added to diethyl ether (30 mL) and stirred at reflux under nitrogen for 1 hour. N-tert-Butyloxycarbonyl-4-piperidone (3.7 g, 18.7 mmol, 1.0 eq) was dissolved in diethyl ether (30 mL), and Grignard reagent was added at -78°C. The mixture was stirred at room temperature for 12 hours. The resulting reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography to afford compound C5-2 (1.25 g, 17.3%) as a colorless oil.
[1072] 1 H NMR (600MHz, DMSO-d6) δ7.46 (dd, J=9.5, 2.0Hz, 1H), 7.34 (dd, J=8.2, 2.0Hz, 1H), 7.27 (t, J=8. 1Hz,1H),4.52(s,1H),3.70–3.60(m,2H),3.10–2.92(m,2H),2.68(s,2H),1.45–1.30(m,13H).
[1073] LCMS(ESI):[M-tBu-OH+H] + =316.18.
[1074] Step 2: tert-Butyl 6-bromo-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate (Compound C5-3)
[1075] Compound C5-2 (1.0 g, 2.6 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (20 mL). Sodium hydride (206 mg, 5.2 mmol, 2.0 eq) was added at 0°C and reacted at 110°C under nitrogen for 2 hours. The reaction system was cooled to room temperature and then added with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate and washed with saturated brine. The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C5-3 (500 mg, 52.7%) as a white solid.
[1076] 1 H NMR(600MHz,DMSO-d6)δ7.16(dd,J=7.8,1.1Hz,1H),7.01–6.97(m,2H),3.53–3.48(m,2 H),3.42–3.36(m,2H),2.99(s,2H),1.79–1.74(m,2H),1.73–1.67(m,2H),1.41(s,9H).
[1077] LCMS(ESI):[M-Boc+H] + =270.27.
[1078] Step 3: tert-Butyl 6-(Benzylamino)-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate (Compound C5-4)
[1079] Compound C5-3 (500 mg, 1.4 mmol, 1.0 eq), benzylamine (363 mg, 3.4 mmol, 2.5 eq), tris(dibenzylideneacetone)dipalladium (124 mg, 0.14 mmol, 0.1 eq), 2-(dicyclohexylphosphine)-3,6-dimethoxy-2'-4'-6'-tri-1-propyl-11'-biphenyl (146 mg, 0.27 mmol, 0.2 eq), and cesium carbonate (668 mg, 4.1 mmol, 3.0 eq) were added to ultra-dry 1,4-dioxane (10 mL) and reacted at 80°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain compound C5-4 (300 mg, 56.0%) as a yellow solid.
[1080] 1H NMR (600MHz, DMSO-d6) δ7.35–7.29(m,4H),7.23–7.20(m,1H),6.82(d,J=8.0Hz,1H),6.13(t,J=6.0Hz,1H),6.07(dt,J=8.1,1.6Hz,1H),5.97–5 .95(m,1H),4.23–4.19(m,2H),3.52–3.43(m,2H),3.40–3.36(m,2H),2. 81(s,2H),1.73–1.65(m,2H),1.65–1.58(m,2H),1.40(d,J=1.2Hz,9H).
[1081] LCMS(ESI):[M+H] + =395.40.
[1082] Step 4: tert-Butyl 6-amino-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate (Compound C5-5)
[1083] Compound C5-4 (300 mg, 0.76 mmol, 1.0 eq) was dissolved in methanol (10 mL) and palladium / carbon (60 mg) was added. The mixture was reacted at room temperature under hydrogen pressure for 12 hours. The reaction system was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product, compound C5-5 (200 mg).
[1084] LCMS (ESI) [M+H] + =305.30.
[1085] Step 5: tert-Butyl 6-((2,6-dioxopiperidin-3-yl)amino)-3H-spiro[benzofuran-2,4'-piperidine]-1'-carboxylate (Compound C5-6)
[1086] Compound C5-5 (100 mg, 0.33 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL), and 3-bromopiperidine-2,6-dione (75 mg, 0.39 mmol, 1.5 eq) and sodium bicarbonate (55 mg, 0.66 mmol, 2.0 eq) were added. The mixture was reacted at 80°C for 12 hours. The reaction system was cooled to room temperature, and water was added. The mixture was extracted with ethyl acetate and washed with saturated brine. The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C5-6 (80 mg, 58.6%) as a light green solid.
[1087] 1H NMR (400MHz, DMSO-d6) δ10.78(s,1H),6.86(d,J=7.9Hz,1H),6.18–6.13(m,2H),5.70(d,J=7.5Hz,1H),4.25(ddd,J=11.9,7.5,4.8Hz,1H),3 .56–3.48(m,2H),3.40–3.32(m,2H),2.85(s,2H),2.79–2.67(m,1H), 2.60–2.52(m,1H),2.13–2.05(m,1H),1.89–1.59(m,5H),1.41(s,9H).
[1088] LCMS (ESI) [M+H] + =416.25.
[1089] Step 6: 3-((3H-spiro[benzofuran-2,4'-piperidinyl]-6-yl)amino)piperidine-2,6-dione (Compound C5)
[1090] Compound C5-6 (75 mg, 0.18 mmol, 1.0 eq) was dissolved in dichloromethane (1 mL). A solution of hydrochloric acid in 1,4-dioxane (1 mL) was added and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography to afford compound C5 (50 mg, 78.7%) as a white solid.
[1091] 1 H NMR(600MHz,DMSO-d6)δ10.82(s,1H),6.90(d,J=8.0Hz,1H),6.26–6.19(m,2H),4.31–4.25(m,1H),3.22–3.09(m,4H),2.9 3(s,2H),2.73(ddd,J=17.5,12.2,5.4Hz,1H),2.61–2.54(m,1H),2.11–2.04(m,1H),2.02–1.91(m,4H),1.90–1.80(m,1H).
[1092] LCMS (ESI) [M+H] + =316.40.
[1093] Example 30
[1094] Synthesis of compound C6
[1095] 3-(Spiro[benzopyran-3,4'-piperidin]-7-ylamino)piperidine-2,6-dione
[1096] Synthesis scheme
[1097] Step 1: 4-(4-bromo-2-fluorobenzyl)piperidine-1,4-dicarboxylic acid-1-tert-butyl-4-ethyl ester (Compound C6-1)
[1098] Dissolve diisopropylamine (2.91 g, 28.74 mmol, 1.1 eq) in ultra-dry tetrahydrofuran (50 mL). Add n-butyllithium (1.84 g, 11.0 mmol, 1.1 eq) to the reaction system and react at -30°C under nitrogen for 30 minutes. Cool to -70°C and add a solution of 1-tert-butyl 4-ethylpiperidine-1,4-dicarboxylate (6.72 g, 26.13 mmol, 1 eq) in tetrahydrofuran dropwise. After the addition is complete, react at -70°C for 1 hour. Add a solution of C6-1 (7.0 g, 26.13 mmol, 1.0 eq) in tetrahydrofuran to the reaction system. After the addition is complete, react at -70°C for 2 hours. Add saturated aqueous ammonium chloride to the reaction system and extract with ethyl acetate. Wash with saturated brine. Combine the organic phases and dry over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain yellow oily compound C6-1 (8.5 g, 75.9%).
[1099] 1 H NMR(600MHz,DMSO-d6)δ7.50–7.45(m,1H),7.36–7.31(m,1H),7.17–7.11(m,1H),4.10–4.00(m,3H),3.83–3.79(m,2H),2 .81(s,2H),2.71–2.68(m,1H),2.65–2.62(m,1H),1.93–1.87(m,2H),1.38(s,9H),1.19–1.15(m,2H),1.14–1.11(m,2H).
[1100] LCMS(ESI):[M-Boc+H] + =344.29.
[1101] Step 2: tert-Butyl 4-(4-bromo-2-fluorobenzyl)-4-hydroxymethylpiperidine-1-carboxylate (Compound C6-2)
[1102] Compound C6-1 (8.5 g, 19.13 mmol, 1.0 eq) was dissolved in tetrahydrofuran (200 mL). After cooling to 0°C, lithium aluminum hydride (798 mg, 11.04 mmol, 1.1 eq) was added portionwise. The mixture was allowed to return to room temperature and reacted for 8 hours. The mixture was quenched by adding water, extracted with ethyl acetate, washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C6-2 (4.26 g, 55.35%) as a white solid.
[1103] 1 H NMR (600MHz, DMSO-d6) δ7.49–7.44(m,1H),7.37–7.31(m,1H),7.29–7.24(m,1H),4.75–4.71m,1H),3.45–3. 40(m,1H),3.42–3.38(m,1H),3.27–3.17(m,4H),2.67–2.60(m,2H),1.38–1.32(m,11H),1.21–1.13(m,2H).
[1104] LCMS(ESI):[M-Boc+H] + =302.18.
[1105] Step 3: tert-Butyl 7-bromospiro[benzopyran-3,4'-piperidine]-1'-carboxylate (Compound C6-3)
[1106] Compound C6-2 (4.25 g, 10.59 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (20 mL). Sodium hydride (508 mg, 12.71 mmol, 1.2 eq) was added under ice-cooling, and the reaction was continued at 100°C for 8 hours. The reaction system was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C6-3 (2.2 g, 54.3%) as a yellow solid.
[1107] 1 H NMR(400MHz,DMSO-d6)δ7.01–6.95(m,3H),3.91(s,2H),3.50–3.39(m,2H),3.30–3.21(m ,2H),2.64(s,2H),1.40(s,9H),1.38–1.32(m,2H),1.35–1.29(m,1H),1.32–1.14(m,1H).
[1108] LCMS(ESI):[M-Boc+H] +=282.38.
[1109] Step 4: tert-Butyl 7-benzylaminospiro[benzopyran-3,4'-piperidine]-1'-carboxylate (Compound C6-4)
[1110] Compound C6-3 (1.34 g, 3.51 mmol, 1.0 eq) was dissolved in 1,4-dioxane (10 mL). Benzylamine (8.89 g, 49.95 mmol, 1.5 eq), cesium carbonate (3.43 g, 10.52 mmol, 3.0 eq), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-tri-1-propyl-11'-biphenyl (376 mg, 0.701 mmol, 0.2 eq), and tris(dibenzylideneacetone)dipalladium (320 mg, 0.35 mmol, 0.1 eq) were added to the reaction system. The reaction was carried out at 80°C under nitrogen protection for 16 hours. The reaction solution was concentrated under reduced pressure, water was added to the system, and the mixture was extracted with ethyl acetate. The mixture was washed with saturated brine, and the organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to obtain yellow solid compound C6-4 (1.3 g, 90.7%).
[1111] 1 H NMR (400MHz, DMSO-d6) δ7.37–7.27(m,3H),7.26–7.17(m,1H),6.69(d,J=8.2Hz,1H),6.18–6.11(m,1H),6.10–6.03(m,1H),5.90–5.89(m,1H) ),4.18(d,J=6.0Hz,2H),3.75(s,2H),3.41–3.52(m,1H),3.44–3.37(m ,1H),3.28–3.17(m,2H),2.46(s,2H),1.39(s,9H),1.33–1.20(m,4H).
[1112] LCMS(ESI):[M+H] + =409.69.
[1113] Step 5: tert-Butyl 7-aminospiro[benzo[piperidin-3,4'-piperidin]-1'-carboxylate (Compound C6-5)
[1114] Compound C6-4 (1.2 g, 2.94 mmol, 1.0 eq) was dissolved in methanol (50 mL) and ethyl acetate (50 mL), and palladium hydroxide / carbon (170 mg) was added to the system. After hydrogen replacement three times, the reaction was carried out at room temperature for 12 hours. The reaction system was filtered, and the filter cake was washed three times with methanol (15 mL). The filtrate was concentrated under reduced pressure to obtain the crude product C6-5 (900 mg, 96.2%). The crude product was directly used for the next reaction without further purification.
[1115] LCMS(ESI):[M+H] + =319.60.
[1116] Step 6: Tert-butyl 7-((2,6-dioxopiperidin-3-yl)amino)spiro[chromene-3,4'-piperidine]-1'-carboxylate (Compound C6-6): Compound C6-5 (900 mg, 2.83 mmol, 1.0 eq), 3-bromopiperidine-2,6-dione (650 mg, 3.39 mmol, 1.2 eq), and sodium bicarbonate (474 mg, 5.65 mmol, 2.0 eq) were dissolved in N,N-dimethylformamide (5 mL) and reacted at 80°C under nitrogen for 16 hours. The reaction system was cooled to room temperature, concentrated under reduced pressure, and then water was added and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by reverse-phase column chromatography to obtain compound C6-6 (810 mg, 66.7%) as a green solid.
[1117] 1 H NMR(600MHz,DMSO-d6)δ10.77(s,1H),6.75(d,J=8.2Hz,1H),6.25–6.20(m,1H ),6.09(d,J=2.3Hz,1H),5.64(d,J=7.5Hz,1H),4.26–4.20(m,1H),3.80(s,2H ),3.48–3.41(m,2H),3.26(s,2H),2.79–2.69(m,1H),2.62–2.52(m,1H),2.50 (s,2H),2.12–2.04(m,1H),1.87–1.78(m,1H),1.40(s,9H),1.35–1.25(m,4H).
[1118] LCMS(ESI):[M+H] + =430.29.
[1119] Step 7: 3-(Spiro[benzopyran-3,4'-piperidin]-7-ylamino)piperidine-2,6-dione (Compound C6)
[1120] Compound C6-6 (800 mg, 1.86 mmol, 1.0 eq) was dissolved in 1,4-dioxane hydrochloric acid solution (3 mL) and dichloromethane (8 mL). The reaction mixture was allowed to react overnight at room temperature. The reaction mixture was filtered, and the filter cake was washed three times with acetonitrile (10 mL) to obtain compound C6 (500 mg, 81.3%) as a white solid.
[1121] 1 H NMR(600MHz,DMSO-d6)δ10.89(s,1H),9.11(s,1H),9.06(s,1H),6.86–6.8 2m,1H),6.42–6.37(m,1H),6.29–6.25(m,1H),4.36–4.30(m,1H),3.87(s,2 H),3.12–3.05(m,2H),3.08–3.00(m,2H),2.75–2.67(m,1H),2.58(s,2H),2 .61–2.54(m,1H),2.07–1.99(m,1H),1.93–1.83(m,1H),1.66–1.53(m,4H).
[1122] LCMS (ESI) [M+H] + =330.30.
[1123] Example 31
[1124] Synthesis of compound C7
[1125] 3-(Spiro[azetidine-3,2'-chroman]-7'-ylamino)piperidine-2,6-dione
[1126] Synthesis scheme
[1127] Step 1: tert-Butyl 7'-bromo-4'-oxospiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-1)
[1128] Compound C4-1 (10.0 g, 46.5 mmol, 1 eq) was dissolved in ethanol (100 mL), and N-tert-butyloxycarbonyl-3-azetidinone (8.8 g, 51.2 mmol, 1.1 eq) and tetrahydropyrrole (3.6 g, 51.2 mmol, 1.1 eq) were added. The mixture was stirred at 50°C under nitrogen for 12 hours. After cooling to room temperature, the reaction system was extracted with ethyl acetate, washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C7-1 (5.5 g, 32.1%) as a yellow solid.
[1129] 1 H NMR (600MHz, DMSO-d6) δ7.67(d,J=8.4Hz,1H),7.48(d,J=1.8Hz,1H),7.33(dd,J=8.4 ,1.8Hz,1H),3.99(d,J=9.6Hz,2H),3.90(d,J=9.6Hz,2H),3.19(s,2H),1.38(s,9H).
[1130] LCMS(ESI):[M-Boc+H] + =268.17.
[1131] Step 2: tert-Butyl 7'-bromo-4'-hydroxyspiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-2)
[1132] Methanol (50 mL) was added to compound C7-1 (5.5 g, 14.9 mmol, 1 eq). Sodium borohydride (969 mg, 25.6 mmol, 1.5 eq) was added at 0°C and allowed to react at room temperature for 12 hours. The reaction system was concentrated under reduced pressure, water was added, and the mixture was extracted with ethyl acetate. The organic phases were washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure to obtain the crude product, compound C7-2 (5.5 g).
[1133] 1 H NMR (400MHz, DMSO-d6) δ7.31–7.25(m,1H),7.12(dd,J=8.2,2.0Hz,1H),7.07(d,J=2.0Hz,1H),5.56(d,J=5.1Hz,1H),4.75 –4.62(m,1H),4.15(d,J=9.6Hz,1H),4.00(d,J=9.7Hz,1H),3.82(dd,J=19.0,9.5Hz,2H),2.30–2.10(m,2H),1.38(s,9H).
[1134] LCMS(ESI):[M-Boc+H] + =272.17.
[1135] Step 3: 7'-bromospiro[azetidine-3,2'-chroman] (Compound C7-3)
[1136] Compound C7-2 (5.5 g, 14.8 mmol, 1.0 eq) was dissolved in trifluoroacetic acid (20 mL) and triethylsilane (3.5 g, 30.0 mmol, 2.0 eq) was added. The mixture was reacted at 50°C for 1 hour. After cooling the reaction system to room temperature, the reaction solution was concentrated under reduced pressure to obtain the crude product C7-3 (3.8 g).
[1137] LCMS (ESI) [M+H] + =252.17.
[1138] Step 4: tert-Butyl 7'-bromospiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-4)
[1139] Compound C7-3 (3.8 g, 14.8 mmol, 1.0 eq) was dissolved in dichloromethane (40 mL). Triethylamine (4.5 g, 44.5 mmol, 3.0 eq) and di-tert-butyl dicarbonate (4.9 g, 22.3 mmol, 1.5 eq) were added at 0°C. The mixture was allowed to react at room temperature for 12 hours. Water was added to the reaction system, and the mixture was extracted with dichloromethane. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentration of the organic phase was purified by column chromatography to obtain compound C7-4 (2.3 g, 43.2%) as a white solid.
[1140] 1 H NMR (400MHz, DMSO-d6) δ7.09–7.02(m,3H),3.93(d,J=9.3Hz,2H),3.82(d,J=9.3Hz,2H),2.74(t,J=6.5Hz,2H),2.06(t,J=6.5Hz,2H),1.39(s,9H).
[1141] LCMS(ESI)[M-Boc+H] + =254.17.
[1142] Step 5: tert-Butyl 7'-(Benzylamino)spiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-5)
[1143] Compound C7-4 (3.5 g, 9.8 mmol, 1.0 eq), benzylamine (2.6 g, 24.6 mmol, 2.5 eq), tris(dibenzylideneacetone)dipalladium (901 mg, 0.89 mmol, 0.1 eq), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-tri-1-propyl-11'-biphenyl (1.05 g, 2.0 mmol, 0.2 eq), and cesium carbonate (9.6 g, 29.5 mmol, 3.0 eq) were added to ultra-dry 1,4-dioxane (40 mL) and reacted at 80°C under nitrogen for 12 hours. The reaction system was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by column chromatography to obtain compound C7-5 (2.0 g, 52.2%) as a white solid.
[1144] 1H NMR (400MHz, DMSO-d6) δ7.35–7.28(m,4H),7.26–7.18(m,1H),6.72(d,J=8.3Hz,1H),6.23–6.09(m,2H),5.96(d,J=2.2H z,1H),4.20(s,2H),3.84(d,J=9.1Hz,2H),3.74(d,J=9.1Hz,2H),2.58(t,J=6.5Hz,2H),2.01–1.92(m,2H),1.38(s,9H).
[1145] LCMS(ESI):[M+H] + =381.49.
[1146] Step 6: tert-Butyl 7'-aminospiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-6)
[1147] Compound C7-5 (2.0 g, 5.1 mmol, 1.0 eq) was dissolved in methanol (20 mL) and palladium / carbon (400 mg) was added. The reaction was allowed to proceed at room temperature under hydrogen pressure for 12 hours. The reaction system was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product, compound C7-6 (1.0 g).
[1148] LCMS (ESI) [M+H] + =291.37.
[1149] Step 7: tert-Butyl 7'-((2,6-piperidin-3-yl)amino)spiro[azetidine-3,2'-chroman]-1-carboxylate (Compound C7-7) Compound C7-6 (1.0 g, 3.5 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (15 mL), and 3-bromopiperidine-2,6-di...
Claims
1. A compound as shown in formula I or its isomer, isotopic derivative, polymorph, prodrug, or pharmaceutically acceptable salt or solvate: in, G a and G b Each independently selected from O, S, and Se; preferably, G a and G b Each independently is O; R 31 , and R 32 Each time it appears, it is independently CR a R b ; R 33 , R 34 , R a , and R b Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl, wherein the alkyl, heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, an alkyl, a heteroalkyl, an alkoxyl, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclyl, an alkenyl, an alkynyl, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, an aryl and a heteroaryl; preferably, R 33 , R 34 , R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, hydroxyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl and C3-C6 heterocyclyl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, wherein the alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyl and heterocyclyl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cycloalkyl and heterocyclyl; preferably, R 33 , R 34 , R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, hydroxyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl and C1-C6 alkoxy, wherein the alkyl, haloalkyl, hydroxyalkyl and alkoxy are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl and hydroxyl; preferably, R 33 , R 34 , R a , and R b Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl and C1-C3 alkoxy; n is 0, 1, 2 or 3; When R 35 and R 36 The carbon atom to which it is attached, and R 41 When they form a ring together and d1 is 1: R 35 and R 36 Each independently selected from CR a R b 、C(=S)、C(=O)、NR a or SO2, and R 35 and R 36 At least one of them is C(=O); R 41 is N; R 37 and R 38 The carbon atom attached to it forms And R 39 and R 40 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 39 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, and a hydroxyl group; or R 38 and R 39 The carbon atom attached to it forms And R 37 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group alkyl, alkyloxy, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; or R 39 and R 40 The carbon atom attached to it forms And R 37 and R 38 each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, R d , R e , R f , R g , R D , R E , R F , R J , R K , R L , R Q , R W , R M , and R G Each occurrence is independently C(R m )2. NR m , C(=O), O or S; preferably, R d and R e Each occurrence has at least one O and at least one R D and R E Each occurrence has at least one and at least one is O; preferably, R d and R e Each occurrence has at least one O, and R D and R E Each occurrence has one and at least one value of O; preferably, R d and R e Each time it occurs, there is one and only one O, and R D and R E Each time it appears, there is one and one is O; W 3 , W 4 , W 5 and W 6 Each time it appears, it is independently CR m or N, preferably, W 3 , W 4 , W 5 and W 6 Each occurrence is independently CH or N; and R h and R H Each time it appears, it is NR independently 1h , C(=O), SO2 or CR 2h R 3h Preferably, R h and R H Each occurrence is independently NH, C(═O), C(Cl)H or C(OH)H; preferably, R h and R H Each occurrence is independently NH; When d1 is 0, R 35 and R 41 When forming a ring with the carbon atom to which it is attached: R 35 -N(R a )-W 11 -, W 11 Selected from CR a R b 、C(=O)、C(=S)、NR a and SO2, preferably W 11 is C(=O); preferably, R 35 is -N(CH3)-C(=O)-; R 41 is N; R 37 and R 38 The carbon atom attached to it forms And R 39 and R 40 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 39 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, and a hydroxyl group; or R 38 and R 39 The carbon atom attached to it forms And R 37 and R 40 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 37 and R 40 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, and a hydroxyl group; or R 39 and R 40 The carbon atom attached to it forms And R 37 and R 38 each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, R d1 , R e1 , R f1 , R g1 , R D1 , R E1 , R F1 , and R G1 Each occurrence is independently C(R m )2. NR m , C(=O), O or S; preferably, R d1 , and R e1 Each occurrence has at least one O and at least one R D1 , and R E1 Each time it appears, there is at least one occurrence and at least one of them is O; W 31 and W 41 Each time it appears, it is independently CR m or N, preferably CH or N; and R h1 and R H1 Each time it appears, it is NR independently 1h , C(=O), SO2 or CR 2h R 3h Preferably, R h1 and R H1 Each occurrence is independently NH, C═O, CHCl or CHOH; When R 36 and R 41 There is no chemical bond between 35 and R 36 The carbon atom to which it is attached, and R 41 No ring is formed and d1 is 1: R 35 is a single bond; R 41 Selected from -NR a -、-NR a CO-, C1-C6 alkylene, C1-C6 haloalkylene; preferably, R 41 Selected from -NH-CO-, -NH- and -N(CH3)-; R 37 and R 38 The carbon atom attached to it forms And R 39 , R 40 and R 36 Each is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group. alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; preferably, R 39 , R 40 and R 36 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; more preferably, R 39 , R 40 and R 36 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group; or R 38 and R 39 The carbon atom attached to it forms And R 37 , R 40 and R 36 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 37 , R 40 and R 36 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; more preferably, R 37 , R 40 and R 36 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group; or R 39 and R 40 The carbon atom attached to it forms And R 36 , R 37 and R 38 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 36 , R 37 and R 38 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; more preferably, R 36 , R 37 and R 38 Each independently selected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterium alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and hydroxy; or R 40 and R 36 The carbon atom attached to it forms And R 37 , R 38 and R 39 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 37 , R 38 and R 39 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, and an amino group; more preferably, R 37 , R 38 and R 39 Each is independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, and a hydroxyl group; R 3a , R 3b , R 4a , R 4b , R 3A , R 3B , R 4A , and R 4B Each occurrence is independently selected from C(R a )2. NR a , C(O), O and S, and R 3A or R 4A Each occurrence has at least one O and at least one R 3a or R 4a At least one of each occurrence is O or N(CH3); preferably, R 3A or R 4A Each occurrence has at least one O and at least one R 3a or R 4a Each time it appears, there is at least one occurrence and at least one of them is O; W 3a and W 4a Each time it appears, it is independently CR a or N, and W 3a and W 4a At least one of them is a N atom; R a and R A Each time it appears, it is NR independently 4h , C(=O), SO2 or CR 2h R 3h Preferably, R a and R A Each time it appears, it is NR independently 4h , SO2 or CR 2h R 3h Preferably, R A or R a is -NH or -NC(O)CH3; and R 4h is selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxyl, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclic group, an aryl, and a heteroaryl, wherein the alkyl, heteroalkyl, alkoxyl, cycloalkyl, a heterocyclic group, an aryl, and a heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, an alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclic group, an alkylamino, an alkylacyl, an alkylaminoacyl, an aryl and a heteroaryl; preferably, R 4h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, hydroxyl and C1-C3 alkoxy; and When R 41 Selected from -NR a CO-, and R 38 and R 39 The carbon atom attached to it forms or R 39 and R 40 The carbon atom attached to it forms m1 is 2, R 3a The two occurrences are independently O and CH2, respectively. When m2 is 0, R 37 , R 36 At least one is not H, and R 36 Not for F; R m , R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclyl, an aryl, and a heteroaryl, wherein the alkyl, heteroalkyl, alkoxy, cycloalkyl, a heterocyclyl, an aryl, and a heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, an alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclyl, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, an aryl, and a heteroaryl; preferably, R m , R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, a hydroxyl group, and an alkyl acyl group; preferably, R m , R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, hydroxy, C1-C3 alkylacyl and C1-C3 alkoxy; m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6; m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8; m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m5+m6≤7; m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m7+m8≤7; m13 and m14 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8 when they appear, and m13 and m14 are not 0 at the same time, and m13+m14≤8; m15 and m16 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m15+m16≤7; m17 and m18 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6 at each occurrence, and m17+m18≤6; and The compound is not 2. The compound of claim 1, wherein the compound is selected from: When the compound is of formula IA, W 1 and W 2 The same or different, each independently CR a R b 、C(=S)、C(=O)、NR a or SO2, and W 1 and W 2 At least one of them is C(=O); G and Z are the same or different, and are independently selected from O, S, and Se. Preferably, G and Z are independently O; R 3b and R 3c The carbon atom attached to it forms And R 3a and R 3d each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, or R 3c and R 3d The carbon atom attached to it forms And R 3a and R 3b each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, an alkynyl group, or R 3a and R 3b The carbon atom attached to it forms And R 3c and R 3d R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R 3c and R 3d are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, an alkoxy group, and a hydroxyl group; R d , R e , R f , R g , R D , R E , R F , R J , R K , R L , R Q , R W , R M , and R G Each occurrence is independently C(R m )2. NR m , C(=O), O or S; preferably, R d and R e Each occurrence has at least one O and at least one R D and R E Each time it appears, there is at least one occurrence and at least one of them is O; W 3 , W 4 , W 5 and W 6 Each time it appears, it is independently CR m or N; preferably, W 3 , W 4 , W 5 and W 6 Each occurrence is independently CH or N; R h and R H Each time it appears, it is NR independently 1h , C(=O), SO2 or CR 2h R 3h Preferably, R h and R H Each occurrence is independently NH, C(═O), C(Cl)H or C(OH)H; m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6; m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8; m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m5+m6≤7; m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m7+m8≤7; m13 and m14 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8 when they appear, and m13 and m14 are not 0 at the same time, and m13+m14≤8; m15 and m16 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m15+m16≤7; m17 and m18 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, And m17+m18≤6; R m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl, wherein the alkyl, heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, an alkyl, a heteroalkyl, an alkoxyl, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclyl, an alkenyl, an alkynyl, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, an aryl and a heteroaryl; preferably, R m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; preferably, R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, and hydroxyl; R 1h , R 2h , and R 3h Each is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group, and the heteroaryl group are each independently optionally substituted with one or more substituents selected from halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group and a heteroaryl group; preferably, R 1h , R 2h , and R 3h are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a halogenated alkyl group, a hydroxyl group, and an alkyl acyl group; preferably, R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, C1-C3 deuterated alkyl, C1-C3 haloalkyl, hydroxyl and C1-C3 alkoxy; R 1 is selected from H, halogen, a deuterium atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, a cycloalkyl group, a C1-C6 haloalkyl group, and a hydroxyalkyl group, preferably selected from H, F, Cl, Br, I, a C1-C3 alkyl group, a C1-C3 alkoxy group, a C3-C6 cycloalkyl group, a C1-C3 haloalkyl group, a hydroxyl group, and a C1-C6 hydroxyalkyl group; R 2 , R a , and R b are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, and a C1-C6 alkoxy group; and n is 0, 1, 2 or 3; When the compound is selected from the structure of formula IB, W 11 Selected from CR a R b 、C(=O)、C(=S)、NR a or SO2; preferably W 11 is C(=O); G and Z are the same or different and are each independently selected from O, S, and Se; R 3b1 and R 3c1 The carbon atom attached to it forms And R N , R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, amino, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; preferably, R N , R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; or R 3c1 and R 3d1 The carbon atom attached to it forms And R N , R 3a1 and R 3b1 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R N , R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; or R 3a1 and R 3b1 The carbon atom attached to it forms And R N , R 3c1 and R 3d1 R is each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group, and the heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group; preferably, R N , R 3c1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, an alkoxy group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; R d1 , R e1 , R f1 , R g1 , R D1 , R E1 , R F1 , and R G1 Each occurrence is independently C(R m )2. NR m , C(=O), O or S; preferably, R d1 , and R e1 Each occurrence has at least one and at least one O, and R D1 , and R E1 Each time it appears, at least one of them is O; W 31 and W 41 Each time it appears, it is independently CR m or N, preferably, W 31 and W 41 Each occurrence is independently CH or N; R h1 and R H1 Each time it appears, it is NR independently 1h , C(=O), SO2 or CR 2h R 3h Preferably, R h1 and R H1 Each occurrence is independently NH, C═O, CHCl or CHOH; m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6; m3 is independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, m4 is an integer of 1, 2, 3, 4, 5, 6, 7, or 8, and m3+m4≤8; m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m5+m6≤7; m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m7+m8≤7; R m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl, a nitro, a cyano, an amino, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl, wherein the alkyl, heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, a heterocyclyl, an aryl and a heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, an alkyl, a heteroalkyl, an alkoxyl, a haloalkyl, a hydroxyl, a hydroxyalkyl, a cyano, an amino, a nitro, a cycloalkyl, a heterocyclyl, an alkenyl, an alkynyl, an alkylamino, an alkylacyl, an alkyloxyacyl, an alkylaminoacyl, an aryl and a heteroaryl; preferably, R m Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, and a hydroxyl group; preferably, R m , each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxyl and C1-C3 alkoxy; R 1h , R 2h , and R 3h Each is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group, and the heteroaryl group are each independently optionally substituted with one or more substituents selected from halogen, an alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, an aryl group and a heteroaryl group; preferably, R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a haloalkyl group, a hydroxyl group, and an alkyl acyl group; preferably, R 1h , R 2h , and R 3h Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, hydroxyl and C1-C3 alkoxy; R 11 is selected from H, halogen, deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, and hydroxyalkyl, preferably H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, and C1-C6 hydroxyalkyl; R 21 , R a , and R b are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, and a C1-C6 alkoxy group; and n is 0, 1, 2 or 3, preferably 0, 1 or 2; When the compound is selected from Formula IC, G1 and G2 are each independently selected from O, S, Se; preferably, G1 and G2 are each independently O; R 2s Selected from -NR 2A 、-NR 2A CO-, C1-C6 alkylene, and C1-C6 haloalkylene. Preferably, R 2s Selected from -NH-CO-, -NH- and -N(CH3)-; R3 and R4 form the carbon atom to which they are attached and R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group and a heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; preferably, R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxyl, a hydroxyl, a hydroxyalkyl and an amino group; more preferably, R5, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxyl, C1-C6 haloalkyl, C1-C6 haloalkoxyl, and a hydroxyl group; Or R4 and R5 form the carbon atom to which they are connected and R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group and a heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; preferably, R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxyl, a hydroxyl, a hydroxyalkyl and an amino group; more preferably, R3, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxyl, C1-C6 haloalkyl, C1-C6 haloalkoxyl, and a hydroxyl group; Or R5 and R6 form the carbon atom to which they are connected and R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group and a heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl; preferably, R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxyl, a haloalkyl, a haloalkoxyl, a hydroxyl, a hydroxyalkyl and an amino group; more preferably, R3, R4 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxyl, C1-C6 haloalkyl, C1-C6 haloalkoxyl, and a hydroxyl group; Or R6 and R7 form the carbon atom to which they are connected and R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, an alkyl group, a deuterated alkyl group, a heteroalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a hydroxyl group, a hydroxyalkyl group, a nitro group, a cyano group, an amino group, an alkylamino group, an alkylacyl group, an alkyloxyacyl group, an alkylaminoacyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, the heteroalkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, an aryl group and a heteroaryl group are each independently selected from halogen, an alkyl group, a heteroalkyl group, an alkoxy group, a haloalkyl group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclic group, an alkenyl group, alkynyl, alkylamino, alkylacyl, alkyloxyacyl, alkylaminoacyl, aryl and heteroaryl are substituted with one or more substituents; preferably, R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, an alkyl, a deuterated alkyl, a heteroalkyl, an alkenyl, an alkynyl, an alkoxy, a haloalkyl, a haloalkoxy, a hydroxyl, a hydroxyalkyl and an amino group; more preferably, R3, R4 and R5 are each independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, and a hydroxyl group; R 3a , R 3b , R 4a , R 4b , R 3A , R 3B , R 4A , R 4B Each occurrence is independently selected from C(R 2A )2. NR 2A , C(O), O and S; preferably, R 3A or R 4A Each occurrence has at least one O and at least one R 3a or R 4a At least one of each occurrence is O or N(CH3); preferably, R 3A or R 4A Each occurrence has at least one O and at least one R 3a or R 4a Each time it appears, there is at least one occurrence and at least one of them is O; W 3a and W 4a Each time it appears, it is independently CR 2A or N, and W 3a and W 4a At least one of them is a N atom, and Contains at least one O atom or N atom; R a and R A Each occurrence is independently C(R 2A )2. NR 2A , or C(O); preferably, R a and R A Each occurrence is independently -NH or -NC(O)CH3; m1 and m2 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6, and m1+m2≤6; m3 and m4 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m3+m4≤8, and m3 and m4 are not 0 at the same time; m5 and m6 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m5+m6≤7; m7 and m8 are each independently an integer of 0, 1, 2, 3, 4, 5, 6, or 7 at each occurrence, and m7+m8≤7; R 2A , and R 1s Each occurrence is independently selected from H, halogen, a deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, -C(O)-CH3 and hydroxyalkyl, preferably H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, -C(O)-CH3 and C1-C6 hydroxyalkyl; When R 2s Selected from -NR 2A CO-, and R4 and R5 form the carbon atom to which they are connected Or R5 and R6 form the carbon atom to which they are connected When m1+m2=2, at least one of R3 and R7 is not H, and R7 is not F; and The compound is not 3. The compound of claim 2, wherein: When the compound is of Formula IA, W 1 and W 2 are the same or different, and are each independently C(═S), CH2 or C(═O), and W 1 and W 2 At least one of them is C(=O); preferably, W 1 When it is CH2, W 2 C(=O) or W 1 When C(=O), W 2 is CH2 or C(=O); preferably, W 1 When it is CH2, W 2 C(=O) or W 1 When C(=O), W 2 is CH2; and / or G and Z are O; and / or R 3b and R 3c The carbon atom attached to it forms And R 3a and R 3d Each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group, preferably R 3a and R 3d are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3a and R 3b The carbon atom attached to it forms And R 3c and R 3d Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3c and R 3d each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3c and R 3d Each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group, preferably R 3c and R 3d Each is independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; and / or R d , R e , R f , R g , R D , R E , R F , R J , R K , R L , R Q , R W , R M , and R G Each occurrence is independently C(R m )2 or O, preferably each independently is CF2, CH2 or O; preferably, R d and R e Each occurrence has at least one O and at least one R D and R E Each occurrence has at least one and at least one is O; preferably, R d and R e Each occurrence has at least one O, and R D and R E Each occurrence has one and at least one value of O; preferably, R d and R e Each time it occurs, there is one and only one O, and R D and R E Each time it occurs, there is one and one of them is O; and / or R h and R H NR 1h , C(=O), or CR 2h R 3h ; R 1h , R 2h , and R 3h each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl, and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 Alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in a heteroaryl group; preferably, R 1h , R 2h , and R 3h Each is independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl, and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in the heteroaryl group; preferably R 1h , R 2h , and R 3h Each is independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, a hydroxyl group and a C1-C3 alkoxy group; preferably R 1h , R 2h , and R 3h are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, a hydroxyl group, and a C1-C3 alkoxy group; preferably, R h and R H is selected from NH, C(═O), C(Cl)H and C(OH)H; and / or m1 and m2 are each independently an integer of 0, 1, 2, or 3, and m1+m2≤3; preferably m1+m2=1, m1+m2=2, or m1+m2=3; and / or m3 is independently an integer of 0, 1, 2, 3, or 4 at each occurrence, m4 is an integer of 1, 2, 3, 4, or 5, and m3+m4≤5, preferably m3+m4=1, m3+m4=2, m3+m4=3, or m3+m4=4; and / or m5 and m6 are each independently an integer of 0, 1, 2, 3 or 4, and m5+m6≤4, preferably m5+m6=2 or m5+m6=3; and / or m7 and m8 are each independently an integer of 0, 1, 2, 3 or 4, and m7+m8≤4, preferably m7+m8=2 or m7+m8=3; and / or m13 and m14 are each independently an integer of 0, 1, 2, 3 or 4 when they appear each time, m13 and m14 are not 0 at the same time, and m13+m14≤5, preferably m13+m14=3 or m13+m14=4; preferably m13 and m14 are both 2; and / or m15 and m16 are each independently an integer of 0, 1, 2, 3 or 4 when they appear, and m15+m16≤4, preferably m15+m16=2 or m15+m16=3; and / or m17 and m18 are each independently an integer of 0, 1, 2, 3 or 4, and m15+m16≤3, preferably m15+m16=1 or m15+m16=2; and / or R m Each occurrence is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 Haloalkyl, hydroxyl, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in the heteroaryl group; preferably R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in the heteroaryl group; preferably R m Each occurrence is independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; preferably R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; and / or R 1 is selected from H, halogen, C1-C3 alkyl, and hydroxyl; preferably R 1 is selected from H, F, Cl, Br, I, C1-C3 alkyl, and hydroxyl; and / or R 2 Selected from H, and C1-C3 alkyl; and / or n is 0 or 1; or When the compound is of formula IB, W 11 is selected from CH2, C(=S) or C(=O); preferably, W 11 is C(=O) or C(=S); preferably W 11 is C(═O); and / or G and Z are O; and / or R N is selected from the group consisting of H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 It is substituted by one or more substituents in heterocyclic, aryl and heteroaryl, preferably R N is selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in the heteroaryl group, more preferably, R N is selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a hydroxyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, a C1-C6 alkoxy group, a C3-C8 cycloalkyl group, and a C4-C8 heterocyclic group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, wherein the C1-C6 alkyl group, the C1-C6 haloalkyl group, the C1-C6 hydroxyalkyl group, the C1-C6 alkoxy group, the C3-C8 cycloalkyl group, and the C4-C8 heterocyclic group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are each independently selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in a heteroaryl group; and / or R 3b1 and R 3c1 The carbon atom attached to it forms And R 3a1 and R 3d1 Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 is substituted by one or more substituents selected from heterocyclic, aryl and heteroaryl; preferably, R 3a1 and R 3d1 each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 is substituted by one or more substituents in the heteroaryl group, more preferably, R 3a1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3c1 and R 3d1 The carbon atom attached to it forms And R 3a1 and R 3b1 Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3a1 and R 3b1 each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 Heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3a1 and R 3b1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R 3a1 and R 3b1 The carbon atom attached to it forms And R 3c1 and R 3d1 Each is independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3c1 and R 3d1 each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C6 alkyl group, a C1-C6 heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a hydroxyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R 3c1 and R 3d1 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; and / or R d1 , R e1 , R f1 , R g1 , R D1 , R E1 , R F1 , and R G1 Each occurrence is independently C(R m )2 or O; R m Each occurrence is independently selected from H, a deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; and / or W 31 and W 41 is CH or N; and / or m1 and m2 are each independently an integer of 0, 1, 2, or 3, and m1+m2≤3; preferably m1+m2=1, m1+m2=2, m1+m2=3; and / or m3 is independently an integer of 0, 1, 2, 3, or 4 at each occurrence, m4 is an integer of 1, 2, 3, 4, or 5, and m3+m4≤5, preferably m3+m4=1, m3+m4=2, m3+m4=3, or m3+m4=4; and / or m5 and m6 are each independently an integer of 0, 1, 2, 3 or 4, and m5+m6≤4, preferably m5+m6=2 or m5+m6=3; and / or m7 and m8 are each independently an integer of 0, 1, 2, 3 or 4, and m7+m8≤4, preferably m7+m8=2 or m7+m8=3; and / or R 11 is selected from H, halogen, C1-C3 alkyl, and hydroxyl; R 11 is selected from H, F, Cl, Br, I, C1-C3 alkyl, and hydroxyl; and / or R 21 Selected from H, and C1-C3 alkyl; or When the compound is of Formula IC, G1 and G2 are each independently selected from O; and / or R 2s Selected from -NR 2A -, and -NR 2A CO-;R 2A Each occurrence is independently selected from H and C1-C6 alkyl; preferably, R 2s is selected from -NH-CO-, -NH- and -N(CH3)-; and / or R3 and R4 form the carbon atom to which they are attached R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 The present invention is substituted by one or more substituents selected from heterocyclic, aryl and heteroaryl, preferably R5, R6 and R7 are each independently selected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R5, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; preferably R5, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R4 and R5 form a carbon atom to which they are connected. R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 The present invention is substituted by one or more substituents selected from heterocyclic, aryl and heteroaryl, preferably R3, R6 and R7 are each independently selected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R3, R6 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group; preferably R3, R6 and R7 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; or R5 and R6 form a carbon atom to which they are connected. R3, R4 and R7 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 The present invention is substituted by one or more substituents selected from heterocyclic, aryl and heteroaryl, preferably R3, R4 and R7 are each independently selected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R3, R4 and R7 are each independently selected from H, deuterium atom, F, Cl, Br, I, C1-C3 alkyl, and C1-C3 alkoxy; or the carbon atom to which R6 and R7 are attached forms R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, a C1-C6 alkyl group, a heteroalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a hydroxyl group, a C1-C6 hydroxyalkyl group, a nitro group, a cyano group, an amino group, a C3-C8 cycloalkyl group, a C4-C 10 Heterocyclic, aryl and heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclyl, aryl and heteroaryl are each independently optionally selected from halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C6 alkyl, C5-C6 alkyl, C6-C6 alkyl, C7-C6 alkyl, C8-C8 alkyl, C9-C9 alkyl, C1-C6 ... 10 The present invention is substituted by one or more substituents selected from heterocyclic, aryl and heteroaryl, preferably R3, R4 and R5 are each independently selected from H, deuterium atoms, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxyl, nitro, cyano, amino, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 Heteroaryl, wherein the C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl groups are each independently optionally selected from F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, C1-C6 hydroxyalkyl, cyano, amino, nitro, C3-C8 cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 The heteroaryl group is substituted by one or more substituents, preferably R3, R4 and R5 are each independently selected from H, a deuterium atom, a halogen, a C1-C3 alkyl group, and a C1-C3 alkoxy group, preferably R3, R4 and R5 are each independently selected from H, a deuterium atom, F, Cl, Br, I, a C1-C3 alkyl group, and a C1-C3 alkoxy group; and / or R 3a , R 3b , R 4a , R 4b , R 3A , R 3B , R 4A , R 4B Each occurrence is independently selected from C(R 2A )2. NR 2A and O; and / or W 3a and W 4a Each occurrence is independently C(R 2A )2 or N; and / or R a and R A Each occurrence is independently NR 2A or CR 2h R 3h Preferably, R A and R a is -NH, or -NC(O)CH3; and / or R 2A and R 1s Each occurrence is independently selected from H, halogen, a deuterium atom, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, cycloalkyl, C1-C6 haloalkyl, and hydroxyalkyl, preferably H, F, Cl, Br, I, C1-C3 alkyl, C1-C3 alkoxy, C3-C6 cycloalkyl, C1-C3 haloalkyl, hydroxy, and C1-C6 hydroxyalkyl.
4. The compound according to any one of claims 1 to 3, wherein the compound is selected from the following structures: in: R H1 , R H , R h , R f , R g , R W , R M , W 3 , W 4 , W 5 , W 6 , R d , R e , R 3a , R 3b 、R3 c , R 3d , W 1 , W 2 , R F , R G , R J , R K , R L , R Q , R f1 , R g1 , W 31 , W 41 , R d1 , R e1 , R 3a1 , R 3b1 , R 3c1 , R 3d1 , W 11 、m3、m4、R E1 , R D1 , R G1 , R F1 , m2, m5, m6, m8, m13, m14, m15, m16, m17, m18, W 11 , W 31 , W 41 , R N and R h1 As defined in claim 1, 2 or 3 respectively, m1, m9 and m10 are each independently an integer of 0, 1, 2, 3, 4, or 5 when they appear, and m1+m9+m10≤5; preferably m1, m9 and m10 are each independently an integer of 0, 1, or 2 when they appear, and m1+m9+m10≤2, preferably m1+m9+m10=1 or m1+m9+m10=0; and m7, m11 and m12 are each independently an integer of 0, 1, 2, 3, 4, 5, or 6 when they appear, and m7+m11+m12≤6; preferably, m7, m11 and m12 are each independently an integer of 0, 1, 2, or 3 when they appear, and m7+m11+m12≤3, preferably m7+m11+m12=2 or m7+m11+m12=1.
5. The compound according to any one of claims 1 to 3, wherein the compound is selected from the following structures: R H1 、R H 、R h 、R f 、R g 、R W 、R M 、W 3 、W 4 、W 5 、W 6 、R d 、R e 、R 3a 、R 3b 、R 3c 、R 3d 、W 1 、W 2 、R F 、R G 、R J 、R K 、R L 、R Q 、R f1 、R g1 、W 31 、W 41 、R d1 、 R e1 , R 3a1 , R 3b1 , R 3c1 , R 3d1 , W 11 , R N , G1, G2, R 1s , R 2s , R3, R4, R5, R6, R 3A 、R4 A , R 3B , R 4B , R 3a , R 4a , R 4b , R 4a , R a , R b , m3, m4, m5, m6, m13, m14, m15, m16, m17, m18 and R h1 As defined in claim 1, 2 or 3 respectively.
6. The compound according to any one of claims 1 to 5, wherein the compound is selected from the following structures:
7. A compound of formula II or its isomers, isotopic derivatives, polymorphs, prodrugs, or pharmaceutically acceptable salts or solvates: CLM-L-PTM (Formula II), in: PTMs are target protein binding moieties; L is a bond or chemical linking moiety that covalently links the CLM and the PTM, and The CLM is a cerebellum protein E3 ubiquitin ligase binding portion selected from the following structures: in: W 11 、W 1 、W 2 、G、Z、R 3a 、R 3b 、R 3c 、R 3d 、R N 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、 R d 、R e 、R f 、R g 、R D 、R E 、R F 、R G 、R J 、R K 、R L 、R Q 、R W 、R M 、R d1 、R e1 、R f1 、R g1 、R D1 、R E1 、R F1 、R G1 、W 31 、W 41 、W 3 、W 4 、W 5 、W 6 、m1、m2、m3、m4、m5、m6、m7、m8、m13、m14、m15、m16、m17、 m18, R m , R 1 , R 11 , R 2 , R 21 ,n,R 2h , G1, G2, R 1s , R3, R4, R5, R6, R7, R 3a , R 4a , R 3b , R 4b , R 3A , R 4A , R 3B , R 4B , W 3a , W 4a , and R 2A As defined in any one of claims 1 or 2 to 6; R N1 Each occurrence is independently C(R m )2. NR m , C(=O), O or S; R T1 , R t1 , R NT , R t and R T Each occurrence is N or CR independently 2h ; n1 and n2 are each independently an integer of 0, 1, 2, 3, 4, or 5 when they appear, and n1+n2≤5; preferably n1+n2=2 or n1+n2=3, preferably, n1 is 1 or 2, and n2 is 1; R 2m Selected from -NR 2A -、-NR 2A CO-, C1-C6 alkylene, and C1-C6 haloalkylene; R aa , R AA , R BB , and R bb Each occurrence is independently selected from CR m or N; When PTM is CLM is When L is not and When PTM is CLM is When L is not 8. The compound according to claim 7, wherein the CLM is selected from the following structures: W 11 、W 1 、W 2 、R 3a 、R 3b 、R 3c 、R 3d 、R N 、R 3a1 、R 3b1 、R 3c1 、R 3d1 、 R d , R e , R f , R g , R D , R E , R F , R G , R J , R K , R L , R Q , R W , R M , R d1 , R e1 , R f1 , R g1 , R D1 , R E1 , R F1 , R G1 , W 31 , W 41 , W 3 , W 4 , W 5 , W 6 , m1, m2, m3, m4, m5, m6, m7, m8, m13, m14, m15, m16, m17, m18, n1, n2, R N1 , R NT , R t , R T , R t1 , and R T1 As defined in any one of claims 1 or 2 to 7.
9. The compound according to claim 7 or 8, wherein the CLM is selected from the following structures: W 11 , W 1 , W 2 , R 3a , R 3b , R 3c , R 3d , R N , R 3a1 , R 3b1 , R 3c1 , R 3d1 , R d , R e , R f , R g , R D , R E , R F , R G , R J , R K , R L , R Q , R W , R M , R d1 , R e1 , R f1 , R g1 , R D1 , R E1 , R F1 , R G1 , W 31 , W 41 , W 3 , W 4 , W 5 , W 6 , m1, m2, m3, m4, m5, m6, m7, m8, m13, m14, m15, m16, m17, m18, n1, n2, R N1 , R NT , R t , R T , R t1 , R T1 , G1, G2, R 1s , R 2m , R3, R4, R5, R6, R7, R 3a , R 4a , R 3b , R 4b , R 3A , R 4A , R 3B , and R 4B As defined in any one of claims 1, 2 to 6, 7 or 8.
10. The compound according to any one of claims 7 to 9, wherein the CLM is selected from the following structures:
11. The compound according to any one of claims 7 to 10, wherein L is a bond or -(B L ) q -: B L Each occurrence is the same or different and is independently selected from: CR L1 R L2 、O、S、SO、SO2、NR L3 、SO2NR L3 ,SONR L3 ,CONR L3 NR L3 CONR L4 NR L3 SO2NR L4 ,CO,CR L1 =CR L2 、C≡C、SiR L1 R L2 、P(O)R L1 、P(O)OR L1 NR L3 C(=NCN)NR L4 NR L3 C(=NCN),NR L3 C(=CNO2)NR L4 , cycloalkylene, heterocyclylene, arylene, or heteroarylene, wherein the cycloalkylene, heterocyclylene, arylene, and heteroarylene are optionally substituted by 0-6 R L1 and / or R L2 Group substitution; R L1 , R L2 , R L3 , and R L4 Each occurrence is independently selected from H, halogen, C 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NH-C 1-8 Alkyl, N(C 1-8 Alkyl)2, C 3-11 Cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclic group, OC 3-8 Cycloalkyl, OC 3-11 Heterocyclyl, O-aryl, O-heteroaryl, SC 3-8 Cycloalkyl, NH-C 3-8 Cycloalkyl, N(C 3-8 Cycloalkyl)2, N(C 3-8 Cycloalkyl)(C 1-8 Alkyl), NH-C 3-8 Heterocyclic group, N(C 3-8 Heterocyclic)2, N(C 3-8 Heterocyclic group (C 1-8 alkyl), NH-aryl, N(aryl)(C 1-8 alkyl), NH-heteroaryl, N(heteroaryl)(C 1-8 alkyl), OH, NH2, SH, SO2P(O)(OC 1-8 Alkyl)(C 1-8 alkyl), P(O)(OC 1-8 Alkyl)2, C≡CC 1-8 Alkyl, C≡CH, CH=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=C(C 1-8 alkyl)2, Si(OH)3, Si(C 1-8 Alkyl)3, Si(OH)(C 1-8 Alkyl)2, CO-C 1-8 Alkyl, CO2H, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NH-C 1-8 Alkyl, SO2N(C 1-8 Alkyl)2, SONH-C 1-8 Alkyl, SON(C 1-8 Alkyl)2, CONH-C 1-8 Alkyl, CON(C 1-8 Alkyl)2, N(C 1-8 alkyl)CONH(C 1-8 Alkyl), N(C 1-8 alkyl)CON(C 1-8 Alkyl)2, NHCONH(C 1-8 alkyl), NHCON(C 1-8 alkyl)2, NHCONH2, N(C 1-8 Alkyl)SO2NH(C 1-8 Alkyl), N(C 1-8 Alkyl)SO2N(C 1-8 Alkyl)2, NHSO2NH(C 1-8 alkyl), NH SO2 N(C 1-8 alkyl)2, and NH SO2NH2, optionally, the C 1-8 Alkyl, C 3-11 Cycloalkyl, C 3-11 Heterocyclic group, C 6-10 Aryl and C 5-10 The heteroaryl groups are each independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, halocycloalkyl, haloheteroalkyl, alkylamino, aryl, heteroaryl, haloaryl, and haloheteroaryl; and q is an integer greater than or equal to 1; preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
12. The compound of claim 11, wherein B L One or more selected from the following structures: -O-, -S-, -SO-, -SO2-, -CH2-, -CO-, -NH-, -N(CH3)- For the connection point.
13. The compound of claim 12, wherein L is selected from the following structures: Covalent bond, -(CH2) j -, -(CH2) p -NH-(CH2) s -, -(CH2) y -NH-(CH2) j -NH-(CH2) s -, -(CH2) p -CO-(CH2) s -, -(CH2) p -O-(CH2) s -, -(CH2) y -CO-(CH2) j -CO-(CH2) s -, -(CH2) y -O-(CH2) j -O-(CH2) s -, -(CH2) y -O-(CH2) j -CO-(CH2) s -, -(CH2) y -CO-(CH2) j -O-(CH2) s -, -(CH2) p -NH-(CH2) y -O-(CH2) j -CO-(CH2) s -, -(CH2) y -CO-(CH2) j -O-(CH2) s -NH-(CH2) p -, in, j is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; k, s, p and y are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; It is the connection point with CLM or PTM; Preferably, L is selected from the following structures: covalent bond, -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -NH-CH2-, -NH-(CH2)2-, -NH-(CH2)3-, -NH-(CH2)4-, -NH-(CH2)5-, -NH-(CH2)6-, -NH-(CH2)7-, -NH-(CH2)8-, -CO-NH-CH2-, -CO-NH-(CH2)2-, -CO-NH-(CH2)3-, -CO-NH-(CH2)4-, -CO-NH-(CH2)5-, -CO-NH-(CH2)6-, -CO-NH-(CH2)7-, -CO-NH-(CH2)8-, -CH2-NH-, -(CH2)2-NH-, -(CH2)3-NH-, -(CH2)4-NH-, -(CH2)5-NH-, -(CH2)6-NH-, -(CH2)7-NH-, -(CH2)8-NH-, -NH-CH2-NH-, -NH-(CH2)2-NH-, -NH-(CH2)3-NH-, -NH-(CH2)4-NH-, -NH-(CH2)5-NH-, -NH-(CH2)6-NH-, -NH-(CH2)7-NH-, -NH-(CH2)8-NH-, -(CH2-CH2-O)-CH2-CH2-, -(CH2-CH2-O)2-CH2-CH2-, -(CH2-CH2-O)3-CH2-CH2-, -NH-(CH2-CH2-O)-CH2-CH2-, -NH-(CH2-CH2-O)2-CH2-CH2-, -NH-(CH2-CH2-O)3-CH2-CH2-, -CO-NH-(CH2-CH2-O)-CH2-CH2-, -CO-NH-(CH2-CH2-O)2-CH2-CH2-, -CO-NH-(CH2-CH2-O)3-CH2-CH2-, -(CH2-CH2-O)-CH2-CH2-NH-, -(CH2-CH2-O)2-CH2-CH2-NH-, -(CH2-CH2-O)3-CH2-CH2-NH-, -NH-(CH2-CH2-O)-CH2-CH2-NH-, -NH-(CH2-CH2-O)2-CH2-CH2-NH-, -NH-(CH2-CH2-O)3-CH2-CH2-NH-, -CO-NH-(CH2-CH2-O)-CH2-CH2-NH-, -CO-NH-(CH2-CH2-O)2-CH2-CH2-NH-, -CO-NH-(CH2-CH2-O)3-CH2-CH2-NH--CH2-CH2-(O-CH2-CH2)-、-CH2-CH2-(O-CH2-CH2)2-、-CH2-CH2-(O-CH2-CH2)3-、 -NH-CH2-CH2-(O-CH2-CH2)-、-NH-CH2-CH2-(O-CH2-CH2)2-、-NH-CH2-CH2-(O-CH2-CH2)3-、-CO-NH-CH2-CH2-(O-CH2-CH2)-、-CO-NH-CH2-CH2-(O-CH2-CH2)2-、-CO-NH-CH2-CH2-(O-CH2-CH2)2-、-CO-NH-CH2-CH2-(O-CH2-CH2)3-、-CH2-CH2-(O-CH2-CH2)-NH-、-CH2-CH2-(O-CH2-CH2)2-NH-、-CH2-CH2-(O-CH2-CH2)3-NH-、-NHCH2CH 2-(O-CH2-CH2)-NH-、-NH-CH2-CH2-(O-CH2-CH2)2-NH-、-NH-CH2-CH2-(O-CH2-CH2)3-NH-、-NH-CH2-CH2-O-CH2-CH2-CO-、-CO-CH2-CH2-O-CH2-CH2-NH-、-NH-(CH2)4-CO-、-NH-(CH2)5-CO-、-NH-(CH2)6-CO-、-CO-(CH2)4-NH-、-CO-(CH2)5-NH-、-CO-(CH2)6-NH-、-NH-(CH2-CH2-O)-(CH2)3-、-NH-(CH2 -CH2-O)-(CH2)4-、-NH-(CH2-CH2-O)-(CH2)5-、-NH-(CH2-CH2-O)-(CH2)6-、-(CH2)3-(O-CH2-CH2)-NH-、-(CH2)4-(O-CH2-CH2)-NH-、-(CH2)5-(O-CH2-CH2)-NH-、-(CH2)6-(O-CH2-CH2)-NH-、-CH2-CH2-O-(CH2)2-CO-、-CH2-CH2-O-(CH2)3-CO-、-CH2-CH2-O-(CH2)4-CO-、-CO-(CH2)2-O-CH2CH2-、-C O-(CH2)3-O-CH2-CH2-、-CO-(CH2)4-O-CH2-CH2-、-CO-(CH2)2-、-CO-(CH2)3-、-CO-(CH2)4-、-CO-(CH2)5-、-CO-(CH2)6-、-(CH2)2-CO-、-(CH2)3-CO-、-(CH2)4-CO-、-(CH2)5-CO-、-(CH2)6-CO-、-CO-(CH2)2-CO-、-CO-(CH2)3-CO-、-CO-(CH2)4-CO-、-CO-(CH2)5-CO-、-CO-(CH2)6-CO-、-CH2-CO-(CH2)2-、-CH2-CO-(CH2)3-、-CH2-CO-(CH2)4-、-(CH2)2-CO-CH2-、-(CH2)2-CO-(CH2)2-、-(CH2)2-CO-(CH2)3-、-(CH2)2-CO-(CH2)4-、-(CH2)3-CO- CH2-、-(CH2)3-CO-(CH2)2-、-(CH2)3-CO-(CH2)3-、-(CH2)3-CO-(CH2)4-、-(CH2)4-CO-CH2-、-(CH2)4-CO-(CH2)2-、-(CH2)4-CO-(CH2)3-、-(CH2)4-CO-(CH2)4 -、-CH2-O-CH2-、-CH2-O-(CH2)2-、-CH2-O-(CH2)3-、-CH2-O-(CH2)4-、-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2 )3-O-CH2-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)4-O-CH2-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、 14. The compound according to any one of claims 7-13, wherein the PTM is a portion that binds to a target protein or polypeptide, wherein the target protein is selected from: structural proteins, receptors, enzymes, cell surface proteins; proteins associated with cell integration functions, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes, antioxidant activity, proteolysis, biosynthesis; proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulatory activity, signal transduction activity, structural molecules activity, binding activity, receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, stimulus response; behavioral proteins; cell adhesion proteins; proteins involved in cell necrosis; and proteins involved in transport, including proteins with protein transport activity, nuclear transport activity, ion transport activity, channel transport activity, carrier activity, permease activity, secretion activity, electron transport activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcriptional regulator activity, extracellular tissue and biological origin activity, and translation regulator activity.
15. The compound of any one of claims 7-14, wherein the PTM is a moiety that binds to a target protein or polypeptide, wherein the target protein is selected from B7.1 and B7, TNFR2, NADPH oxidase, BclIBax and other partners in the apoptotic pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDEII, PDEII, PDEIII, squalene epoxidase, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5HT receptor, dopamine receptor, G protein (i.e., Gq), histamine receptor, 5-lipoxygenase, trypsin-like serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosome, glycogen phosphorylase, carbonic anhydrase, chemokine receptor, JAW STAT, RXR and its analogs, HIV1 protease, HIV1 integrase, influenza neuraminidase, hepatitis B reverse transcriptase, sodium channel, multidrug-resistant bacteria, protein P-glycoprotein, tyrosine kinase, CD23, CD124, tyrosinase p561ck, CD4, CD5, 1L-2 receptor, 1L-1 receptor, TNF-αR, ICAM1, Cat+ channel, VCAM, VLA-4 integrin, selectin, CD40 / CD40L, inosine monophosphate dehydrogenase, p38MAP kinase, Ras1Raf1MEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyltransferase, rhinovirus, 3C protease, herpes simplex virus-I (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin-dependent kinase 4 / 6, vascular endothelial growth factor, oxytocin receptor, inhibitor of microsomal transfer protein, bile acid transport inhibitor, 5-alpha reductase inhibitor, angiotensin 11, glycine receptors, norepinephrine reuptake receptors, endothelin receptors, neuropeptide Y and receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y 1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferase, geranylgeranyltransferase, TrkA receptor of NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 nerve sheath, telomerase inhibition, cytosolic phospholipase A2, EGF receptor tyrosine kinase, ecdysone 20-monooxygenase, ion channels of GABA-gated chloride channels, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel and chloride channel, acetyl-CoA carboxylase, adenylate succinate synthetase, protoporphyrinogen oxidase, enolpyruvylshikimate phosphate synthetase, MYC protein, androgen receptor, estrogen receptor, interleukin-1 receptor-associated kinase-4 (IRAK4), Aurora kinase A, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein, bromodomain protein 4.
16. The compound of any one of claims 7-15, wherein the PTM is part of the following compounds: Hsp90 inhibitors, kinase inhibitors, phosphatase inhibitors, MDM2 inhibitors, compounds that bind to proteins containing human BET bromodomains, HDAC inhibitors, human lysine methyltransferase inhibitors, compounds that bind to RAF receptors, compounds that bind to FKBP, angiogenesis inhibitors, immunosuppressive compounds, compounds that bind to aryl hydrocarbon receptors, compounds that bind to androgen receptors, compounds that bind to estrogen receptors, compounds that bind to IRAK4, compounds that bind to thyroid hormone receptors, compounds that bind to HIV protease Compounds that bind to HIV integrase, compounds that bind to HCV protease, compounds that bind to acyl protein thioesterase 1 and / or 2, compounds that bind to c-MYC protein, compounds that bind to aurora kinase A, compounds that bind to Bcr-Abl protein, compounds that bind to bromodomain protein 4 (BRD4), compounds that bind to anaplastic lymphoma kinase (ALK), compounds that bind to Bruton's tyrosine kinase (BTK), compounds that bind to cyclin-dependent kinase 4 / 6 (CDK4 / 6), compounds that bind to SMARCA2 / 4 (BRM / BRG1), or compounds that bind to epidermal growth factor receptor.
17. The compound according to claim 16, wherein the PTM is a portion that binds to an androgen receptor, preferably, the PTM is selected from the following structures: Among them, F6, F 16 and F 21 Each occurrence is independently selected from a single bond, NH, SO, S, O, SO2, alkylene, haloalkylene, heteroalkylene, alkyleneoxy, heteroalkoxy, alkenylene, alkynylene, C(=O), OC(=O), C(=O)O, C(=O)NH, and NHC(=O) One or more combinations; wherein the alkylene, alkyleneoxy, alkenylene is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 Rc; preferably, F6, F 16 and F 21 Each occurrence is independent Ground is selected from a single bond, NH, SO, S, O, SO2, C(=O), OC(=O), and NHC(=O); F A1 , and F A3 Each is independently a 6-10 membered aryl or a 6-10 membered heteroaryl; the aryl or heteroaryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da preferably, F A1 is phenyl, which is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da Replace; F A3 is phenyl or a 6-membered heteroaryl group containing 1, 2, or 3 N, O, or S heteroatoms, optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R da replace; F A2 is 3-15 membered cycloalkylene, 5-15 membered spirocycloalkylene, 3-15 membered heterocycloalkylene or 5-15 membered spiroheterocycloalkylene, and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca preferably, F A2 is a 4-6 membered cycloalkylene group, a 7-11 membered spirocycloalkylene group, a 4-6 membered heterocyclylene group, a 7-11 membered heterospirocyclylene group, and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca preferably, F A2 is a 4-, 5- or 6-membered cycloalkylene group, a 10-membered heterospirocyclylene group containing 1, 2 or 3 N atoms; and is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R ca replace; F A4 is a 6-10 membered aryl-fused 7-15 membered heterospirocyclic group, which is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da preferably, F A4 is a phenyl-fused 7-15 membered heterospirocyclic group containing 1, 2, 3, or 4 N, O, S, which is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 R da replace; R da Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, OH, NH2, CN and NO2, preferably H, F, Cl, Br, I, CH3, OCH3, CF3, OH, NH2, CN and NO2; R ca Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, oxo (=O), thio (=S), OH, NH2, CN and NO2, preferably H, F, Cl, Br, I, CH3, OCH3, CF3, OH, NH2, CN and NO2; Preferably, the PTM is selected from: Preferably, the PTM is selected from 18. The compound according to claim 17, whose structure is selected from the following compounds:
19. The compound according to claim 16, wherein the PTM is a moiety that binds to an estrogen receptor, preferably, the PTM is selected from the following structures: R ea Selected from CR e1a and N; R e1a , R e2 and R e3 Each occurrence is independently selected from H, F, Cl, Br, I, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, hydroxy, nitro, cyano, and amino. Preferably, R e1a and R e2 Each occurrence is independently selected from hydroxy, H, F, Cl, Br, I, and C1-C3 alkyl; Each occurrence of e is independently selected from 0, 1, 2, 3, and 4; R e4 is selected from 6-10 membered aryl, 6-10 membered heteroaryl, C1-C6 alkyl, C1-C6 haloalkyl, wherein the 6-10 membered aryl and 6-10 membered heteroaryl may be optionally substituted by 0, 1, 2, 3, 4, or 5 R e1a Substituted; preferably, R e4 is selected from phenyl, and difluoroethyl, wherein the phenyl group may be optionally substituted by 0, 1, 2, 3, 4, or 5 R e1a replace; Preferably, the PTM is selected from:
20. The compound of claim 19, wherein the structure is selected from:
21. The compound according to claim 16, wherein the PTM is a portion that binds to SMARCA2 / 4, preferably, the PTM is selected from the following structures: R s1 is selected from a single bond, NH, SO, S, O, SO2, alkylene, haloalkylene, heteroalkylene, alkyleneoxy, heteroalkoxy, alkenylene, alkynylene, C(=O), OC(=O), C(=O)O, C(=O)NH, and NHC(=O) in one or more combinations; preferably R s1 Selected from single bond, C 2-6 Alkenylene, C 2-6 Alkyne; R s2 is selected from 6-10 membered arylene, 6-10 membered heteroarylene, 3-15 membered cycloalkylene, 3-15 membered heterocyclylene, 5-15 membered spirocyclylene, wherein the 6-10 membered arylene, 6-10 membered heteroarylene, 3-15 membered cycloalkylene, 5-15 membered spirocyclylene may be optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R s5 Substituted; preferably, R s2 is selected from 5-8 membered heteroaryl groups containing 1, 2, or 3 N, O, or S heteroatoms, 4-6 membered heterocyclyl groups containing 1, 2, or 3 N, O, or S heteroatoms, and 7-11 membered spirocyclyl groups, wherein the 5-8 membered heteroaryl groups containing 1, 2, or 3 N, O, or S heteroatoms, 4-6 membered heterocyclyl groups containing 1, 2, or 3 N, O, or S heteroatoms, and 7-11 membered spirocyclyl groups may be optionally substituted by 0, 1, 2, 3, 4, 5, or 6 R s5 Substituted; preferably, R s2 is selected from pyrazolylene, 4-membered heterocyclylene containing 1 N atom, and 8-membered spirocyclylene; R s3 , R s4 , R s5 , and R s6 Each occurrence is independently selected from H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 1-6 Heteroalkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocyclic group, C 6-8 Aryl, C 5-8 heteroaryl, OH, NH2, CN and NO2, preferably H, F, Cl, Br, I, CH3, OCH3, CF3, OH, NH2, CN or NO2; preferably, R s3 OH, R s4 is NH2; and s1 is selected from 0, 1, 2, 3 and 4; Preferably, the PTM is selected from the following structures:
22. The compound of claim 21, wherein the structure is selected from: and 23. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 and a pharmaceutically acceptable excipient.
24. Use of the compound of any one of claims 7 to 22, or the pharmaceutical composition of claim 23, in the preparation of a medicament for treating or preventing a disease treated by degrading a target protein that binds to a target protein ligand, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, IRAK4, SMARCA2 / 4, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
25. Use of a compound according to any one of claims 7 to 22, or a pharmaceutical composition according to claim 23, in the preparation of a medicament for treating or preventing a disease that is treated by binding to cerebellin in vivo.
26. Use of the compound of any one of claims 7 to 22, or the pharmaceutical composition of claim 23, in the treatment or prevention of a disorder associated with the accumulation and / or aggregation of a target protein, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, SMARCA2 / 4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
27. The compound of any one of claims 7 to 22, or the pharmaceutical composition of claim 23, for treating or preventing a disease that is treated by degrading a target protein that binds to a target protein ligand, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, SMARCA2 / 4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
28. A compound as claimed in any one of claims 18 to 42, or a pharmaceutical composition as claimed in claim 23, for use in the treatment or prevention of a condition which is treated by binding to cerebellin in vivo.
29. The compound of any one of claims 7 to 22, or the pharmaceutical composition of claim 23, for treating or preventing a condition associated with the accumulation and / or aggregation of a target protein, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, SMARCA2 / 4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
30. A method for treating or preventing a disease treated by degrading a target protein bound to a target protein ligand, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 7 to 22, or a pharmaceutical composition according to claim 23, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, IRAK4, SMARCA2 / 4, Bcr-Abl protein, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
31. A method for treating or preventing a condition that is treated by binding to cerebellin in vivo, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 7 to 22, or a pharmaceutical composition according to claim 23.
32. A method for treating or preventing a condition associated with the accumulation and / or aggregation of a target protein, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 7 to 22, or a pharmaceutical composition according to claim 23, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, SMARCA2 / 4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
33. The method of any one of claims 30 to 32, wherein the disorder is a tumor or cancer.
34. A method for inducing degradation of a target protein in a cell, the method comprising administering an effective amount of a compound as described in any one of claims 7 to 22, or a pharmaceutical composition as described in claim 23, wherein the target protein is preferably cyclin-dependent kinase 4 / 6, androgen receptor, estrogen receptor, Aurora kinase A, Bcr-Abl protein, IRAK4, SMARCA2 / 4, epidermal growth factor receptor, anaplastic lymphoma kinase, Bruton's tyrosine kinase, BRM / BRG1 protein or bromodomain protein 4.
Citation Information
Patent Citations
CEREBLON E3 ligase inhibitors
CN114641337A
Bifunctional agents for protein recruitment and / or degradation
CN115348872A
Fused heterocyclic compound as well as composition and pharmaceutical application thereof
CN117050058A
Condensed ring compound as well as preparation method and medical application thereof
CN118005655A
Bicyclic imide derivative, preparation method thereof, and application thereof in medicine
WO2021143822A1
Cited By
Tricyclic compound, and preparation method therefor and use thereof
EP4696691A4
Compound for selectively degrading smarca2 / 4 and use thereof
WO2026026885A1
Polycyclic compound
WO2026048766A1
Compound for use in targeted degradation of androgen receptors, and method
WO2026061104A1
Preparation of STAT6 protein degradation agent and use thereof in medicine
WO2026189405A1
